Macrocyclic compounds

By developing a new compound general formula as compound [Ca1], the problem of insufficient IRAK-4 inhibitors in the prior art was solved, and efficient inhibition of IRAK-4 and therapeutic effects on related diseases were achieved.

CN116348472BActive Publication Date: 2024-12-03ASAHI KASEI PHARMA CORP +1
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202080105435.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-09-30
Publication Date
2024-12-03
Estimated Expiration
2040-09-30

AI Technical Summary

Technical Problem

The prior art is difficult to effectively inhibit IRAK-4-related inflammation and autoimmune diseases, and there is a lack of effective compounds and drugs with IRAK-4 inhibitory activity.

Method used

A new compound, the general formula is Compound [Ca1], has developed a new compound that has excellent IRAK-4 inhibitory activity through specific structural composition and bonding methods, and can be used to prevent and treat IRAK-4 inhibition. disease.

Benefits of technology

Compound [Ca1] showed highly selective inhibition of IRAK-4, low genotoxicity, and could be used to prevent and treat autoimmune diseases such as rheumatism, and had significant therapeutic effects as an IRAK-4 inhibitor.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116348472B_ABST
    Figure CN116348472B_ABST
Patent Text Reader

Abstract

The present invention provides a compound of the following general formula (1) or a salt thereof, which has excellent IRAK‑4 inhibitory activity and is useful as an active ingredient of a drug for preventing and / or treating diseases associated with IRAK‑4 inhibition.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to novel macrocyclic compounds or drugs using the same as active ingredients. Background Art

[0002] Interleukin 1 receptor-associated kinase 4 (IRAK-4) is a protein phosphatase that plays an important role in downstream signal transduction of Toll-like receptors (TLRs), interleukin 1 receptor (IL-1R), IL-18R and IL-33R (Non-patent Document 1). The TLRs / IL-1 receptor family plays an important role in inflammation or body defense, so it is believed that this downstream signal plays a major role in a variety of diseases including inflammatory diseases and autoimmune diseases.

[0003] TLRs use pathogen-associated molecular patterns (PAMPs) derived from infectious microorganisms such as bacteria, fungi, parasites, and viruses as ligands. In addition, they can also recognize damage-associated molecular patterns (DAMPs) released by damaged cells or apoptotic cells and activate them. When the ligand binds to the TLRs and IL-1 receptor family, MyD88, which acts as a linker molecule, is recruited to a common intracellular region called the TIR (Toll / IL-1 receptor) region. It is believed that IRAK-4 is recruited to the receptor by interacting with MyD88 and initiates downstream signal transduction (Non-patent Document 2). IRAK-4 activates IRAK-1 and IRAK-2, and further controls the production of inflammatory mediators such as cytokines and chemokines through the activation of downstream signaling molecules such as NF-kB and MAPK.

[0004] It is reported that cells of human origin with IRAK-4 gene defect do not react with TLRs agonists other than TLR3 and IL-1β, IL-18 (non-patent literature 3). In addition, IRAK-4 gene defect mice also do not react with TLRs agonists other than TLR3 and IL-1β, IL-18 (non-patent literature 4). On the other hand, in IRAK-1 gene defect mice and IRAK-2 gene defect mice, it is only confirmed that these signals are partially suppressed (non-patent literature 5). Therefore, in the IRAK family, IRAK-4 is also considered to play a core role in these signal transductions. It is reported that in kinase activity-deficient IRAK-4 knock-in mice, the severity of arthritis or experimental autoimmune encephalomyelitis and atherosclerosis models is suppressed compared to wild-type mice (non-patent literature 6). Therefore, the kinase activity of IRAK-4 is essential for the signal transduction involved in pathogenesis, and IRAK-4 inhibitors may show high effectiveness in the treatment of acute and chronic inflammation, autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematosus, metabolic diseases such as gout or diabetes, tumors and other diseases.

[0005] As compounds having IRAK-4 inhibitory activity, for example, compounds described in Patent Documents 1 to 6 are known.

[0006] Prior art literature

[0007] Patent Literature

[0008] Patent Document 1: International Publication No. WO2016 / 144846 Pamphlet

[0009] Patent Document 2: International Publication No. WO2016 / 053771 Pamphlet

[0010] Patent Document 3: International Publication No. WO2015 / 048281 Pamphlet

[0011] Patent Document 4: International Publication No. WO2013 / 042137 Pamphlet

[0012] Patent Document 5: International Publication No. WO2012 / 068546 Pamphlet

[0013] Patent Document 6: International Publication No. WO2015 / 150995 Pamphlet

[0014] Non-patent literature

[0015] Non-patent document 1: Flannery S. & Bowie AG, Biochemical Pharmacology 80 (2010) 1981-1991

[0016] Non-patent document 2: Jain A. et al., Fronters in Immunology 5 (2014) Article 553

[0017] Non-patent document 3: Picad C. et al., Science 299 (2003) 2076-2079

[0018] Non-patent document 4: Suzuki N. et al., Nature 416 (2002) 750-754

[0019] Non-patent document 5: Wan Y. et al., J Biol Chem 284 (2009) 10367-10375

[0020] Non-patent document 6: Koziczak-Holbro M. et al., Arthritis & Rheumatism 60 (2009) 1661-1671 Summary of the invention

[0021] Problems to be solved by the invention

[0022] The problem to be solved by the present invention is to provide a new compound having IRAK-4 inhibitory activity. In addition, another problem is to provide a new compound useful as an active ingredient of a drug for preventing and / or treating a disease associated with IRAK-4 inhibition. Furthermore, another problem is to provide a drug containing the compound.

[0023] Means for solving problems

[0024] The present inventors have conducted intensive studies to solve the above problems and have found that the compounds of the present invention represented by the following formula (1) have excellent IRAK-4 inhibitory activity and are useful for the prevention and / or treatment of diseases associated with IRAK-4 inhibition, thereby completing the present invention.

[0025] That is, the present invention includes the following aspects.

[0026] [1] The following general formula (1):

[0027] [Chemistry 1]

[0028]

[0029] [In formula (1),

[0030] R 1 -H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, -C(O)R 12 、-S(O2)R 12 、-C(O)NR 11 R 12 、-C(O)OR 12 or a 3- to 7-membered saturated ring group, the above R 1 Can be substituted with a selected from G 1 1 to 3 identical or different substituents in the group;

[0031] The above G 1 The group is composed of -F, hydroxyl, cyano, halogenated C 1-6 Alkyl, C 1-4 The group consisting of an alkoxy group, a phenyl group, a 5- to 6-membered heteroaryl group, and a 3- to 7-membered saturated ring group, G 1 The phenyl or 5- to 6-membered heteroaryl group in the group may be substituted with a Ar 1 to 3 identical or different substituents in the group;

[0032] The above G Ar The group is composed of -F, -Cl, hydroxyl, cyano, C 1-6 Alkyl, halogenated C 1-6 The group consisting of alkyl and -NH2;

[0033] R 11 -H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, halogenated C 1-6 Alkoxy C 1-6 Alkyl or 3-7 membered saturated ring group;

[0034] R 12 C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, halogenated C 1-6 Alkoxy C 1-6 Alkyl, 3-7 membered saturated ring group, phenyl or 5-6 membered heteroaryl, R 12 The phenyl or 5- to 6-membered heteroaryl group in the Ar 1 to 3 identical or different substituents in the group;

[0035] R 2 -H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl or 3-7 membered saturated ring group;

[0036] R 3 -H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl or 3-7 membered saturated ring group;

[0037] Ar is a 6- to 10-membered aryl group or a 5- to 10-membered heteroaryl group, and the above Ar may be substituted with a group selected from G 2 1 to 3 identical or different substituents in the group;

[0038] The above G 2 The group is composed of -F, -Cl, hydroxyl, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, R Ar1 -OC 1-3 Alkyl, RAr1 -NR 13 -C 1-3 Alkyl, -NR 13 C(O)R 14 、-C(O)NR 13 R 14 、-C(O)NH2、-NR 13 S(O2)R 14 、-S(O2)NR 13 R 14 、-NH2、-S(O2)NH2、-NR 13 R 14 and -NHC(O)NHR 15 The group composed of;

[0039] R Ar1 -H, C 1-6 Alkyl, halogenated C 1-6 Alkyl or 3-7 membered saturated ring group, the above R Ar1 Can be substituted with a selected from G 3 1 to 3 identical or different substituents in the group;

[0040] The above G 3 The group is composed of -F, hydroxyl, C 1-3 Alkyl, halogenated C 1-3 Alkyl, oxy, C 1-3 Alkoxy, halogenated C 1-3 A group consisting of an alkoxy group and a 3- to 7-membered saturated ring group;

[0041] R 13 -H, C 1-3 Alkyl, halogenated C 1-3 Alkyl, C 1-3 Alkoxy C 1-3 Alkyl, halogenated C 1-3 Alkoxy C 1-3 Alkyl or 3-7 membered saturated ring group;

[0042] R 14 C 1-3 Alkyl, halogenated C 1-3 Alkyl, C 1-3 Alkoxy C 1-3 Alkyl, halogenated C 1-3 Alkoxy C 1-3 Alkyl or 3-7 membered saturated ring group;

[0043] R 15 is -H, phenyl or 5- to 6-membered heteroaryl, the above R 15 Can be substituted with a selected from G 4 1 to 3 identical or different substituents in the group;

[0044] The above G 4 The group is composed of halogen, cyano, C 1-3 Alkyl and halogenated C 1-3 A group consisting of alkyl groups;

[0045] X 1 N or CH;

[0046] X 2 NH or O;

[0047] X 3 It is the following general formula (1-1):

[0048] [Chemistry 2]

[0049]

[0050] Or the following general formula (1-2):

[0051] [Chemistry 3]

[0052]

[0053] Or the following general formula (1-3):

[0054] [Chemistry 4]

[0055]

[0056] (a and b represent bonding directions),

[0057] R 21 and R 22 Each independently is -H, C 1-3 Alkyl, halogenated C 1-3 alkyl;

[0058] X 4 The following general formula (2-1):

[0059] [Chemistry 5]

[0060]

[0061] (b and c represent bonding directions);

[0062] In formula (2-1),

[0063] n is an integer from 1 to 3;

[0064] Y is NR 51 or O;

[0065] R 31 and R 32 Each independently is -H, C 1-3 Alkyl, halogenated C1-3 alkyl;

[0066] or R 31 With R 32 They can form a 3- to 6-membered saturated ring together;

[0067] R 41 and R 42 are independently -H, -F, hydroxyl, C 1-3 Alkyl, halogenated C 1-3 Alkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy;

[0068] or R 41 With R 42 They can form a 3- to 6-membered saturated ring together;

[0069] R 51 -H, C 1-3 Alkyl, halogenated C 1-3 alkyl;

[0070] or R 51 With the above R 31 They can form a 4- to 6-membered saturated ring together;

[0071] The above X 4 Can be substituted with a selected from G 5 1 to 3 identical or different substituents in the group;

[0072] The above G 5 The group is composed of -F, hydroxyl, C 1-3 Alkyl, halogenated C 1-3 Alkyl, C 1-3 Alkoxy, halogenated C 1-3 group composed of alkoxy groups].

[0073] [2] The compound or a salt thereof according to [1], wherein Ar is a 5- to 6-membered heteroaryl group.

[0074] [2-2] The compound or a salt thereof according to the above [1], wherein Ar is thienyl, thiazolyl, isothiazolyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrimidinyl or pyrazinyl.

[0075] [2-3] The compound or a salt thereof according to the above [1], wherein Ar is thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, pyridyl, pyrimidinyl or pyrazinyl.

[0076] [2-4] The compound or a salt thereof according to the above [1], wherein Ar is thiazolyl, isothiazolyl, pyridyl or pyrimidinyl.

[0077] [2-5] The compound or a salt thereof according to the above [1], wherein Ar is thiazolyl or pyrimidinyl.

[0078] [3] The compound or salt thereof according to any one of [1] to [2] above, wherein R 1 -H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl or 3-7 membered saturated ring group, the above R 1 Can be substituted with a selected from G 1 Group (G 1 The group has the same meaning as above) and 1 to 3 identical or different substituents.

[0079] [3-2] The compound or salt thereof according to any one of [1] to [2] above, wherein R 1 -H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl or 3-7 membered saturated ring group, the above R 1 Can be substituted with a selected from G 1 Group (G 1 The group has the same meaning as above) and 1 to 3 identical or different substituents.

[0080] [3-3] The compound or salt thereof according to any one of [1] to [2] above, wherein R 1 -H, C 1-6 Alkyl or 3-7 membered saturated ring group, the above R 1 Can be substituted with a selected from G 1 Group (G 1 The group has the same meaning as above) and 1 to 3 identical or different substituents.

[0081] [4] The compound or salt thereof according to any one of [1] to [3-3] above, wherein X 2 For NH.

[0082] It should be noted that the item numbers cited as [1] to [3-3] are shown as a range, and if an item with a branch number such as [3-2] is configured within the range, it means that the item with a branch number such as [3-2] is also cited. The same applies to the following.

[0083] [5] The compound or salt thereof according to any one of [1] to [4] above, wherein X 3 It is the following general formula (1-1):

[0084] [Chemistry 6]

[0085]

[0086] (R 21 and R 22 Same meaning as above).

[0087] [6] The compound or salt thereof according to any one of [1] to [5] above, wherein X 3 It is the following general formula (1-1-1):

[0088] [Chemistry 7]

[0089]

[0090] [7] The compound or salt thereof according to any one of [1] to [6] above, wherein X 4 In the general formula (2-1), n ​​is 1.

[0091] [8] The compound or salt thereof according to any one of [1] to [8] above, wherein Ar is the following general formula (3-1):

[0092] [Chemistry 8]

[0093]

[0094] In formula (3-1),

[0095] R Ar2 -H, -F, -Cl, hydroxyl, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, R Ar1 -OC 1-3 Alkyl or -NR 13 R 14 (R Ar1 , R 13 and R 14 Same meaning as above).

[0096] [8-2] The compound or salt thereof according to any one of [1] to [7] above, wherein Ar is the general formula (3-1), wherein R Ar2 -H, C 1-6 Alkyl, hydroxyl C 1-6 Alkyl or R Ar1 -OC 1-3 Alkyl (R Ar1 Same meaning as above).

[0097] [8-3] The compound or salt thereof according to any one of [1] to [8] above, wherein Ar is the general formula (3-1), wherein R Ar2 For R Ar1 -OC 1-3 Alkyl (R Ar1 Same meaning as above).

[0098] [8-4] The compound or salt thereof according to any one of [1] to [8] above, wherein Ar is the general formula (3-1), wherein R Ar2 For R Ar1 -OC 1-3 Alkyl (R Ar1 Same as above), R Ar1 C 1-6 Alkyl or 3-7 membered saturated ring group, the above R Ar1 Can be substituted with a selected from G 3 Group (G 3 The group has the same meaning as above) and 1 to 3 identical or different substituents.

[0099] [8-5] The compound or salt thereof according to any one of [1] to [8] above, wherein Ar is the general formula (3-1), wherein R Ar2 For R Ar1 -OC 1-3 Alkyl (R Ar1 Same as above), R Ar1 C 1-6 Alkyl, the above R Ar1 Can be substituted with a selected from G 3 Group (G 3 The group has the same meaning as above) and 1 to 3 identical or different substituents.

[0100] [8-6] The compound or salt thereof according to any one of [1] to [8] above, wherein Ar is the general formula (3-1), wherein R Ar2 For R Ar1 -OC 1-3 Alkyl (R Ar1 Same as above), R Ar1 is a 3- to 7-membered saturated ring group, the above R Ar1 Can be substituted with a selected from G 3 Group (G 3 The group has the same meaning as above) and 1 to 3 identical or different substituents.

[0101] [8-7] The compound or salt thereof according to any one of [1] to [7] above, wherein Ar is the general formula (3-1), wherein R Ar2 For RAr1 -OC 1-3 Alkyl (R Ar1 Same as above), R Ar1 C 3-7 Cycloalkyl, the above R Ar1 Can be substituted with a selected from G 3 Group (G 3 The group has the same meaning as above) and 1 to 3 identical or different substituents.

[0102] [9] The compound or salt thereof according to any one of [1] to [8-7] above, wherein Ar is the general formula (3-1);

[0103] In formula (3-1),

[0104] R Ar2 -H, methyl, hydroxymethyl, -CH2-OR Ar1 (R Ar1 Same meaning as above).

[0105] [9-2] The compound or salt thereof according to any one of [1] to [8-7] above, wherein Ar is the general formula (3-1), wherein R Ar2 For R Ar1 -O-CH2-(R Ar1 Same as above), R Ar1 C 1-6 Alkyl or 3-7 membered saturated ring group, the above R Ar1 Can be substituted with a selected from G 3 Group (G 3 The group has the same meaning as above) and 1 to 3 identical or different substituents.

[0106] [9-3] The compound or salt thereof according to any one of [1] to [8-7] above, wherein Ar is the general formula (3-1), wherein R Ar2 For R Ar1 -O-CH2-(R Ar1 Same as above), R Ar1 C 1-6 Alkyl, the above R Ar1 Can be substituted with a selected from G 3 Group (G 3 The group has the same meaning as above) and 1 to 3 identical or different substituents.

[0107] [9-4] The compound or salt thereof according to any one of [1] to [8-7] above, wherein Ar is the general formula (3-1), wherein R Ar2 For R Ar1 -O-CH2-(R Ar1Same as above), R Ar1 is a 3- to 7-membered saturated ring group, the above R Ar1 Can be substituted with a selected from G 3 Group (G 3 The group has the same meaning as above) and 1 to 3 identical or different substituents.

[0108] [9-5] The compound or salt thereof according to any one of [1] to [8-7] above, wherein Ar is the general formula (3-1), wherein R Ar2 For R Ar1 -O-CH2-(R Ar1 Same as above), R Ar1 C 3-7 Cycloalkyl, the above R Ar1 Can be substituted with a selected from G 3 Group (G 3 The group has the same meaning as above) and 1 to 3 identical or different substituents.

[0109] [9-6] The compound or salt thereof according to any one of [1] to [8-7] above, wherein Ar is the general formula (3-1), wherein R Ar2 It is methyl or hydroxymethyl.

[0110] [9-7] The compound or salt thereof according to any one of [1] to [8-7] above, wherein Ar is the general formula (3-1), wherein R Ar2 It is methyl.

[0111] [9-8] The compound or salt thereof according to any one of [1] to [8-7] above, wherein Ar is the general formula (3-1), wherein R Ar2 It is hydroxymethyl.

[0112]

[10] The compound or salt thereof according to any one of [1] to [9-8] above, wherein R 3 is -H.

[0113]

[11] The compound or salt thereof according to any one of [1] to

[10] above, wherein R 2 It is -H or methyl.

[0114]

[12] The compound or salt thereof according to any one of [1] to

[11] above, wherein R 1 -H or C 1-3 alkyl.

[0115] [12-2] The compound or salt thereof according to any one of [1] to

[11] above, wherein R 1 is -H.

[0116] [12-3] The compound or salt thereof according to any one of [1] to

[11] above, wherein R 1 C 1-3 alkyl.

[0117] [12-4] The compound or salt thereof according to any one of [1] to

[11] above, wherein R 1 It is methyl or ethyl.

[0118] [12-5] The compound or salt thereof according to any one of [1] to

[11] above, wherein R 1 It is methyl.

[0119] [12-6] The compound or salt thereof according to any one of [1] to

[11] above, wherein R 1 It is ethyl.

[0120]

[13] A compound represented by the following formula or a salt thereof.

[0121] [Chemistry 9]

[0122]

[0123]

[14] A compound represented by the following formula or a salt thereof.

[0124] [Chemistry 10]

[0125]

[0126]

[15] A compound represented by the following formula or a salt thereof.

[0127] [Chemistry 11]

[0128]

[0129]

[16] A compound represented by the following formula or a salt thereof.

[0130] [Chemistry 12]

[0131]

[0132]

[17] A compound represented by the following formula or a salt thereof.

[0133] [Chemistry 13]

[0134]

[0135]

[18] A compound represented by the following formula or a salt thereof.

[0136] [Chemistry 14]

[0137]

[0138]

[19] A compound represented by the following formula or a salt thereof.

[0139] [Chemistry 15]

[0140]

[0141]

[20] A medicament comprising the compound according to any one of [1] to

[19] above or a pharmaceutically acceptable salt thereof as an active ingredient.

[0142]

[21] The medicament as described in

[20] above, which is used for preventing and / or treating a disease associated with IRAK4 inhibition.

[0143]

[22] The drug as described in

[20] above, which is used for the prevention and / or treatment of rheumatic diseases.

[0144]

[23] An IRAK4 inhibitor comprising the compound described in any one of [1] to

[19] above or a pharmaceutically acceptable salt thereof as an active ingredient.

[0145]

[24] A pharmaceutical composition for preventing and / or treating rheumatic diseases, comprising the compound described in any one of [1] to

[19] above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0146]

[25] The compound according to any one of [1] to

[19] above, or a pharmaceutically acceptable salt thereof, for use in the prevention and / or treatment of rheumatic diseases.

[0147]

[26] A method for preventing and / or treating rheumatic disease in a mammal, comprising the step of administering an effective amount of the compound described in any one of [1] to

[19] above or a pharmaceutically acceptable salt thereof to the mammal.

[0148] Effects of the Invention

[0149] "The compound represented by formula (1) or a salt thereof" (hereinafter sometimes simply described as "the compound of the present invention") has excellent IRAK-4 inhibitory activity. In addition, a certain embodiment of the compound of the present invention shows high selectivity for other kinases, particularly FLT3. In addition, a certain embodiment of the compound of the present invention shows low genotoxicity. In addition, a certain embodiment of the compound of the present invention can be used as an active ingredient of a drug for the prevention and / or treatment of diseases related to IRAK-4 inhibition, such as for the prevention and / or treatment of autoimmune diseases. In addition, a certain embodiment of the compound of the present invention can be used as a reagent having IRAK-4 inhibitory activity. DETAILED DESCRIPTION

[0150] The present invention is described in detail below.

[0151] Unless otherwise stated, in the present specification, a carbon atom may be represented simply as "C", a hydrogen atom may be represented as "H", an oxygen atom may be represented as "O", a sulfur atom may be represented as "S", and a nitrogen atom may be represented as "N". In addition, a carbonyl group may be represented simply as "-C(O)-", a carboxyl group may be represented as "-COO-", a sulfinyl group may be represented as "-S(O)-", a sulfonyl group may be represented as "-S(O)2-", an ether bond may be represented as "-O-", and a thioether bond may be represented as "-S-" (in this case, "-" indicates a bond).

[0152] Unless otherwise stated, in this specification, an alkyl group is a saturated hydrocarbon group that is a straight chain, branched chain, cyclic or a combination thereof. For example, methyl, ethyl, propyl, butyl, their isomers [normal (n), iso (iso), secondary (sec), tertiary (t), etc.], or cycloalkyl groups such as cyclopropyl or cyclobutyl can be exemplified. As an alkyl group, an alkyl group having 1 to 6 carbon atoms can be exemplified. As another embodiment, an alkyl group having 1 to 3 carbon atoms can be exemplified. An alkyl group having 1 to 6 carbon atoms is sometimes recorded as C 1-6 alkyl.

[0153] "Alkoxy" may be a linear, branched, cyclic or a combination thereof. For example, methoxy, ethoxy, propoxy, butoxy, their isomers [normal (n), iso (iso), secondary (sec), tertiary (t), etc.] or cycloalkoxy such as cyclopropyloxy or cyclobutyloxy. As an alkoxy group, an alkoxy group having 1 to 6 carbon atoms may be exemplified. As another embodiment, an alkoxy group having 1 to 3 carbon atoms may be exemplified. Alkoxy groups having 1 to 6 carbon atoms are sometimes recorded as C 1-6 Alkoxy.

[0154] "Alkylene" also includes straight-chain or branched alkylene groups. For example, methylene, ethylene, propylene, butylene, methylmethylene, ethylmethylene, methylethylene, 1,2-dimethylethylene, 1,1,2,2-tetramethylethylene, or 1-methylbutylene can be exemplified. As an alkylene group, an alkylene group having 1 to 6 carbon atoms can be exemplified. As another embodiment, an alkylene group having 1 to 3 carbon atoms can be exemplified. An alkylene group having 1 to 6 carbon atoms is sometimes recorded as C 1-6 Alkylene.

[0155] "Halogen" is fluorine (-F), chlorine (-Cl), bromine (-Br) or iodine (-I). As another embodiment, -F or -Cl can be exemplified. Furthermore, as another embodiment, -F can be exemplified. "Halo" means substituted with 1 to 7 halogens which may be the same or different. As another embodiment, it means substituted with 1 to 5 halogens which may be the same or different. Furthermore, as another embodiment, it means substituted with 1 to 3 halogens. Furthermore, as another embodiment, it means substituted with 1 halogen. -F can be exemplified.

[0156] As the "aromatic ring", there is no particular limitation as long as it is a ring with aromaticity, and examples include monocyclic to tricyclic aromatic rings. As the aromatic ring, examples include aromatic hydrocarbon rings or aromatic heterocyclic rings. Specifically, examples include benzene, naphthalene, phenanthrene, thiophene, furan, thiazole, isothiazole, oxazole, isoxazole, oxadiazole, pyrrole, pyrazole, imidazole, pyridine, pyrimidine, pyrazine, pyridazine, pyridone, pyrimidone, indole, isoindole, indazole, quinoline, isoquinoline, benzimidazole, benzotriazole, benzothiophene, benzofuran, benzothiazole, phthalazine, quinoxaline, pyrrolopyridine or carbazole.

[0157] Examples of the "aromatic ring group" include monovalent groups obtained by removing any one hydrogen atom from an aromatic ring. Any aromatic ring group may be a monocyclic to tricyclic aromatic ring group. For example, an aryl group or a heteroaryl group may be mentioned.

[0158] The "aryl group" may be a monocyclic to tricyclic aromatic hydrocarbon ring group. Aromatic hydrocarbon ring groups formed by condensation with a saturated hydrocarbon ring described later are also included in the aryl group. Examples include 6- to 14-membered aryl groups. As another embodiment, 6- to 10-membered aryl groups may be illustrated. Furthermore, as another embodiment, 6-membered aryl groups may be illustrated. Specifically, phenyl, naphthyl, anthracenyl, phenanthrenyl, fluorenyl, indanyl or 1,2,3,4-tetrahydronaphthyl may be illustrated. As another embodiment, it is phenyl, and as another embodiment, it is naphthyl. Indanyl and 1,2,3,4-tetrahydronaphthyl are included in the 6- to 10-membered aryl groups.

[0159] The "heteroaryl group" may be a monocyclic to tricyclic aromatic heterocyclic group containing 1 to 4 heteroatoms as ring atoms. As heteroatoms, O, S or N can be exemplified. 5 to 14-membered heteroaryl groups can be exemplified. As another embodiment, 5 to 10-membered heteroaryl groups can be exemplified. Furthermore, as another embodiment, 5 to 6-membered heteroaryl groups can be exemplified. Specifically, thienyl, furanyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyridonyl, pyrimidonyl, indolyl, isoindolyl, indazolyl, quinolyl, isoquinolyl, benzimidazolyl, benzotriazolyl, benzothienyl, benzofuranyl, benzothiazolyl, phthalazinyl, quinoxalinyl, pyrrolopyridinyl or carbazolyl can be exemplified.

[0160] Examples of the "saturated ring" include a saturated hydrocarbon ring and a saturated heterocyclic ring. The saturated ring may have a bridge bond, or may be condensed with the above-mentioned aromatic ring.

[0161] The "saturated hydrocarbon ring" may be a monocyclic to tricyclic saturated hydrocarbon ring. Examples include 3- to 10-membered saturated hydrocarbon rings. As another embodiment, 3- to 7-membered saturated hydrocarbon rings may be exemplified. Furthermore, as another embodiment, 5- or 6-membered saturated hydrocarbon rings may be exemplified. The saturated hydrocarbon ring may have a bridge bond, and may also be condensed with the above-mentioned aromatic ring. Specifically, examples include cyclopropane, cyclobutane, cyclopentane, cyclohexane, or adamantane.

[0162] As a "saturated heterocycle", it is sufficient that it is a monocyclic to tricyclic saturated heterocycle containing 1 to 4 heteroatoms as ring atoms. As heteroatoms, O, S or N can be exemplified. 3 to 10-membered saturated heterocycles can be exemplified. As another embodiment, 3 to 7-membered saturated heterocycles can be exemplified. Furthermore, as another embodiment, 5 or 6-membered saturated heterocycles can be exemplified. The saturated heterocycle may have a bridge bond and may also be condensed with the above-mentioned aromatic ring. Specifically, tetrahydropyran, tetrahydrofuran, piperidine, pyrrolidine, azetidine, oxetane, aziridine, ethylene oxide, tetrahydrothiopyran, tetrahydrothiophene, morpholine, oxazepane or piperazine can be exemplified.

[0163] As a "fused ring", there can be exemplified a cyclic compound in which two or more rings share two or more atoms and are bonded, and the two or more rings are each independently a 3-7 membered saturated ring. The fused ring may have 1 to 3 heteroatoms selected from O, S and N. As a fused ring, there can be exemplified a cyclic compound in which two rings share two adjacent atoms.

[0164] As a "spiro ring", a cyclic compound in which two rings contain a common carbon atom and the two rings are each independently a 3- to 7-membered saturated ring can be exemplified. The spiro ring may have 1 to 3 heteroatoms selected from O, S and N. When the number of atoms constituting the spiro ring is 7 to 11, the spiro ring is sometimes referred to as a 7- to 11-membered spiro ring. As a spiro ring, a 7- to 13-membered spiro ring can be exemplified. As another embodiment, a 7- to 11-membered spiro ring can be exemplified. Furthermore, as another embodiment, a 7- to 9-membered spiro ring can be exemplified.

[0165] As a "saturated cyclic group", a monovalent group obtained by removing any one hydrogen atom from a saturated ring, or a divalent group obtained by removing one hydrogen atom from two different ring-forming atoms in a saturated ring, can be cited. Saturated hydrocarbon ring groups or saturated heterocyclic groups can be exemplified. 3-10-membered saturated cyclic groups can be exemplified. As another embodiment, 3-7-membered saturated cyclic groups can be exemplified. Furthermore, as another embodiment, 5-membered or 6-membered saturated cyclic groups can be exemplified.

[0166] As a "saturated hydrocarbon ring group", a monovalent group obtained by removing any one hydrogen atom from a saturated hydrocarbon ring, or a divalent group obtained by removing one hydrogen atom from two different ring-forming atoms in a saturated hydrocarbon ring can be cited. It is sufficient as a monocyclic to tricyclic saturated hydrocarbon ring group. The saturated hydrocarbon ring group may have a bridge bond and may also be condensed with the above-mentioned aromatic ring. A 3- to 10-membered saturated hydrocarbon ring group can be exemplified. As another embodiment, a 3- to 7-membered saturated hydrocarbon ring group can be exemplified. Furthermore, as another embodiment, a 5- or 6-membered saturated hydrocarbon ring group can be exemplified. As a monovalent group, specifically, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group or an adamantyl group can be exemplified. As a divalent group, specifically, a divalent group obtained by further removing a hydrogen atom from a ring-forming atom other than the ring-forming atom from which a hydrogen atom is removed in the specific examples of the above-mentioned monovalent groups can be cited.

[0167] As a "saturated heterocyclic group", a monovalent group obtained by removing any one hydrogen atom from a saturated heterocyclic ring, or a divalent group obtained by removing one hydrogen atom from two different ring-forming atoms in a saturated heterocyclic ring can be cited. It is sufficient as a monocyclic to tricyclic saturated heterocyclic group containing 1 to 4 heteroatoms as ring-forming atoms. The saturated heterocyclic group may have a bridge bond and may also be condensed with the above-mentioned aromatic ring. As heteroatoms, O, S or N can be exemplified. A 3- to 10-membered heterocyclic group can be exemplified. As another embodiment, a 3- to 7-membered saturated heterocyclic group can be exemplified. Furthermore, as another embodiment, a 5- or 6-membered saturated heterocyclic group can be exemplified. As a monovalent group, specifically, tetrahydropyranyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl, azetidinyl, oxetanyl, tetrahydrothiopyranyl, tetrahydrothienyl, morpholinyl or piperazinyl can be exemplified.

[0168] The "partially unsaturated cyclic group" may be a ring in which a part of a saturated cyclic group is unsaturated, and examples thereof include partially unsaturated hydrocarbon cyclic groups (partially unsaturated hydrocarbon cyclic groups) or partially unsaturated heterocyclic groups (partially unsaturated heterocyclic groups). Examples thereof include 3-10 membered partially unsaturated cyclic groups. As another embodiment, 3-7 membered partially unsaturated cyclic groups may be exemplified. Furthermore, as another embodiment, 5-membered or 6-membered partially unsaturated cyclic groups may be exemplified.

[0169] The "partially unsaturated hydrocarbon ring group" may be a group in which a part of a saturated hydrocarbon ring group is unsaturated. Specific examples thereof include a cyclopentenyl group, a cyclopentadienyl group, a cyclohexenyl group, a cyclohexadienyl group, and a bicyclooctatrienyl group.

[0170] The "partially unsaturated heterocyclic group" may be a group in which a part of a saturated heterocyclic group is unsaturated. Specific examples thereof include dihydropyranyl, dihydrofuranyl, dihydrothiopyranyl, dihydrothiophenyl, 1,2-dihydroquinolinyl, and 1,2,3,4-tetrahydroquinolinyl.

[0171] In the present invention, as long as there is no special explanation, isomers are all included in the present invention. For example, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylene, alkenylene and alkynylene include straight-chain groups and branched groups. In addition, isomers based on double bonds, rings or condensed rings (E or Z isomers, or cis or trans isomers), isomers based on the presence of asymmetric carbon atoms, etc. (R- or S-isomers, isomers based on α- or β-configuration, mirror image isomers or diastereomers, etc.), optically active bodies with optical activity (D- or L-body, or d- or l-body), isomers based on polarity differences due to chromatographic separation (high polar body or low polar body), equilibrium compounds, rotational isomers, or mixtures or racemic mixtures of any proportion thereof are all included in the present invention.

[0172] In this specification, unless otherwise stated, the symbols are as clear to those skilled in the art:

[0173] [Chemistry 16]

[0174]

[0175] Indicates bonding to the back side of the paper plane (i.e., α-configuration), symbol:

[0176] [Chemistry 17]

[0177]

[0178] Indicates bonding to the front side of the paper plane (i.e. β-configuration), symbol:

[0179] [Chemistry 18]

[0180]

[0181] It represents either α-configuration or β-configuration or a mixture thereof.

[0182] The compound represented by formula (1) or a salt thereof will be described in detail below.

[0183] [Chemistry 19]

[0184]

[0185] In this specification, unless otherwise stated, "having or not having a substituent" means having no substitution or having 1 to 5 substituents which may be the same or different. In another embodiment, it means having no substitution or having 1 to 3 substituents which may be the same or different. In another embodiment, it means having no substitution or having 1 substituent. In another embodiment, it means having no substitution.

[0186] As R 1 , which can be exemplified by -H, C1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, -C(O)R 12 、-S(O2)R 12 、-C(O)NR 11 R 12 、-C(O)OR 12 or a 3- to 7-membered saturated ring group. 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 An alkyl group or a 3- to 7-membered saturated ring group. Furthermore, as another embodiment, -H, C 1-6 An alkyl group or a 3- to 7-membered saturated ring group. In another embodiment, -H, a methyl group, and an ethyl group can be exemplified. In another embodiment, a methyl group can be exemplified.

[0187] The above R 1 Can be substituted with a selected from G 1 1 to 3 identical or different substituents in the group.

[0188] As the above G 1 The group can be exemplified by -F, hydroxyl, cyano, halogenated C 1-6 Alkyl, C 1-4 The group consisting of an alkoxy group, a phenyl group, a 5- to 6-membered heteroaryl group, and a 3- to 7-membered saturated ring group. 1-6 Alkyl, C 1-4 G composed of alkoxy and 3-7 membered saturated ring 11 Furthermore, as another embodiment, -F, hydroxyl, C 1-4 G composed of alkoxy and 3-7 membered saturated ring 12 Group.

[0189] The above G 1 The phenyl or 5- to 6-membered heteroaryl group in the group may be substituted with a Ar 1 to 3 identical or different substituents in the group.

[0190] As the above G Ar The group can be exemplified by -F, -Cl, hydroxyl, cyano, C 1-6 Alkyl, halogenated C 1-6 As another embodiment, there can be exemplified a group consisting of -F, -Cl, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl composition GAr1 Group.

[0191] As the above R 11 , which can be exemplified by -H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, halogenated C 1-6 Alkoxy C 1-6 An alkyl group or a 3- to 7-membered saturated ring group. 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl or 3-7 membered saturated ring group.

[0192] As the above R 12 , which can be exemplified by C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, halogenated C 1-6 Alkoxy C 1-6 An alkyl group, a 3- to 7-membered saturated ring group, a phenyl group, or a 5- to 6-membered heteroaryl group. 1-6 An alkyl group, a 3- to 7-membered saturated ring group, a phenyl group, or a 5- to 6-membered heteroaryl group. 1-6 Alkyl, 3- to 7-membered saturated ring group.

[0193] The above R 12 The phenyl or 5- to 6-membered heteroaryl group in the Ar 1 to 3 identical or different substituents in the group.

[0194] As the above G Ar Group, except for the above G Ar In addition to the above-mentioned G Ar1 Group method.

[0195] As R 2 , which can be exemplified by -H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 An alkyl group or a 3- to 7-membered saturated ring group. 1-6 An alkyl group or a 3- to 7-membered saturated ring group. Furthermore, as another embodiment, -H, C 1-3 In another embodiment, -H or methyl can be exemplified. In another embodiment, -H can be exemplified.

[0196] As R3 , which can be exemplified by -H, C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 An alkyl group or a 3- to 7-membered saturated ring group. 1-6 An alkyl group or a 3- to 7-membered saturated ring group. Furthermore, as another embodiment, -H, C 1-3 In another embodiment, -H or methyl can be exemplified. In another embodiment, -H can be exemplified.

[0197] Ar can be exemplified by a 6- to 10-membered aryl group or a 5- to 10-membered heteroaryl group. In another embodiment, a phenyl group or a 5- to 6-membered heteroaryl group can be exemplified. Furthermore, in another embodiment, a 5- to 6-membered heteroaryl group can be exemplified.

[0198] Examples of the 6- to 10-membered aryl group in Ar include phenyl, naphthyl, and indanyl. In another embodiment, phenyl is exemplified.

[0199] In addition, examples of the 5- to 10-membered heteroaryl group in Ar include thienyl, furanyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyridonyl, pyrimidonyl, indolyl, isoindolyl, indazolyl, quinolyl, isoquinolyl, benzimidazolyl, benzotriazolyl, benzothienyl, benzofuranyl, benzothiazolyl, phthalazinyl, quinoxalinyl, or pyrrolopyridinyl. In another embodiment, examples include thienyl, furanyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyridonyl, or pyrimidonyl. Furthermore, as another embodiment, thiophenyl, thiazolyl, isothiazolyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrimidyl or pyrazinyl can be exemplified. Furthermore, as another embodiment, thiophenyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyridyl or pyrimidyl can be exemplified. Furthermore, as another embodiment, thiozolyl, isothiazolyl, pyridyl or pyrimidyl can be exemplified. Furthermore, as another embodiment, thiozolyl or pyrimidyl can be exemplified. Furthermore, as another embodiment, pyrimidyl can be exemplified.

[0200] The above Ar may be substituted with a 2 1 to 3 identical or different substituents in the group.

[0201] As the above G 2 The group can be exemplified by -F, -Cl, hydroxyl, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl C1-6 Alkyl, R Ar1 -OC 1-3 Alkyl, R Ar1 -NR 13 -C 1-3 Alkyl, -NR 13 C(O)R 14 、-C(O)NR 13 R 14 、-C(O)NH2、-NR 13 S(O2)R 14 、-S(O2)NR 13 R 14 、-NH2、-S(O2)NH2、-NR 13 R 14 and -NHC(O)NHR 15 As another example, a group consisting of C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl or R Ar1 -OC 1-3 Alkyl composition G 21 Furthermore, as another example, it can be illustrated that C 1-6 Alkyl, hydroxyl C 1-6 Alkyl or R Ar1 -OC 1-3 Alkyl composition G 22 Furthermore, as another example, it can be illustrated that C 1-6 Alkyl, hydroxyl C 1-6 Alkyl or R Ar1 -OC 1-3 Alkyl composition G 22 Furthermore, as another embodiment, R Ar1 -OC 1-3 Furthermore, as another embodiment, R Ar1 -O-Methyl. Furthermore, as another embodiment, a methyl group can be exemplified.

[0202] As the above R Ar1 , which can be exemplified by -H, C 1-6 Alkyl, halogenated C 1-6 An alkyl group or a 3- to 7-membered saturated ring group. 1-6 An alkyl group or a 3- to 7-membered saturated ring group. Furthermore, as another embodiment, C 1-6As another embodiment, an n-propyl group can be exemplified. As another embodiment, a cyclobutyl group or a cyclopentyl group can be exemplified. As another embodiment, a cyclopentyl group can be exemplified. As another embodiment, a 3- to 7-membered saturated ring group can be exemplified. As the above 3- to 7-membered saturated ring group, C 3-7 Cycloalkyl or 3- to 7-membered saturated heterocyclic group. Examples of the 3- to 7-membered saturated heterocyclic group include oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydrothienyl, tetrahydropyranyl, piperidinyl, tetrahydrothiopyranyl, morpholinyl, and piperazinyl. In another embodiment, tetrahydrofuranyl can be exemplified.

[0203] The above R Ar1 Can be substituted with a selected from G 3 1 to 3 identical or different substituents in the group.

[0204] As the above G 3 The group can be exemplified by -F, hydroxyl, C 1-3 Alkyl, halogenated C 1-3 Alkyl, oxy, C 1-3 Alkoxy, halogenated C 1-3 As another embodiment, G consisting of -F, a hydroxyl group and a 3- to 7-membered saturated ring group can be exemplified. 31 Furthermore, as another embodiment, -F, hydroxyl, C 1-3 Alkyl, halogenated C 1-3 Alkyl, oxy, C 1-3 G composed of alkoxy and 3-7 membered saturated ring 32 Furthermore, as another embodiment, -F, hydroxyl group or C 3-7 Cycloalkyl group G 33 Furthermore, as another embodiment, G consisting of -F, hydroxyl or cyclopropyl can be exemplified. 34 Group.

[0205] As the above R 13 , which can be exemplified by -H, C 1-3 Alkyl, halogenated C 1-3 Alkyl, C 1-3 Alkoxy C 1-3 Alkyl, halogenated C 1-3 Alkoxy C 1-3 An alkyl group or a 3- to 7-membered saturated ring group. 1-3 Alkyl, halogenated C 1-3 Alkyl, C 1-3 Alkoxy C 1-3 Alkyl or halogenated C 1-3 Furthermore, as another embodiment, a 3- to 7-membered saturated ring group can be exemplified.

[0206] As the above R 14 , which can be exemplified by C 1-3 Alkyl, halogenated C 1-3 Alkyl, C 1-3 Alkoxy C 1-3 Alkyl, halogenated C 1-3 Alkoxy C 1-3 An alkyl group or a 3- to 7-membered saturated ring group. 1-3 Alkyl, halogenated C 1-3 Alkyl, C 1-3 Alkoxy C 1-3 Alkyl or halogenated C 1-3 Furthermore, as another embodiment, a 3- to 7-membered saturated ring group can be exemplified.

[0207] As the above R 13 and R 14 The 3- to 7-membered saturated ring group in 3-7 Cycloalkyl or 3- to 7-membered saturated heterocyclic group. In another embodiment, cyclopropyl, cyclobutyl or oxetanyl can be exemplified.

[0208] As the above R 15 , -H, phenyl or 5- to 6-membered heteroaryl can be exemplified. Examples of the 5- to 6-membered heteroaryl include thienyl, furyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrimidyl, pyrazinyl or pyridazinyl. 13 In another embodiment, phenyl or trifluoromethylphenyl can be exemplified.

[0209] The above R 15 Can be substituted with a selected from G 4 1 to 3 identical or different substituents in the group.

[0210] As the above G 4 The group can be exemplified by halogen, cyano, C 1-3 Alkyl and halogenated C 1-3 As another embodiment, G composed of -F, cyano, methyl and trifluoromethyl can be exemplified. 41 Group.

[0211] As another embodiment of the above Ar, formula (3-1) can be illustrated.

[0212] [Chemistry 20]

[0213]

[0214] As R Ar2 , -H, -F, -Cl, hydroxyl, cyano, C 1-6 Alkyl, halogenated C1-6 Alkyl, hydroxyl C 1-6 Alkyl, R Ar1 -OC 1-3 Alkyl or -NR 13 R 14 (R Ar1 , R 13 and R 14 As another embodiment, R Ar1 -OC 1-3 Furthermore, as another embodiment, -CH2-OR Ar1 (R Ar1 The same meaning as above). Furthermore, as another embodiment, a methyl group or a hydroxymethyl group can be exemplified. Furthermore, as another embodiment, a methyl group can be exemplified. Furthermore, as another embodiment, a hydroxymethyl group can be exemplified.

[0215] As the above R Ar1 -OC 1-3 Specific examples of the alkyl group include the following groups.

[0216] [Chemistry 21]

[0217]

[0218] In addition, as the above R Ar1 -OC 1-3 Specific examples of another embodiment of the alkyl group include the following groups.

[0219] [Chemistry 22]

[0220]

[0221] As X 1 , N or CH can be exemplified. As another embodiment, N can be exemplified. Furthermore, as another embodiment, CH can be exemplified.

[0222] As X 2 , NH or O can be exemplified. As another embodiment, NH can be exemplified.

[0223] As X 3 , the following general formulae (1-1) to (1-3) can be exemplified (a and b represent bonding directions).

[0224] [Chemistry 23]

[0225]

[0226] As another embodiment, the above-mentioned general formula (1-1) can be exemplified. Furthermore, as another embodiment, the following general formula (1-1-1) can be exemplified.

[0227] [Chemistry 24]

[0228]

[0229] As R 21 and R 22 , can each independently illustrate -H, C 1-3 Alkyl, halogenated C 1-3 As another embodiment, -H and methyl can be exemplified. Furthermore, as another embodiment, -H can be exemplified.

[0230] As X 4 , the following general formula (2-1) can be illustrated (b, c represent bonding directions).

[0231] [Chemistry 25]

[0232]

[0233] As n, an integer of 1 to 3 can be exemplified. As another embodiment, an integer of 1 can be exemplified.

[0234] As Y, NR 51 Or O. As another embodiment, NR 51 Furthermore, as another embodiment, O can be exemplified.

[0235] As R 31 and R 32 , each independently exemplifies -H, C 1-3 Alkyl, halogenated C 1-3 As another embodiment, -H and methyl can be exemplified. Furthermore, as another embodiment, -H can be exemplified.

[0236] The above R 31 and R 32 They may also form a 3- to 6-membered saturated ring together. Examples of the 3- to 6-membered saturated ring include cyclopropyl, cyclobutyl, oxetanyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, and tetrahydropyranyl. In another embodiment, cyclopropyl, cyclobutyl, and oxetanyl may be exemplified. Furthermore, in another embodiment, cyclopropyl and cyclobutyl may be exemplified.

[0237] As R 41 and R 42 , each independently exemplified by -H, -F, hydroxyl, C 1-3 Alkyl, halogenated C 1-3 Alkyl, C 1-3 Alkoxy, halogenated C 1-3 As another embodiment, -H, -F, C 1-3 Alkyl, halogenated C 1-3 Alkyl, C1-3 Alkoxy, halogenated C 1-3 Furthermore, as another embodiment, -H, -F, C 1-3 Alkyl. In another embodiment, -H, -F, and methyl can be exemplified. In another embodiment, -H and -F can be exemplified.

[0238] The above R 41 With R 42 They may also form a 3- to 6-membered saturated ring together. Examples of the 3- to 6-membered saturated ring include cyclopropyl, cyclobutyl, oxetanyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, and tetrahydropyranyl. In another embodiment, cyclopropyl, cyclobutyl, and oxetanyl may be exemplified. Furthermore, in another embodiment, cyclopropyl and cyclobutyl may be exemplified. Furthermore, in another embodiment, cyclopropyl may be exemplified.

[0239] As the above R 51 , which can be exemplified by -H, C 1-3 Alkyl, halogenated C 1-3 Alkyl. As another embodiment, -H and methyl can be exemplified. Furthermore, as another embodiment, -H can be exemplified.

[0240] The above R 51 With the above R 31 They may form a 4- to 6-membered saturated ring together. Examples of the 4- to 6-membered saturated ring include azetidinyl, pyrrolidinyl, and piperazinyl. Furthermore, as another embodiment, pyrrolidinyl can be exemplified.

[0241] As the above X 4 , can be substituted with a selected from G 5 1 to 3 identical or different substituents in the group.

[0242] As the above G 5 The group can be exemplified by -F, hydroxyl, C 1-3 Alkyl, halogenated C 1-3 Alkyl, C 1-3 Alkoxy, halogenated C 1-3 As another embodiment, there can be exemplified a group consisting of -F, hydroxyl, C 1-3 Alkyl composition G 51 Furthermore, as another embodiment, G consisting of -F and hydroxyl groups can be exemplified. 52 Group.

[0243] As the above X 4 Specifically, for example, the following groups can be exemplified.

[0244] [Chemistry 26]

[0245]

[0246] In addition, as the above X 4 In another embodiment of , specifically, for example, the following groups can be exemplified.

[0247] [Chemistry 27]

[0248]

[0249] As specific compounds included in the present invention, the following compounds can be exemplified, but the scope of the present invention is not limited to these.

[0250] [Table 1]

[0251]

[0252] In the present specification, the "compound represented by formula (1)" is generally understood to be a free compound represented by formula (1). In addition, examples of salts of the compound include the following salts.

[0253] That is, as the salt of the compound represented by formula (1), its type is not particularly limited, and it can be any one of acid addition salt or base addition salt, or it can take the form of intramolecular counterion. In particular, when it is used as the active ingredient of a drug, as the salt, a pharmaceutically acceptable salt is preferred. In this specification, when it is disclosed in connection with the use as a drug, as the salt of the compound represented by formula (1), it is generally understood to be a pharmaceutically acceptable salt. As an acid addition salt, for example, it includes an acid addition salt with an inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid or phosphoric acid, or an acid addition salt with an organic acid such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, citric acid, malic acid, tartaric acid, dibenzoyltartaric acid, mandelic acid, maleic acid, fumaric acid, aspartic acid or glutamic acid. Examples of base addition salts include base addition salts with inorganic bases such as sodium, potassium, magnesium, calcium, and aluminum, and base addition salts with organic bases such as methylamine, 2-aminoethanol, arginine, lysine, or ornithine. In particular, the types of salts are not limited to these, and those skilled in the art can of course select them appropriately.

[0254] The compound of the present invention includes a hydrate form. In addition, the compound of the present invention also includes an anhydrate form.

[0255] The compounds of the present invention include solvate forms. In addition, the compounds of the present invention also include ansolvate form.

[0256] The compound of the present invention includes a crystalline form. In addition, the compound of the present invention also includes an amorphous form.

[0257] The compounds of the present invention also include those labeled with various radioactive or non-radioactive isotopes.

[0258] More specifically, the compound of the present invention includes an anhydrate and ansolvate of the "compound represented by formula (1)", or a hydrate and / or solvate thereof, or further includes crystals thereof.

[0259] The compound of the present invention includes an anhydrate and ansolvate of the "salt of the compound represented by formula (1)", or a hydrate and / or solvate of the salt, or further includes crystals thereof.

[0260] The compounds of the present invention may also include pharmaceutically acceptable prodrugs of the "compound represented by formula (1)". Pharmaceutically acceptable prodrugs refer to compounds having a group that can be converted into an amino group, a hydroxyl group, a carboxyl group, etc. by solvent decomposition or under physiological conditions. For example, as a group that forms a prodrug for a hydroxyl group and an amino group, acyl groups and alkoxycarbonyl groups can be exemplified. In addition, as a group that forms a prodrug for a carboxyl group, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, amino, methylamino, ethylamino, dimethylamino or diethylamino can be exemplified.

[0261] For example, a prodrug-forming reagent such as a corresponding halide can be used to introduce a group that can suitably form a prodrug into any one or more groups selected from hydroxyl and amino groups in the compound of the present invention according to a conventional method, and then appropriately separated and purified according to a conventional method as needed to produce a prodrug. In addition, a prodrug-forming reagent such as a corresponding alcohol or amine can also be used to introduce a group that can suitably form a prodrug into a carboxyl group in the compound of the present invention according to a conventional method.

[0262] <Conventional manufacturing method>

[0263] The compound represented by formula (1) can be manufactured according to a known method, for example, the method shown below, according to the method shown in these methods or the embodiment. It should be noted that the compound as a raw material in each of the following manufacturing methods can be commercially available, or can be manufactured using a known method described in, for example, "Compendium of Organic Synthesis Methods, Vol. I-XII (Wiley-Interscience)".

[0264] Some intermediates can be used by introducing a protecting group or removing the protecting group by a known method, for example, the method described in “Peter GM Wuts, Greene's Protective Groups in Organic Chemistry, John Wiley & Sons, 2014”.

[0265] A mixture of stereoisomers can be separated by a known method, for example, the method described in "EL Eloel, SH Wilen, Stereochemistry of Organic compounds, John Wiley & Sons, 1994", a method in accordance therewith, or a method described in the Examples. Aggregates can also be separated by the above method.

[0266] The reaction for synthesizing the compound of the present invention is carried out in a selected appropriate solvent according to a known method. The appropriate solvent does not react substantially with the starting material, intermediate or product at the temperature (e.g., at a temperature ranging from the melting point to the boiling point of the solvent) at which the reaction is carried out. The reaction can be carried out in a single solvent or a mixed solvent. A solvent suitable for each reaction can be used.

[0267] The reaction can be followed by appropriate methods according to known methods. For example, the product can be detected by spectroscopic methods, such as 1 H or 13 The samples were tracked by nuclear magnetic resonance (NMR), infrared spectrophotometer (IR), mass spectrometer (MS), high performance liquid chromatography (HPLC), thin layer chromatography (TLC), etc.

[0268] The compounds of the present invention can be produced by methods other than the methods described in the present invention by appropriately applying the methods described in the present invention and common technical knowledge in the relevant technical field. The reaction schemes, examples, etc. are for illustration purposes and do not limit the scope of the present invention.

[0269] The abbreviations used in the following routes are generally based on the abbreviations used in the technical field. The chemical abbreviations used in this specification and examples are defined as follows: DMF = N, N-dimethylformamide, DMSO = dimethyl sulfoxide, THF = tetrahydrofuran, DME = 1,2-dimethoxyethane, TFA = trifluoroacetic acid, h = time, rt = room temperature, RT = holding time, LG = leaving group.

[0270] The compound of the present invention represented by formula (1) can be produced, for example, according to the following reaction scheme. In the following scheme, "STEP" means a step, and for example, "STEP1" means step 1.

[0271] The macrocyclic compound represented by formula (1) is composed of four parts, namely, a nitrogen-containing bicyclic heterocyclic core, a substituted piperidine, a linking group connecting the ac sites, and an aromatic ring directly connected to the nitrogen-containing bicyclic heterocyclic core.

[0272] Route 1 is the first method for synthesizing macrocyclic compounds. It is a method in which the linking group connecting the substituted piperidine to the ac site is first bonded, and then reacted with the nitrogen-containing bicyclic heterocyclic core to generate X 2 Bonding. Then forming X 3 The aromatic ring is directly linked to the nitrogen-containing bicyclic heterocyclic core.

[0273] [Chemistry 28]

[0274] Reaction Scheme 1

[0275]

[0276] The compound represented by formula (1) can be obtained by, for example, reaction scheme 1 (in the formula of each compound, M represents a substituent such as ZnI, MgBr, boric acid, boric ester, etc. that can react by various coupling reactions. In addition, LG 1 LG 2 For example, it represents a leaving group such as -Cl, -Br, -I, -OTf, -OMs or -OTs. 1 , Q 2 For example, it represents a hydroxyl group, or a leaving group such as -Cl, -Br, -I, -OTf, -OMs or -OTs, or a substituent that can form a CO bond or a CC bond such as an alkenyl group or a boron derivative, and Q 3 For example, hydroxyl groups, amino groups, etc. can be expressed by 2 The compounds represented by formula (2) to (6) are commercially available or can be produced by known methods, for example, the methods described below, or in accordance with these methods.

[0277] Step 1

[0278] Regarding the compound represented by formula (1), it can be manufactured by a coupling reaction using a metal catalyst in which the compound represented by formula (2) participates. More specifically, it can be manufactured by Suzuki-Miyaura coupling of the compound represented by formula (2) and the reagent represented by formula (6). As a reaction catalyst, for example, Pd(dppf)Cl2, PdAmphos, Pd(PPh3)4, etc. can be used. As a base, cesium carbonate, cesium fluoride, sodium carbonate, etc. can be used. As a reaction solvent, THF, 1,4-dioxane, DMF, acetonitrile, etc. can be used. Regarding the reaction temperature, it can usually be carried out at room temperature to 180°C.

[0279] The reagent represented by formula (6) can use commercially available boric acid, pinacol ester, catechol ester. In addition, commercially available aryl bromide, aryl chloride, aryl iodide compounds can be produced by coupling reaction using metal catalysts, halogen-metal exchange reaction. More specifically, it can be produced by Suzuki-Miyaura coupling with bis(pinacol)diboron, etc. As a reaction catalyst, for example, Pd(dppf)Cl2 can be used. As a base, potassium acetate can be used. As a reaction solvent, 1,4-dioxane can be used. Regarding the reaction temperature, it can usually be carried out at 40°C to 150°C. In addition, in addition to the above 2 methods, by using an iridium catalyst, an electron-donating bidentate ligand, a boron source such as bis(pinacol)diboron, the reagent shown in formula (6) can also be prepared by a CH activated borylation reaction without an aryl halide.

[0280] Step 2

[0281] The compound represented by formula (2) can be prepared from the compound represented by formula (3) by using alkylation, CO bond forming reaction such as Mitsunobu reaction, CC bond forming reaction such as metal coupling. In Mitsunobu reaction, Q in formula (3) 1 .Q 2 Prepare an OH group at the site, and add any of diethyl azodicarboxylate, diisopropyl azodicarboxylate, and di-tert-butyl azodicarboxylate in the presence of triphenylphosphine to react. As a reaction solvent, THF, toluene, etc. can be used. In order to make the intramolecular cyclization reaction take precedence over the intermolecular reaction, it is carried out under a high dilution condition of 0.1 mol / L to 0.001 mol / L. Regarding the reaction temperature, it can usually be carried out at room temperature to 80°C. In the alkylation reaction, at Q 1 Prepare hydroxyl groups at the Q 2 The leaving group such as -Cl, -Br, -I, -OTf, -OMs or -OTs is prepared at the site, and the reaction is carried out under high dilution conditions in the presence of a base such as sodium hydride, potassium carbonate, cesium carbonate, diisopropylethylamine, etc. As a reaction solvent, THF, DMF, acetonitrile, etc. can be used. Regarding the reaction temperature, it can usually be carried out at room temperature to 100°C.

[0282] Step 3

[0283] The compound represented by formula (3) is synthesized by an alkylation reaction or a metal coupling reaction of a substituted piperidine represented by formula (4) and a compound represented by formula (5). Specifically, the alkylation reaction can be carried out in the presence of a base such as sodium hydride, potassium carbonate, cesium carbonate, diisopropylethylamine, etc., using THF, DMF, acetonitrile, etc. as a reaction solvent, at room temperature to 100° C. to form a CO or CN bond.

[0284] As a metal coupling reaction, specifically, a mixture of [(2-di-tert-butylphosphino-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl)-2-(2'-amino-1,1'-biphenyl)] methanesulfonate palladium (II), tris(dibenzylideneacetone) dipalladium (0) and a ligand dicyclohexylphosphine-2',4',6'-triisopropyl-1,1'-biphenyl is added to the catalyst, and a phosphazene base P2-Et or sodium phenolate is used as the base. As a reaction solvent, THF, 1,4-dioxane, DMF, acetonitrile, etc. can be used. Regarding the reaction temperature, the reaction can usually be carried out at room temperature to 180°C. In addition, the compound represented by formula (3) can also be synthesized using a combination of reagents commonly used in the Buchwald-Hartwig cross-coupling reaction in the art, and a CO or CN bond can be formed.

[0285] [Chemistry 29]

[0286] Reaction Scheme 2

[0287]

[0288] The compound represented by formula (4) can be prepared by, for example, reaction scheme 2 (wherein Q 2 represents, for example, a hydroxyl group, or a leaving group such as -Cl, -Br, -I, -OTf, -OMs, or -OTs, or a substituent capable of forming a CO bond or a CC bond such as an alkenyl group or a boron derivative. 3 For example, hydroxyl and amino groups can interact with LG 2 The compounds represented by formula (6) and (7) are commercially available or can be produced by known methods, such as the following methods, or in accordance with the methods described above.

[0289] Step 4

[0290] The compound represented by formula (4) can be synthesized by reducing the ketone site of the compound represented by formula (6). As a reducing agent, sodium borohydride, lithium tri-sec-butylborohydride (L-Selectride), etc., which can only reduce the ketone site in the presence of esters and amides, can be used. Methanol, THF, etc. are used as solvents, and the reaction is usually carried out at -78°C to room temperature. In addition, in Q 3When the group is an amino group, the hydroxyl group generated by reduction is converted into a leaving group such as -Cl, -Br, -I, -OTf, -OMs or -OTs, then converted into an azido group, and finally converted into NH2. For example, in a dichloromethane solvent, for methanesulfonyl chloride, p-toluenesulfonyl chloride, etc., the secondary hydroxyl group can be converted into a leaving group in the presence of a base such as triethylamine. The reaction is usually carried out at 0°C-40°C. By reacting it with sodium azide in DMF, Q 3 The azido group can be reduced to a primary amine by a hydrogenation reaction using palladium-carbon or palladium hydroxide, or by a Staudinger reaction using triphenylphosphine.

[0291] Step 5

[0292] The compound represented by formula (6) is synthesized by an amidation reaction, an esterification reaction or an acylation reaction of a compound represented by formula (7). Specifically, a hydroxyl protected form of an amino alcohol having 2 to 5 carbon atoms or a monohydroxyl protected form of a diol having 2 to 5 carbon atoms is subjected to an amide bond or an ester bond with a 4-oxopiperidine-2-carboxylic acid derivative represented by formula (7). As a condensation agent for amidation or esterification, 1-propanephosphonic anhydride, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, HATU, etc. can be used. As a nucleophilic agent for amidation, HOBt, HOAt, etc. can be used. As a base, diisopropylethylamine, etc. can be used. As a reaction solvent, for example, DMF, dichloromethane, THF, etc. can be used. Regarding the reaction temperature, it can usually be carried out at 0°C to 150°C. In the acylation reaction, the carboxylic acid site of the 4-oxopiperidine-2-carboxylic acid derivative is activated using oxalyl chloride, isobutyl chloroformate, or the like, and a hydroxyl-protected form of an amino alcohol having 2 to 5 carbon atoms or a monohydroxyl-protected form of a diol having 2 to 5 carbon atoms is reacted therewith to form an amide bond or an ester bond.

[0293] Route 3 is a second method for synthesizing macrocyclic compounds. It is the following method: first, a nitrogen-containing bicyclic heterocyclic core is reacted with a substituted piperidine to form X 2 Then, similarly to Scheme 1, a large-membered ring is formed and an aromatic ring is introduced into the nitrogen-containing bicyclic heterocyclic core to obtain the final product.

[0294] In Schemes 1 and 3, the coupling reaction of the compound represented by formula (2) and the reagent represented by formula (6) using a metal catalyst (step 1) and the macrocyclic ring formation reaction using the compound represented by formula (3) as a starting material (step 2) are common.

[0295] [Chemistry 30]

[0296] Reaction Scheme 3

[0297]

[0298] The compound represented by formula (1) can be obtained by, for example, reaction scheme 3 (in the formula of each compound, M represents a substituent such as ZnI, MgBr, boric acid, boric ester, etc. that can react by various coupling reactions. In addition, LG 1 LG 2 For example, it represents a leaving group such as -Cl, -Br, -I, -OTf, -OMs or -OTs. 1 , Q 2 For example, it represents a hydroxyl group, or a leaving group such as -Cl, -Br, -I, -OTf, -OMs or -OTs, or a substituent that can form a CO bond or a CC bond such as an alkenyl group or a boron derivative, and Q 3 For example, hydroxyl and amino groups can be 2 The compounds represented by formula (2), (3), (5), (6), (8) and (9) can be obtained commercially or can be produced by known methods, such as the methods described below, or in accordance with these methods.

[0299] Step 6

[0300] The compound represented by formula (3) can be synthesized by amide bonding or ester bonding of a hydroxyl protected form of an amino alcohol having 2 to 5 carbon atoms or a monohydroxyl protected form of a diol having 2 to 5 carbon atoms with a carboxylic acid represented by formula (8). The reaction used is an amidation reaction, an esterification reaction, an acylation reaction, etc. As a condensation agent for amidation and esterification, 1-propanephosphonic anhydride, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, HATU, etc. can be used. As a nucleophilic agent for amidation, HOBt, HOAt, etc. can be used. As a base, diisopropylethylamine, etc. can be used. As a reaction solvent, for example, DMF, dichloromethane, THF, etc. can be used. Regarding the reaction temperature, it can usually be carried out at 0°C to 150°C. In the acylation reaction, oxalyl chloride, isobutyl chloroformate, etc. are used to activate the carboxylic acid site, and the hydroxyl protected form of an amino alcohol having 2 to 5 carbon atoms or the monohydroxyl protected form of a diol having 2 to 5 carbon atoms is reacted therewith, thereby forming an amide bond or an ester bond.

[0301] Step 7

[0302] The compound represented by formula (8) is synthesized by performing an alkylation reaction or metal coupling reaction of the substituted piperidine represented by formula (9) and the compound represented by formula (5), followed by solvent decomposition of the ester. The reaction conditions used in the alkylation reaction or metal coupling reaction are based on step 3 of route 1. In the hydrolysis of the ester, a base such as sodium hydroxide, potassium hydroxide, lithium hydroxide, etc. is used, and methanol, ethanol, etc. are used as a solvent, and the reaction is carried out at 40°C to 80°C. In order to prevent isomerization of the asymmetric point at the 2-position of piperidine, it is recommended to carry out the reaction at 40°C. The compound represented by formula (9) can be synthesized according to step 5 of route 1-2. That is, it is synthesized by using a 4-oxopiperidine-2-carboxylic acid derivative represented by formula (7) as a raw material, and by methyl esterification based on trimethylsilyldiazomethane or esterification using 1-propanephosphonic anhydride, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, HATU, etc. as a condensation agent.

[0303] Route 4 is the third method for synthesizing macrocyclic compounds. It is a method in which a substituted piperidine is first bonded to a linking group connecting to the ac site, and then reacted with a nitrogen-containing bicyclic heterocyclic core to form X 3 bond. Then form X 2 bonds, thereby forming a large ring, and finally introducing an aromatic ring directly linked to the nitrogen-containing bicyclic heterocyclic core.

[0304] [Chemistry 31]

[0305] Reaction Scheme 4

[0306]

[0307] The compound represented by formula (1) can be obtained by, for example, reaction scheme 4 (in the formula of each compound, M represents a substituent that can react by various coupling reactions, such as ZnI, MgBr, boric acid, or boric ester. In addition, LG 1 LG 2 For example, it represents a leaving group such as -Cl, -Br, -I, -OTf, -OMs or -OTs. 1 , Q 2 For example, it represents a hydroxyl group, or a leaving group such as -Cl, -Br, -I, -OTf, -OMs or -OTs, or a substituent that can form a CO bond or a CC bond such as an alkenyl group or a boron derivative, and Q 3 For example, hydroxyl and amino groups can be 2 The compounds represented by formula (2), (4) to (6) and (10) are commercially available or can be produced by known methods, such as the following methods, or in accordance with the methods described above.

[0308] Step 8

[0309] The compound represented by formula (11) can be synthesized, for example, by an intramolecular alkylation reaction or a metal coupling reaction of the compound represented by formula (10) according to the method of step 10 of route 3. In this case, in order to give priority to the intramolecular reaction over the intermolecular reaction, the compound represented by formula (11) can be synthesized by reacting under a high dilution condition such as a substrate concentration of 0.1 mol / L to 0.001 mol / L.

[0310] Step 9

[0311] The compound represented by formula (14) is synthesized by an intermolecular Mitsunobu reaction or an intermolecular alkylation reaction between the compound represented by formula (4) and the compound represented by formula (5). The reaction conditions are the same as those of step 2 of route 1, and the reaction can be carried out at a substrate concentration of, for example, 1.0 mol / L to 0.1 mol / L.

[0312] The method for producing the compound of the present invention is not limited to the method described herein. For example, the compound of the present invention can be produced by modifying / converting the substituent of the compound serving as a precursor thereof by combining one or more reactions described in common chemical literature.

[0313] Among the compounds of the present invention, as examples of methods for producing compounds containing asymmetric carbon atoms, there can be cited methods based on asymmetric reduction, methods using commercially available raw material compounds (or prepared by known methods or capable of being prepared according to known methods) whose parts corresponding to asymmetric carbon atoms have optical activity in advance, optical resolution using enzymes, or methods for producing optically active compounds, etc. In addition, there are methods for separating the compounds of the present invention or their precursors by conventional methods into optically active isomers. As such methods, there are, for example, the following methods: methods using high performance liquid chromatography (HPLC) or supercritical fluid chromatography (SFC) using optically active columns; classical optical fractional crystallization methods in which an optically active reagent and a salt are formed, separated by fractional crystallization, etc., and then the salt is formed; or methods in which the generated diastereomers are separated and purified by condensation with an optically active reagent and then decomposed again, etc. When the precursor is separated to form an optically active form, the production method shown above is then implemented to produce an optically active compound of the present invention.

[0314] In the compound of the present invention, when the compound contains an acidic functional group such as a carboxyl group, a phenolic hydroxyl group or a tetrazole ring, it can also be made into a pharmaceutically acceptable salt (for example, an inorganic salt with sodium or an organic salt with triethylamine) by known means. For example, in the case of obtaining an inorganic salt, the compound of the present invention is preferably dissolved in water containing a hydroxide, carbonate, bicarbonate, etc. corresponding to the desired inorganic salt. In the reaction, an inert organic solvent miscible with water such as methanol, ethanol, acetone or dioxane can be mixed. For example, a solution of a sodium salt can be obtained by using sodium hydroxide, sodium carbonate or sodium bicarbonate.

[0315] In addition, in the compound of the present invention, when containing an amino group contained in the compound, or when containing a basic functional group in addition thereto, or when containing an aromatic ring (such as a pyridine ring, etc.) having a basic property itself, they can be made into pharmaceutically acceptable salts (such as salts with inorganic acids such as hydrochloric acid or salts with organic acids such as acetic acid) by known means. For example, in the case of obtaining a salt with an inorganic acid, the compound of the present invention is preferably dissolved in an aqueous solution containing the desired inorganic acid. In the reaction, an inert organic solvent miscible with water such as methanol, ethanol, acetone or dioxane can be mixed. For example, a solution of a hydrochloride can be obtained by using hydrochloric acid.

[0316] When a solid salt is desired, the solution may be evaporated or a water-miscible organic solvent having a certain degree of polarity such as n-butanol or ethyl methyl ketone may be further added to obtain the solid salt.

[0317] The various compounds described in the present invention can be purified by known methods, for example, various chromatography methods (column chromatography, flash column chromatography, thin layer chromatography, high performance liquid chromatography, supercritical fluid chromatography).

[0318] A certain embodiment of the compound of the present invention has IRAK-4 inhibitory activity and can be used as an IRAK-4 inhibitor. That is, a certain embodiment of the compound of the present invention can be used as a drug for preventing and / or treating diseases associated with IRAK-4 inhibition. Regarding diseases associated with IRAK-4 inhibition, if described in detail, diseases associated with IRAK-4 inhibition are diseases that exert effects through IRAK-4 inhibition, and more specifically, there is no particular limitation as long as the disease can be prevented and / or treated by inhibiting the production of inflammatory mediators such as TNFα and IL-6 due to the inhibition of TLRs or IL-1 family signal transduction system.

[0319] The IRAK-4 inhibitory activity can be measured, for example, by the method described in Test Example 1 or 2 below.

[0320] Diseases associated with IRAK-4 inhibition are not particularly limited as long as they are diseases that exert their effects through IRAK-4 inhibition. Specifically, examples include acute or chronic inflammation, autoimmune diseases (rheumatic arthritis, systemic lupus erythematosus, lupus nephritis, etc.), autoinflammatory diseases (TNF receptor-associated periodic syndrome (TRAPS), familial Mediterranean fever, cryopyrin-associated periodic fever syndrome, high IgD syndrome, etc.), metabolic diseases (gout, etc.), etc.

[0321] As shown in the test examples described below, one embodiment of the compound of the present invention has a TLR / IL-1β signaling inhibitory effect and is useful as an active ingredient of a drug. In particular, one embodiment of the compound of the present invention is preferably used for the prevention and / or treatment of diseases associated with IRAK-4 signaling.

[0322] One embodiment of the compound of the present invention shows high selectivity for other kinases. Examples of other kinases include FLT3, ITK, CK2, IKKb, JAK1, Syk, PKCθ, or p38. In another embodiment, FLT3 is particularly exemplified.

[0323] One embodiment of the drug of the present invention is useful for the prevention and / or treatment of diseases related to IRAK-4 signaling, which can be confirmed by, for example, a cytokine production inhibition test using immune cells or a collagen-induced arthritis model. Specifically, the method described in Test Example 3 described below can be exemplified.

[0324] A certain aspect of the drug of the present invention can be prepared in the form of a drug containing the compound represented by formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient. For example, the case where a compound or a pharmaceutically acceptable salt thereof administered as a prodrug is metabolized in vivo to generate a compound represented by formula (1) or a pharmaceutically acceptable salt thereof is also included in the scope of the drug of the present invention.

[0325] The administration route of a certain aspect of the drug of the present invention is not particularly limited, and can be appropriately selected from, for example, oral administration, subcutaneous administration, intradermal administration, intramuscular injection, intravenous administration, transnasal administration, transvaginal administration, intrarectal administration, or topical administration to an affected area.

[0326] As the drug of the present invention, the compound represented by formula (1) or its pharmaceutically acceptable salt can be used directly, but it is preferred to add one or two or more pharmaceutically acceptable carriers to the compound represented by formula (1) or its pharmaceutically acceptable salt to prepare a pharmaceutical composition for administration. In addition, as the active ingredient of the drug of the present invention, a hydrate or solvate of the compound represented by formula (1) or its pharmaceutically acceptable salt can be used.

[0327] As the dosage form used for the preparation of the above-mentioned pharmaceutical composition, tablets, powders, granules, syrups, suspensions, capsules, inhalants or injections can be cited. In order to manufacture these dosage forms, various carriers corresponding to these preparations are used. For example, as a carrier for oral agents, excipients, adhesives, lubricants, fluidity promoters or colorants can be cited. As inhalants, powders of the pharmaceutical composition can be directly inhaled or reagents formed by dissolving or suspending the pharmaceutical composition in a solvent can be cited, or methods for inhaling the powders can be made into mist using a sprayer called an atomizer or a spray inhaler. In addition, in the case of injections, distilled water for injection, saline, glucose aqueous solution, vegetable oil for injection, propylene glycol or polyethylene glycol can usually be used as diluents. Further, bactericides, preservatives, stabilizers, isotonic agents or painless agents can be added as needed. The compound of the present invention can also be enclosed in cyclodextrin to form an inclusion compound and used as the drug of the present invention.

[0328] When a certain mode of administering the medicine of the present invention is used, it is appropriate to select a suitable dosage form and administer it by a suitable route. For example, it can be orally administered in the form of tablets, powders, granules, syrups, suspensions or capsules. In addition, it can be administered through the trachea in the form of an inhalant. In addition, it can be administered subcutaneously, intradermally, intravascularly, intramuscularly or intraperitoneally in the form of an injection including drip. In addition, it can be administered through the mucosa in the form of a sublingual agent or a suppository, and can be administered transdermally in the form of a gel, a lotion, an ointment, a cream or a spray. In addition, it can also be made into a continuous preparation, such as a sustained-release injection or an implant preparation (such as a film preparation) for administration.

[0329] The administration period of a certain mode of the medicine of the present invention is not particularly limited, and the principle is to administer the medicine during the period when it is judged that the disease shows clinical symptoms, usually for several weeks to one year. However, the administration period can be further extended according to the condition of the disease, or the administration can be further continued after the clinical symptoms recover. In addition, even in the state where clinical symptoms are not shown, preventive administration can be carried out according to the judgment of the clinician. The dosage of a certain mode of the medicine of the present invention is not particularly limited, for example, when the medicine of the present invention is orally administered, an adult can usually be given 0.01 to 1000 mg of the active ingredient once. The frequency of administration in this case can be once every 6 months to continuous administration, preferably once / day.

[0330] The daily and / or single dosage, dosage period, and dosage frequency can be appropriately increased or decreased depending on the patient's age, weight, physical health, and the type and severity of the disease to be treated, the route of administration, the dosage form (the sustained release of the active ingredient possessed by the carrier, etc.), and other conditions.

[0331] When a certain mode of medicine of the present invention is used for the prevention and / or treatment of the above-mentioned disease, a certain mode of medicine of the present invention can be used simultaneously with 1 or 2 or more medicaments selected from the medicament shown below or used together at different times. In addition, a certain mode of medicine of the present invention can also be prepared into so-called compound preparation together with the medicament illustrated above and be administered. As this compound preparation, not only can the form of administration with the form of complete mixture of active ingredients as typical compositions, but also comprise the administration form, test kit, packaging based on non-mixed type combination that is administered respectively from a plurality of containers equipped with each active ingredient.

[0332] Examples of drugs that can be used in combination with a certain embodiment of the drug of the present invention include immunosuppressants (tacrolimus, cyclosporin, rapamycin, mycophenolic acid mofetil, interferon preparations, cyclophosphamide, azathioprine, methotrexate, etc.), anti-inflammatory drugs (steroids (prednisolone, dexamethasone, betamethasone, cortisone), non-steroidal anti-inflammatory drugs (NSAIDs) (ibuprofen, celecoxib), disease-modifying antirheumatic drugs (gold preparations, methotrexate, leflunomide, sulfasalazine, penicillamine, iguratimod, chloroquine, tofacitinib, etc.), antimalarials (hydroxychloroquine, etc.), Multiple sclerosis therapeutic drugs (interferon, anti-α4 integrin preparations, fingolimod, mitoxantrone, etc.), anti-cytokine preparations (anti-TNFα preparations, anti-IL-6 preparations, anti-IL-12 / 23 preparations, etc.). In addition, biological drugs used as therapeutic drugs for autoimmune diseases (anti-CD20 preparations, CTLA-4-Ig, etc.), drugs for abnormal uric acid metabolism (colchicine, probenecid, bucolome, benzbromarone, allopurinol, etc.), hypoglycemic drugs (alogliptin, nateglinide, acarbose, methotrexate, etc.), guanidine, pioglitazone, insulin preparations, etc.), antihypertensive drugs (imidapril, valsartan, candesartan, etc.), bile secretion promoting drugs (ursodeoxycholic acid), bronchodilators (salmeterol and salbutamol as adrenergic β2 agonists, ipratropium and tiotropium bromide as anticholinergics, etc.), allergic disease therapeutic drugs (theophylline, etc.), antiallergic drugs (fexofenadine, epinastine, olopatadine, loratadine, cetirizine, bepotastine, ketotifen, sodium cromoglycate, pemirolast, chlorpheniramine, etc.), leukotriene antagonists (zafirlukast, montelukast, pranlukast, etc.), anti Hyperlipidemia drugs (atorvastatin, simvastatin, clinofibrate, bezafibrate, probucol, elastase, icosapentaenoic acid ethyl ester, etc.), neurotransmitter regulators (donepezil, galantamine, memantine, etc.), antioxidants (vitamin E, acetylcysteine, carnitine, betaine, pentoxifylline, etc.), antibiotics (various preparations such as β-lactam, macrolide, tetracycline, aminoglycoside, quinolone, chloramphenicol, etc.). In addition, it can be used in combination with various drugs to be created in the future. There is no limitation on these combined drugs as long as they are clinically significant combinations.

[0333] One embodiment of the compound of the present invention includes a compound having excellent safety (various toxicities, safety pharmacology) and pharmacokinetic properties, and its usefulness as an active ingredient of a drug can be confirmed by, for example, the method described below.

[0334] As safety-related tests, for example, the following tests are included, but not limited to the examples, including: cytotoxicity tests (tests using HL60 cells, hepatocytes, etc.), genotoxicity tests (Ames test, mouse lymphoma TK test, chromosome aberration test, micronucleus test, etc.), skin sensitization tests (Bueler method, GPMT method, APT method, LLNA test, etc.), skin photosensitivity tests (adjuvant and strip method, etc.), eye irritation tests (single eye drop, short-term continuous eye drop, repeated eye drop, etc.), safety pharmacology tests for the cardiovascular system (telemetry method, APD method, hERG inhibition evaluation method, etc.), safety pharmacology tests for the central nervous system (FOB method, Irwin's modified method, etc.), safety pharmacology tests for the respiratory system (measurement method using a respiratory function measurement device, measurement method using a blood gas analyzer, etc.), general toxicity tests, reproductive developmental toxicity tests, etc.

[0335] In addition, as tests related to pharmacokinetic performance, for example, the tests listed below are included, but not limited to the examples, including cytochrome P450 enzyme blocking or induction tests, cell permeability tests (tests using CaCO-2 cells, MDCK cells, etc.), drug transporter ATPase assay, oral absorption test, blood drug concentration transition measurement test, metabolic test (stability test, metabolic molecule species test, reactivity test, etc.), solubility test (solubility test based on turbidity method, etc.), etc.

[0336] The usefulness of a certain aspect of the compound of the present invention as an active ingredient of a drug can be confirmed by, for example, performing a cytotoxicity test. As a cytotoxicity test, methods using various cultured cells (e.g., human preleukemia cells HL-60 cells, primary isolated cultured cells of liver cells, neutrophil fractions prepared from human peripheral blood, etc.) can be cited. This test can be implemented by the method described below, but is not limited to this description. Prepare the cells into 10 5 / ml to 10 7 / ml of cell suspension, 0.01mL to 1mL of the suspension is dispensed into a microtube or microplate. A solution in which the compound is dissolved is added in an amount of 1 / 100 to 1 times the amount of the cell suspension, and cultured in a cell culture medium at a final concentration of the compound, such as 0.001μM to 1000μM, at 37°C and 5% CO2 for 30 minutes to several days. After the culture is completed, the cell survival rate is evaluated using the MTT method or the WST-I method (Ishiyama, M., et al., In Vitro Toxicology, 8, p.187, 1995). By measuring the cytotoxicity of the compound to cells, the usefulness of the active ingredient as a drug can be confirmed.

[0337] A certain aspect of the compound of the present invention is useful as an active ingredient of a drug, which can be confirmed by, for example, performing a genotoxicity test. As genotoxicity tests, Ames test, mouse lymphoma TK test, chromosome aberration test, micronucleus test, etc. can be cited. Ames test refers to the following method: using a specified strain of Salmonella, Escherichia coli, etc., to culture the bacteria on a petri dish mixed with a compound, thereby determining the reverse mutation (refer to II-1. Genotoxicity test in "Genetic Toxicity Test Guidelines" No. 1604 of the Japanese Pharmaceutical Review in 1999, etc.). In addition, the mouse lymphoma TK test refers to a test for detecting gene mutations using the thymidine kinase gene of mouse lymphoma L5178Y cells as a target (refer to II-3. Mouse lymphoma TK test in the 1999 Japanese Pharmaceutical Review No. 1604 "Guidelines for Genotoxicity Tests"; Clive, D. et al., Mutat. Res., 31, pp. 17-29, 1975; Cole, J., et al., Mutat. Res., 111, pp. 371-386, 1983, etc.). In addition, the chromosome aberration test refers to a method in which mammalian cultured cells are co-cultured with a compound, the cells are fixed, and the activity of causing chromosome aberrations is determined by staining and observing chromosomes (refer to II-2. Chromosome aberration test using mammalian cultured cells in the 1999 Japanese Pharmaceutical Review No. 1604 "Guidelines for Genotoxicity Tests", etc.). Furthermore, the micronucleus test is a test for evaluating the micronucleus formation ability caused by chromosomal aberrations, including methods using rodents (in vivo tests) (refer to II-4. Micronucleus test using rodents in the "Guidelines for Genotoxicity Tests" of Japan Pharmaceutical Review No. 1604 in 1999; Hayashi, M. et al., Mutat. Res., 312, pp. 293-304, 1994; Hayashi, M. et al., Environ. Mol. Mutagen., 35, pp. 234-252, 2000), methods using cultured cells (in vitro tests) (Fenech, M. et al., Mutat. Res., 147, pp. 29-36, 1985; Miller, B., et al., Mutat. Res., 392, pp. 45-59, 1997), etc. By clarifying the genotoxicity of a compound using any one or two or more of these methods, its usefulness as an active ingredient of a drug can be confirmed.

[0338] The usefulness of a certain embodiment of the compound of the present invention as an active ingredient of a drug can be confirmed by, for example, performing a skin sensitization test. Among the skin sensitization tests, as skin sensitization tests using guinea pigs, there are Buehler's method (Buehler, EV Arch. Dermatol., 91, pp. 171-177, 1965), GPMT method (maximum method (Magnusson, B. et al., J. Invest. Dermatol., 52, pp. 268-276, 1969)) or APT method (adjuvant and patch method (Sato, Y. et al., Contact Dermatitis, 7, pp. 225-237, 1981)). Furthermore, as a skin sensitization test using mice, there is the LLNA (Local Lymph node assay) method (OECD Guideline for the testing of chemicals 429, skin sensitization 2002; Takeyoshi, M. et al., Toxicol. Lett., 119 (3), pp. 203-8, 2001; Takeyoshi, M. et al., J. Appl. Toxicol., 25 (2), pp. 129-34, 2005), etc. By clarifying the skin sensitization of a compound using any one or two or more of these methods, the usefulness of the compound as an active ingredient of a drug can be confirmed.

[0339] The fact that a certain embodiment of the compound of the present invention is useful as an active ingredient of a medicine can be confirmed by conducting, for example, a skin photosensitivity test. Examples of the skin photosensitivity test include a skin photosensitivity test using a guinea pig (see "Explanation of the Guidelines for Non-clinical Trials of Pharmaceuticals 2002" Japan Yakuji Shimbun, 2002, 1-9: Skin photosensitivity test, etc.), and examples of the method include an adjuvant and keratostripping method (Ichikawa, H. et al., J. Invest. Dermatol., 76, pp. 498-501, 1981), a Harber method (Harber, LC, Arch. Dermatol., 96, pp. 646-653, 1967), a Horio method (Horio, T., J. Invest. Dermatol., 67, pp. 591-593, 1976), a Jordan method (Jordan, WP, Contact Dermatitis, 8, pp. 109-116, 1982), a Kochever method (Kochever, IE et al., J. Invest. Dermatol., 96, pp. 646-653, 1967), a al., J. Invest. Dermatol., 73, pp. 144-146, 1979), Maurer method (Maurer, T. et al., Br. J. Dermatol., 63, pp. 593-605, 1980), Morikawa method (Morikawa, F. et al., "Sunlight and man", Tokyo Univ. Press, Tokyo, pp. 529-557, 1974), Vinson method (Vinson, LJ, J. Soc. Cosm. Chem., 17, pp. 123-130, 1966), etc. By clarifying the skin photosensitivity of a compound using any one or two or more of these methods, its usefulness as an active ingredient of a drug can be confirmed.

[0340] A certain aspect of the compound of the present invention is useful as an active ingredient of a drug, which can be confirmed by, for example, performing an eye irritation test. As an eye irritation test, a single eye drop test method (only one eye drop) using rabbit eyes, monkey eyes, etc., a short-term continuous eye drop test method (eye drops multiple times at fixed intervals in a short period of time), a repeated eye drop test method (intermittent repeated eye drops between several days and dozens of days), etc., can be cited. There is a method for evaluating eye irritation symptoms for a certain period of time after eye drops based on the modified Draize score (Fukui, N. et al., Gendai no Rinsho, 4 (7), pp. 277-289, 1970). By using any one or more of these methods to clarify the eye irritation of the compound, the usefulness of the compound as an active ingredient of the drug can be confirmed.

[0341] The usefulness of a certain embodiment of the compound of the present invention as an active ingredient of a medicine can be confirmed by conducting, for example, a safety pharmacology test on the cardiovascular system. Examples of safety pharmacological tests for the cardiovascular system include telemetry (a method in which a compound is administered without anesthesia and the effects thereof on electrocardiogram, heart rate, blood pressure, blood flow, etc. are measured (Electrocardiogram, Echocardiography, Blood Pressure, and Pathological Examination of Animals for Basic and Clinical Use, edited by Shigeru Kanno, Hirokazu Tsubone, and Yoshitaka Nakata, published in 2003 by Maruzen Co., Ltd.), APD method (a method for measuring the duration of action potential of cardiomyocytes (Muraki, K. et al., AM. J. Physiol., 269, H524-532, 1995; Ducic, I. et al., J. Cardiovasc. Pharmacol., 30 (1), pp. 42-54, 1997)), hERG blockade evaluation method (patch clamp method (Chachin, M. et al., Nippon Yakurigaku Zasshi, 119, pp. 345-351, 2002), binding assay (Binding assay), and cytotoxicity assay. assay) method (Gilbert, JDet al., J.Pharm.Tox.Methods, 50, pp.187-199, 2004), Rb +Efflux assay (Cheng, CS et al., Drug Develop. Indust. Pharm., 28, pp. 177-191, 2002), membrane potential assay (Dorn, A. et al., J. Biomol. Screen., 10, pp. 339-347, 2005), etc. By using any one or two or more of these methods to clarify the effect of the compound on the cardiovascular system, the usefulness of the compound as an active ingredient of the drug can be confirmed.

[0342] A certain aspect of the compound of the present invention is useful as an active ingredient of a drug, which can be confirmed by, for example, conducting a safety pharmacology test for the central nervous system. As a safety pharmacology test for the central nervous system, the FOB method (Functional Observation Comprehensive Evaluation Method (Mattson, J. Let al., J. American College of Technology, 15 (3), pp. 239-254, 1996)), Irwin's modified method (a method for evaluating general symptoms and behavioral observations (Irwin, S. Comprehensive Observational Assessment (Berl.) 13, pp. 222-257, 1968), etc. can be cited. By using any one or more of these methods to clarify the effect of the compound on the central nervous system, the usefulness of the active ingredient as a drug can be confirmed.

[0343] A certain embodiment of the compound of the present invention is useful as an active ingredient of a drug, which can be confirmed by conducting, for example, a safety pharmacology test for the respiratory system. As a safety pharmacology test for the respiratory system, there can be cited a measurement method using a respiratory function measurement device (measuring the respiratory rate, ventilation volume per time, ventilation volume per time, etc.) (Drorbaugh, JE et al., Pediatrics, 16, pp. 81-87, 1955; Epstein, MA et al., Respir. Physiol., 32, pp. 105-120, 1978), a measurement method using a blood gas analyzer (measuring blood gas, hemoglobin oxygen saturation, etc.) (Matsuo, S. Medicina, 40, pp. 188-, 2003), etc. By using any one or two or more of these methods to clarify the effect of the compound on the respiratory system, the usefulness of the compound as an active ingredient of the drug can be confirmed.

[0344] A certain aspect of the compound of the present invention is useful as an active ingredient of a drug, which can be confirmed by, for example, performing a general toxicity test. A general toxicity test refers to the following method: using rodents such as rats and mice or non-rodents such as monkeys and dogs, a compound dissolved or suspended in an appropriate solvent is administered orally or intravenously once or repeatedly (over multiple days), and the observation of the general state of the administered animal, clinical chemical changes, pathological tissue changes, etc. are evaluated. By using these methods to clarify the general toxicity of the compound, the usefulness as an active ingredient of a drug can be confirmed.

[0345] The usefulness of a certain embodiment of the compound of the present invention as an active ingredient of a drug can be confirmed by, for example, conducting a reproductive developmental toxicity test. The reproductive developmental toxicity test is a test that uses rodents such as rats and mice or non-rodents such as monkeys and dogs to study the adverse effects of a compound on inducing reproductive development (see "Explanation of the Guidelines for Non-clinical Trials of Pharmaceuticals 2002" Japan Yakuji Shimbun 2002 Annual Issue 1-6: Reproductive Developmental Toxicity Test, etc.). Examples of reproductive developmental toxicity tests include tests related to fertilization ability and early embryonic development before implantation, tests related to prenatal and postnatal development and maternal function, and tests related to embryonic / fetal development (see "Reproductive Developmental Toxicity Test" in the Annex to the 2000 Japanese Pharmaceutical Review No. 1834 "Guidelines for Toxicity Testing of Pharmaceuticals" [3]). By clarifying the reproductive developmental toxicity of a compound using these test methods, its usefulness as an active ingredient of a drug can be confirmed.

[0346] That a certain embodiment of the compound of the present invention is useful as an active ingredient of a drug can be confirmed by, for example, performing a cytochrome P450 enzyme blocking or induction test (Gomez-Lechon, MJ et al., Curr. Drug Metab. 5(5), pp. 443-462, 2004). As a test for blocking or inducing cytochrome P450 enzymes, for example, there are methods of measuring in vitro whether a compound blocks the enzyme activity of cytochrome P450 enzymes of various molecular species purified from cells or prepared using genetic recombinants or human P450 expression microsomes (Miller, V et al., Ann. NY Acad. Sci., 919, pp. 26-32, 2000); methods of measuring the expression of cytochrome P450 enzymes of various molecular species and changes in enzyme activity using human liver microsomes or cell disrupted fluid (Hengstler, J G et al., Drug Metab. Rev., 32, pp. 81-118, 2000); or methods of extracting RNA from human hepatocytes exposed to a compound and comparing the mRNA expression level with that of a control to investigate the enzyme inducing ability of the compound (Kato, M. et al., Drug Metab. Pharmacokinet., 20 (4), pp. 236-243, 2005). By using any one or two or more of these methods to clarify the enzyme-blocking or enzyme-inducing effect of the compound on cytochrome P450, the usefulness of the compound as an active ingredient of a drug can be confirmed.

[0347] The usefulness of a certain embodiment of the compound of the present invention as an active ingredient of a drug can be confirmed by, for example, performing a reactive metabolite generation confirmation test. Examples of reactive metabolite generation confirmation tests include a method in which a human liver microsome and a compound are cultured in the presence of NADPH and dansyl fluorescently labeled glutathione (dGSH), reactive metabolites are captured as dGSH adducts, and the peak caused by the reactive metabolites is detected as a whole according to the amount of dGSH adducts generated using fluorescence intensity as an index (Junping Gan et al., Chem. Res. Toxicol. 2005, 18, 896-903); a method in which a 14C-labeled form of a compound is cultured together with human liver microsomes in the presence of NADPH and the radioactivity covalently bound to the protein is measured (Baillie TA, Drug Metabolizing Enzymes. Cytochrome P450 and Other Enzymes in Drug Discovery and Development, pp. 147-154, 2003). By using any one or two or more of these methods, the risk of a compound causing idiosyncratic drug toxicity due to the generation of reactive metabolites can be clarified, thereby confirming its usefulness as an active ingredient of a drug.

[0348] The usefulness of a certain embodiment of the compound of the present invention as an active ingredient of a drug can be confirmed by, for example, performing a cell permeability test. Examples of cell permeability tests include a method for measuring the cell membrane permeability of a compound in an in vitro cell culture system using Caco-2 cells (Delie, F. et al., Crit. Rev. Ther. Drug Carrier Syst., 14, pp. 221-286, 1997; Yamashita, S. et al., Eur. J. Pham. Sci., 10, pp. 195-204, 2000; Ingels, FM et al., J. Pham. Sci., 92, pp. 1545-1558, 2003), or a method for measuring the cell membrane permeability of a compound in an in vitro cell culture system using MDCK cells (Irvine, J. Det al., J. Pham. Sci., 88, pp. 28-33, 1999). By clarifying the cell permeability of a compound using any one or two or more of these methods, its usefulness as an active ingredient of a drug can be confirmed.

[0349] A certain aspect of the compound of the present invention is useful as an active ingredient of a drug, which can be confirmed by, for example, performing a drug transporter ATPase assay as an ATP-binding cassette (ABC) transporter. As a drug transporter ATPase assay, there can be mentioned a method of investigating whether a compound is a substrate of P-gp using a baculovirus expression system of P-glycoprotein (P-gp) (Germann, UA, Methods Enzymol., 292, pp. 427-41, 1998). In addition, it can be confirmed by, for example, performing a transport assay using oocytes collected from Xenopus laevis as a solute carrier transporter (SLC) transporter. As a transport assay, there can be mentioned a method of investigating whether a compound is a substrate of OATP2 using an OATP2-expressing oocyte (Tamai I. et.al., Pharm Res. 2001 Sep; 18 (9): 1262-1269). By using these methods to clarify the action of a compound on an ABC transporter or an SLC transporter, it is possible to confirm its usefulness as an active ingredient of a drug.

[0350] A certain aspect of the compound of the present invention is useful as an active ingredient of a drug, which can be confirmed by, for example, performing an oral absorption test. As an oral absorption test, the following methods can be cited: using rodents, monkeys, dogs, etc., a certain amount of the compound is dissolved or suspended in an appropriate solvent, and the blood drug concentration after oral administration is measured over time, and the blood transportability of the compound after oral administration is evaluated by LC-MS / MS method (Kenichi Harada et al., "The Latest Mass Spectrometry for Life Sciences" Kodansha Science 2002, etc.). By clarifying the oral absorption of the compound using these methods, the usefulness as an active ingredient of a drug can be confirmed.

[0351] A certain aspect of the compound of the present invention is useful as an active ingredient of a drug, which can be confirmed by, for example, performing a blood drug concentration transition test. As a blood drug concentration transition test, the following methods can be cited: after the compound is administered orally or parenterally (for example, intravenously, intramuscularly, intraperitoneally, subcutaneously, transdermally, by eye drops or nasally, etc.) to rodents, monkeys or dogs, the concentration transition of the compound in the blood is measured by LC-MS / MS method (Kenichi Harada et al., "The Latest Mass Spectrometry for Life Sciences" Kodansha Science 2002, etc.). By clarifying the blood drug concentration transition of the compound using these methods, the usefulness as an active ingredient of a drug can be confirmed.

[0352] The usefulness of a certain embodiment of the compound of the present invention as an active ingredient of a drug can be confirmed by, for example, performing a metabolism test. Examples of metabolism tests include a blood stability test (a method for predicting the metabolic clearance rate in vivo from the metabolic rate of a compound in liver microsomes of humans or other animal species (see Shou, WZ et al., J. Mass Spectrom., 40 (10), pp. 1347-1356, 2005; Li, C. et al., Drug Metab. Dispos., 34 (6), 901-905, 2006), a metabolic molecular species test, and a reactive metabolite test. By using any one or two or more of these methods to clarify the metabolic profile of a compound, its usefulness as an active ingredient of a drug can be confirmed.

[0353] A certain aspect of the compound of the present invention is useful as an active ingredient of a drug, which can be confirmed by, for example, a solubility test. The evaluation of solubility in water can be exemplified by a method for confirming under acidic conditions, neutral conditions, or alkaline conditions, and further includes confirming the change in solubility caused by bile acid. As a solubility test, a solubility test method based on turbidity method (Lipinski, CA et al., Adv. Drug Deliv. Rev., 23, pp. 3-26, 1997; Bevan, CD et al., Anal. Chem., 72, pp. 1781-1787, 2000) and the like can be cited. By using these methods to clarify the solubility of the compound, it is possible to confirm its usefulness as an active ingredient of a drug.

[0354] A certain mode of the compound of the present invention is useful as an active ingredient of a drug, which can be confirmed by, for example, adjusting upper gastrointestinal disorders, renal dysfunction, etc. As a pharmacological test for the upper gastrointestinal tract, a fasting rat gastric mucosal injury model can be used to investigate the effect on the gastric mucosa. As a pharmacological test for renal function, renal blood flow glomerular filtration volume determination method [Physiology 18th Edition (Benkogdo), 1986, Chapter 17], etc. can be cited. By using any one or two or more of these methods to clarify the effect of the compound on the upper gastrointestinal tract and renal function, the usefulness of the active ingredient as a drug can be confirmed.

[0355] Example

[0356] The present invention will be described in more detail below by way of Examples and Test Examples (hereinafter sometimes referred to as “Examples, etc.”), but the scope of the present invention is not limited to the following Examples, etc.

[0357] All the purchased reagents are used without further refining. The purchased anhydrous solvent is used without further drying. In column chromatography, the BIOTAGE Dalton as an MS detector is connected to the medium-pressure preparative refining system SmartFlash manufactured by Shanshan or the medium-pressure preparative refining system Isolera ONE manufactured by BIOTAGE for use. The column uses either SNAP Ultra manufactured by Biotage or DispoPack AT manufactured by YMC. In some cases, BondElute SCX manufactured by Agilent is used as an ion exchange resin for refining. It should be noted that BondElute SCX is sometimes referred to as SCX below. As an example of the use of SCX, the following method can be cited: after the extraction column is washed with methanol and dichloromethane, the crude product is dissolved in a minimum volume of solvent (such as a mixed solvent of dichloromethane-methanol, etc.) to adsorb it. Thereafter, the impurities are rinsed with methanol while applying pressure, and the product is eluted with 2.0M ammonia-methanol. Thin layer chromatography (TLC) uses Precoated silica gel 60F254 (Merck, product number 5715-1M). After developing with chloroform:methanol (1:0 to 1:1) or ethyl acetate:hexane (1:0 to 0:1), UV (254nm or 365nm) is irradiated and confirmed by color development using iodine solution, potassium permanganate aqueous solution, phosphomolybdic acid (ethanol solution), etc. In preparative thin layer chromatography (hereinafter sometimes referred to as PTLC), one or more PLC plates of silica gel60F254, 20×20cm, layer thickness 2mm, with a concentration zone (4cm) (Merck, product number 13793-1M) are used for chromatography according to the amount of the sample. Anhydrous magnesium sulfate or anhydrous sodium sulfate is used for drying the organic solvent.

[0358] NMR

[0359] For the 1H (400 MHx) nuclear magnetic resonance analysis (hereinafter sometimes referred to as NMR), AVANCE III HD-400 MHz or AVANCE III HD-600 MHz manufactured by Bruker was used.

[0360] The internal standard uses the known value of the solvent or additive used. 1HNMR data record chemical shift, parts per million (hereinafter referred to as ppm), integral value (for example, recorded as 1H), multiple peaks (s, singlet; d, doublet; t, triplet; q, quartet; qui, quintet; m, multiplet; br, broad peak; dd, doublet of doublets; etc.).

[0361] Regarding LCMS, mass spectra were determined using liquid chromatography-mass spectrometry (LC-MS). Unless otherwise stated, a single quadrupole mass spectrometer SQD system (manufactured by Waters) was used as a mass spectrometer, and the mass spectrometer was measured by electrospray (ESI). The liquid chromatograph was manufactured using AcquityΜLtra Performance LC system manufactured by Waters. The separation column used ACQUITYUPLCBEHC18 2.1×50mm 1.7μm (manufactured by Waters).

[0362] Regarding LC conditions, for the examples or reference examples that are specifically described, the measurements were performed under the following solvent conditions. + or MH - ).

[0363] (LC-1) was measured under the following conditions: flow rate 0.6 mL / min, solution A = 10 mM ammonium acetate aqueous solution, solution B = acetonitrile, solution B was eluted with a linear gradient of 5-90% (v / v) from 0 min to 2.0 min, and solution B was eluted with a linear gradient of 90-98% (v / v) from 2.0 min to 2.5 min.

[0364] (LC-6) was measured under the following conditions: flow rate 0.6 mL / min, solution A = 10 mM ammonium acetate aqueous solution, solution B = acetonitrile, solution B was eluted with a linear gradient of 70-90% (v / v) from 0 min to 2.0 min, and solution B was eluted with a linear gradient of 90-98% (v / v) from 2.0 min to 2.5 min.

[0365] For HPLC purification, a preparative purification apparatus manufactured by Waters Japan was used, a Triart C18ExRS (manufactured by YMC) or the like was used as a column, and a 10 mM ammonium acetate aqueous solution-acetonitrile solution was used as an eluent.

[0366] The term "quant." in the following examples and descriptions of the synthesis methods of intermediates means that the target product was obtained in a quantitative manner.

[0367] [Chemistry 32]

[0368] Method A-1

[0369]

[0370] Intermediate A-1-2: 6-bromo-3-fluoro-2-nitrophenol

[0371] [Chemistry 33]

[0372]

[0373] 3-Fluoro-2-nitrophenol (intermediate A-1-1; 30.9 g, 196 mmol) was dissolved in acetonitrile (20 mL), and concentrated sulfuric acid (44 mL) was added while maintaining the reaction temperature below 30°C. Then, N-bromosuccinimide (35.4 g, 198 mmol) in acetonitrile (281 mL) was added dropwise over 1.5 hours under ice cooling. Thereafter, the reaction system was stirred for 12 hours while naturally warming from 0°C to room temperature. After the reaction was completed, ice water (300 mL) was added and extracted with ethyl acetate, and then the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained crude product (62.1 g) was a mixture of bromine position isomers of the target product, but it was not separated and purified at this stage and used in the next stage.

[0374] LCMS(LC-1);RT=1.03,m / z234[MH] +

[0375] Intermediate A-1-3: 2-(Benzyloxy)-1-bromo-4-fluoro-3-nitrobenzene

[0376] [Chemistry 34]

[0377]

[0378] 6-Bromo-3-fluoro-2-nitrophenol (intermediate A-1-2; 62.1 g, the above bromine position isomer mixture) was dissolved in acetonitrile (1000 mL), benzyl bromide (24.6 mL, 206 mmol) and potassium carbonate (95.0 g, 689 mmol) were added, and stirred at 90°C for 1 hour. Water (300 mL) was then added to the reaction mixture at room temperature, and after extraction with ethyl acetate, the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent; hexane: ethyl acetate = 100:0 to 40:60) to obtain 2-(benzyloxy)-1-bromo-4-fluoro-3-nitrobenzene (17.5 g, 2-step yield 27%).

[0379] LCMS (LC-1); RT = 1.95 (UV detection only)

[0380] 1H-NMR (CDCl3): δ (ppm) 7.71 (1H, dd, J = 9.2, 5.6Hz), 7.51-7.44 (2H, m), 7.43-7.34 (3H, m), 6.99 (1H, t, 8.7Hz), 5.19 (2H, s).

[0381] Intermediate A-1-4: Methyl (3-(benzyloxy)-4-bromo-2-nitrophenyl) glycine ester

[0382] [Chemistry 35]

[0383]

[0384] 2-(Benzyloxy)-1-bromo-4-fluoro-3-nitrobenzene (Intermediate A-1-3; 30.5 g, 93.5 mmol) and glycine methyl ester hydrochloride (41.1 g, 327 mmol) were dissolved in acetonitrile (467 mL), and N,N-diisopropylethylamine (95.0 mL, 542 mmol) and molecular sieve 4A (30.5 g) were added, and stirred at 50 ° C for 72 hours. Thereafter, the reaction solution was filtered through diatomaceous earth, and the filtrate was extracted with ethyl acetate, and the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained crude product was purified by silica gel column chromatography (eluent; hexane: ethyl acetate = 100:0 to 50:50), thereby obtaining a crude purified product (43.1 g). It was used for the next reaction without purification.

[0385] LCMS(LC-1);RT=1.88,m / z395[M+H] +

[0386] 1H-NMR (CDCl3): δ (ppm) 7.56-7.49 (3H,m), 7.43-7.32 (3H,m), 6.39-6.30 (2H,m), 5.18 (2H,s), 3.98 (2H,d,J=5.3Hz), 3.81 (3H,s).

[0387] Intermediate A-1-5: 8-(Benzyloxy)-7-bromo-3,4-dihydroquinoxalin-2(1H)-one

[0388] [Chemistry 36]

[0389]

[0390] To methyl (3-(benzyloxy)-4-bromo-2-nitrophenyl) glycine ester (intermediate A-1-4; 43.1 g, the above crude product), iron (97.5 g, 1744 mmol), ammonium chloride (58.3 g, 1090 mmol) were added ethanol (550 mL) and water (550 mL) for suspension, and stirred at 80 ° C for 4 hours. After the reaction was completed, ethanol (100 mL) and chloroform (100 mL) were added at room temperature, and diatomaceous earth filtration was performed. The filtrate was concentrated under reduced pressure to obtain a crude product (29.6 g). It was used for the next reaction without purification.

[0391] LCMS (LC-1); RT=1.51, m / z331[MH] +

[0392] 1H-NMR (DMSO-d6): δ (ppm) 9.84 (1H, s), 7.58 (2H, d, J = 6.9Hz), 7.43-7.30 (3H, m), 6 .99(1H,d,J=8.6Hz),6.45(1H,d,J=8.6Hz),6.22(1H,s),4.93(2H,s),3.68(2H,s).

[0393] Intermediate A-1-6: 8-(Benzyloxy)-7-bromoquinoxalin-2(1H)-one

[0394] [Chemistry 37]

[0395]

[0396] 8-(Benzyloxy)-7-bromo-3,4-dihydroquinoxaline-2(1H)-one (Intermediate A-1-5; 29.6 g, the above crude product) was dissolved in tetrahydrofuran (592 mL), manganese dioxide (27.0 g, 311 mmol) was added, and the mixture was stirred at 70°C for 12 hours. After the reaction was completed, tetrahydrofuran (300 mL) was added at room temperature, and diatomaceous earth was filtered. After the filtrate was concentrated under reduced pressure, tetrahydrofuran (40 mL), ethyl acetate (250 mL), and hexane (250 mL) were added to the obtained solid, and the mixture was stirred at room temperature for 30 minutes. Thereafter, the suspension was filtered, and the filtered solid was dried under reduced pressure to obtain 8-(benzyloxy)-7-bromoquinoxaline-2(1H)-one (19.9 g, 3-step yield 64%).

[0397] LCMS(LC-1);RT=1.49,m / z331[M+H] +

[0398] 1H-NMR (CDCl3): δ (ppm) 9.05 (1H, brs), 8.18 (1H, s), 7.55-7.48 (2H, m), 7.47-7.36 (5H, m), 5.18 (2H, s).

[0399] Intermediate A-1-7: 8-(Benzyloxy)-7-bromo-2-chloroquinoxaline

[0400] [Chemistry 38]

[0401]

[0402] 8-(Benzyloxy)-7-bromoquinoxaline-2(1H)-one (intermediate A-1-6; 1.0 g, 3.02 mmol) was dissolved in thionyl chloride (10 mL), N,N-dimethylformamide (0.234 mL, 3.02 mmol) was added, and stirred at 80°C for 1 hour. After the reaction was completed, water (30 mL) was added at room temperature, and after extraction with ethyl acetate, the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent; hexane: ethyl acetate = 100:0 to 60:40) to obtain 8-(benzyloxy)-7-bromo-2-chloroquinoxaline (644 mg, yield 61%).

[0403] LCMS(LC-1);RT=2.06,m / z349[M+H] +

[0404] 1H-NMR (CDCl3): δ (ppm) 8.77 (1H, s), 7.91 (1H, d, J = 9.1Hz), 7.75 (1H, d, J = 9.1Hz), 7.63 (2H, d, J = 7.4Hz), 7.42-7.31 (3H, m), 5.48 (2H, s).

[0405] [Chemistry 39]

[0406] Method A-2

[0407]

[0408] Intermediate A-2-3: tert-butyl (S)-2-((3-((tert-butyldiphenylsilyl)oxy)propyl)carbamoyl)-4-oxopiperidine-1-carboxylate

[0409] [Chemistry 40]

[0410]

[0411] (S)-1-(tert-Butyloxycarbonyl)-4-oxopiperidine-2-carboxylic acid (Intermediate A-2-1; 1.57 g, 6.46 mmol) was dissolved in tetrahydrofuran (33 mL), triethylamine (1.32 mL, 9.69 mmol) and isobutyl chloroformate (1.02 mL, 7.75 mmol) were added under ice cooling, and stirred for 30 minutes. Then 3-((tert-butyldiphenylsilyl)oxy)propane-1-amine (Intermediate A-2-2; 2.43 g, 7.76 mmol) was added, and stirred at room temperature for 1 hour. After the reaction was completed, water (50 mL) was added, and after extraction with ethyl acetate, the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained crude product was purified by silica gel column chromatography (eluent; hexane:ethyl acetate=100:0 to 70:30) to obtain tert-butyl (S)-2-((3-((tert-butyldiphenylsilyl)oxy)propyl)carbamoyl)-4-oxopiperidine-1-carboxylate (2.15 g, yield 62%).

[0412] LCMS(LC-1);RT=2.26,m / z539[M+H] +

[0413] 1H-NMR (CDCl3): δ (ppm) 7.64 (4H, dd, J = 7.8, 1.6Hz), 7.46-7.35 (6H, m), 6.58 (1H, brs),4.82(1H,m),3.96-3.80(1H,m),3.69(2H,t,J=5.4Hz),3.55(1H,ddd,J=13.3 ,8.3,5.0Hz),3.39(2H,m),2.82(1H,dd,J=16.5,2.8Hz),2.64-2.46(2H,m),2.45 -2.35(1H,m),1.72(1H,q,J=6.3Hz),1.59-1.52(1H,m),1.47(9H,s),1.05(9H,s).

[0414] Intermediate A-2-4: tert-butyl (2S, 4R)-2-((3-((tert-butyldiphenylsilyl)oxy)propyl)carbamoyl)-4-hydroxypiperidine-1-carboxylate

[0415] [Chemistry 41]

[0416]

[0417] Tert-butyl (S)-2-((3-((tert-butyldiphenylsilyl)oxy)propyl)carbamoyl)-4-oxopiperidin-1-carboxylate (Intermediate A-2-3; 2.15 g, 4.00 mmol) was dissolved in tetrahydrofuran (8 mL), and L-Selectride (lithium tri-sec-butylborohydride) 1M-tetrahydrofuran solution (6.0 mL, 6.00 mmol) was added at -78 °C and stirred for 1 hour. After the reaction was completed, saturated aqueous ammonium chloride solution (20 mL) was added, and after extraction with ethyl acetate, the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained crude product was purified by silica gel column chromatography (eluent; hexane:ethyl acetate=100:0 to 0:100) to obtain tert-butyl (2S,4R)-2-((3-((tert-butyldiphenylsilyl)oxy)propyl)carbamoyl)-4-hydroxypiperidine-1-carboxylate (1.72 g, yield 80%).

[0418] LCMS(LC-1);RT=2.25,m / z541[M+H] +

[0419] 1H-NMR (CDCl3): δ (ppm) 7.65 (4H, dd, J = 7.8, 1.4Hz), 7.46-7.35 (6H, m), 6.82 (1H, brs), 5.75(1H,brs),4.81-4.70(1H,m),4.08-4.00(1H,br),3.87-3.74(1H,m),3.73-3.53(2H ,m),3.50-3.39(1H,m),3.38-3.28(1H,m),3.14(1H,td,J=13.3,2.6Hz),2.30-2.16(1H ,m),1.89-1.80(1H,m),1.79-1.67(3H,m),1.64-1.53(1H,m),1.46(9H,m),1.05(9H,s).

[0420] Intermediate A-2-5: tert-butyl (2S, 4R)-2-((3-((tert-butyldiphenylsilyl)oxy)propyl)carbamoyl)-4-((methylsulfonyl)oxy)piperidine-1-carboxylate

[0421] [Chemistry 42]

[0422]

[0423] Tert-butyl (2S, 4R)-2-((3-((tert-butyldiphenylsilyl)oxy)propyl)carbamoyl)-4-hydroxypiperidine-1-carboxylate (Intermediate A-2-4; 1.72 g, 3.19 mmol) was dissolved in dichloromethane (6.4 mL), triethylamine (0.80 mL, 5.74 mmol) and methanesulfonyl chloride (0.345 mL, 4.47 mmol) were added under ice cooling, and stirred at 0°C for 2 hours. Water (20 mL) was then added at room temperature, and after extraction with ethyl acetate, the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained crude product (2.46 g) was used in the next reaction without purification.

[0424] LCMS(LC-1);RT=2.25,m / z619[M+H] +

[0425] Intermediate A-2-6: tert-butyl (2S, 4S)-4-azido-2-((3-((tert-butyldiphenylsilyl)oxy)propyl)carbamoyl)piperidine-1-carboxylate

[0426] [Chemistry 43]

[0427]

[0428] Tert-butyl (2S, 4R)-2-((3-((tert-butyldiphenylsilyl)oxy)propyl)carbamoyl)-4-((methylsulfonyl)oxy)piperidine-1-carboxylate (Intermediate A-2-5; 2.46 g, the above crude product) was dissolved in N,N-dimethylformamide (40 mL), sodium azide (388 mg, 5.79 mmol) was added, and stirred at 90°C for 6 hours. After the reaction was completed, water (80 mL) was added at room temperature, and after extraction with ethyl acetate, the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained crude product was purified by silica gel column chromatography (eluent; hexane:ethyl acetate = 100:0 to 80:20) to obtain tert-butyl (2S,4S)-4-azido-2-((3-((tert-butyldiphenylsilyl)oxy)propyl)carbamoyl)piperidine-1-carboxylate (362 mg, 2-step yield 20%).

[0429] LCMS(LC-1);RT=2.47,m / z566[M+H] +

[0430] 1H-NMR (CDCl3): δ (ppm) 7.64 (4H, dd, J = 6.5, 4.0Hz), 7.46-7.35 (6H, m), 6.46-5.85 (1H,m),4.92-4.62(1H,m),4.07-3.93(0.5H,m),3.91-3.75(0.5H,m),2.89-2.68(1 H,m),2.58-2.35(1H,m),3.69(2H,t,J=6.0Hz),3.49-3.29(2H,m),1.91-1.83(1H, m),1.73(1H,quint,J=6.4Hz),1.49-1.23(12H,m),1.05(9H,s),0.91-0.84(1H,m).

[0431] Intermediate A-2-7: tert-butyl (2S, 4S)-4-amino-2-((3-((tert-butyldiphenylsilyl)oxy)propyl)carbamoyl)piperidine-1-carboxylate

[0432] [Chemistry 44]

[0433]

[0434] Tert-butyl (2S, 4S)-4-azido-2-((3-((tert-butyldiphenylsilyl)oxy)propyl)carbamoyl)piperidine-1-carboxylate (Intermediate A-2-6; 362 mg, 0.64 mmol) was dissolved in methanol (6.4 mL), palladium hydroxide (181 mg, 50 wt%) was added, and the mixture was stirred at room temperature for 2 hours under a hydrogen atmosphere. The reaction system was replaced under a nitrogen atmosphere, and then filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure to obtain tert-butyl (2S, 4S)-4-amino-2-((3-((tert-butyldiphenylsilyl)oxy)propyl)carbamoyl)piperidine-1-carboxylate (345 mg, yield 97%).

[0435] LCMS(LC-1);RT=1.93,m / z540[M+H] +

[0436] 1H-NMR (CDCl3): δ (ppm) 7.64 (4H, dd, J = 6.4, 4.0Hz), 7.46-7.34 (6H, m), 6. 34-5.96(1H,m),4.90-4.63(1H,m),4.24-3.89(1H,m),3.75-3.64(2H,m),3 .45-3.28(3H,m),3.15-2.98(0.5H,m),2.92-2.64(1.5H,m),2.55-2.30(1 H,m),1.79-1.68(3.5H,m),1.46(9H,m),1.32-1.13(2.5H,m),1.05(9H,m).

[0437] [Chemistry 45]

[0438] Method A-3

[0439]

[0440] Intermediate A-3-1: tert-butyl (2S, 4S)-4-((8-(benzyloxy)-7-bromoquinoxalin-2-yl)amino)-2-((3-((tert-butyldiphenylsilyl)oxy)propyl)carbamoyl)piperidine-1-carboxylate

[0441] [Chemistry 46]

[0442]

[0443] Tert-butyl (2S, 4S)-4-amino-2-((3-((tert-butyldiphenylsilyl)oxy)propyl)carbamoyl)piperidine-1-carboxylate (Intermediate A-2-7; 345 mg, 0.64 mmol) was dissolved in dimethyl sulfoxide (5.8 mL), 8-(benzyloxy)-7-bromo-2-chloroquinoxaline (Intermediate A-1-7; 202 mg, 0.582 mmol) and N,N-diisopropylethylamine (0.152 mL, 0.87 mmol) were added, and stirred at 120°C for 12 hours. After the reaction was completed, water (30 mL) was added, and the organic layer was extracted with ethyl acetate, and then washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained crude product was purified by silica gel column chromatography (eluent; chloroform:methanol=100:0 to 90:10) to obtain tert-butyl (2S,4S)-4-((8-(benzyloxy)-7-bromoquinoxalin-2-yl)amino)-2-((3-((tert-butyldiphenylsilyl)oxy)propyl)carbamoyl)piperidine-1-carboxylate (147 mg, yield 27%).

[0444] LCMS(LC-1);RT=2.31,m / z852[M+H] +

[0445] 1H-NMR(CDCl3): δ(ppm)8.24-8.18(1H,m),7.68-7.57(6H,m),7.55-7.48(2H,m),7.45-7.29(9H, m),6.34(1H,brs),5.44(1H,d,J=10.8Hz),5.29(1H,d,J=10.8Hz),4.79(1H,d,J=8.0Hz),4.48-3 .86(1H,m),3.67(2H,t,J=8.0Hz),3.48-3.26(2H,m),2.89-2.74(1H,m),2.72-2.57(1H,m),2.29 (1H,d,J=12.0Hz),1.75-1.65(2H,m),1.54-1.42(10H,m),1.34-1.18(2H,m),1.09-1.01(10H,m).

[0446] Intermediate A-3-2: tert-butyl (2S, 4S)-4-((8-(benzyloxy)-7-bromoquinoxalin-2-yl)amino)-2-((3-hydroxypropyl)carbamoyl)piperidine-1-carboxylate

[0447] [Chemistry 47]

[0448]

[0449] Tert-butyl (2S, 4S)-4-((8-(benzyloxy)-7-bromoquinoxalin-2-yl)amino)-2-((3-((tert-butyldiphenylsilyl)oxy)propyl)carbamoyl)piperidine-1-carboxylate (Intermediate A-3-1; 147 mg, 0.172 mmol) was dissolved in tetrahydrofuran (0.86 mL), tetrabutylammonium fluoride 1M-tetrahydrofuran solution (0.863 mL, 0.863 mmol) was added, and the mixture was stirred at room temperature for 2 hours. After the reaction, the reaction mixture was directly purified by automatic silica gel column chromatography (eluent; chloroform: methanol = 100:0 to 80:20) to obtain tert-butyl (2S, 4S)-4-((8-(benzyloxy)-7-bromoquinoxaline-2-yl)amino)-2-((3-hydroxypropyl)carbamoyl)piperidine-1-carboxylate (104 mg, yield 98%).

[0450] LCMS(LC-1);RT=1.77,m / z614[M+H] +

[0451] 1H-NMR (CDCl3): δ (ppm) 8.24-8.18 (1H, m), 7.61 (2H, d, J = 7.3Hz), 7.55-7.48 (2H, m ),7.42-7.30(3H,m),6.51(1H,brs),5.43(1H,d,J=10.8Hz),5.30(1H,d,J=10.8Hz) ,5.02-4.82(2H,m),4.45-3.95(1H,m),3.60-3.51(2H,m),3.06-2.94(2H,m),2.93- 2.64(2H,m),2.39-2.28(1H,m),1.86-1.73(2H,m),1.50(9H,s),1.44-1.21(4H,m).

[0452] Intermediate A-3-3: tert-Butyl (2S, 4S)-2-((3-(benzoyloxy)propyl)carbamoyl)-4-((8-(benzyloxy)-7-bromoquinoxalin-2-yl)amino)piperidine-1-carboxylate

[0453] [Chemistry 48]

[0454]

[0455] Tert-butyl (2S, 4S)-4-((8-(benzyloxy)-7-bromoquinoxalin-2-yl)amino)-2-((3-hydroxypropyl)carbamoyl)piperidine-1-carboxylate (Intermediate A-3-2; 104 mg, 0.170 mmol) was dissolved in a mixed solvent of dichloromethane (0.85 mL) and pyridine (0.85 mL), and benzoyl chloride (0.024 mL, 0.20 mmol) and N,N-dimethylaminopyridine (2 mg, 0.017 mmol) were added under ice cooling at 0°C, and the mixture was stirred at room temperature for 1 hour. After the reaction, the reaction mixture was directly purified by automated silica gel column chromatography (eluent; chloroform:methanol = 100:0 to 90:10) to obtain tert-butyl (2S,4S)-2-((3-(benzoyloxy)propyl)carbamoyl)-4-((8-(benzyloxy)-7-bromoquinoxaline-2-yl)amino)piperidine-1-carboxylate (109 mg, yield 89%).

[0456] LCMS(LC-1);RT=2.18,m / z718[M+H] +

[0457] 1H-NMR (CDCl3): δ (ppm) 8.22 (1H, s), 8.02 (2H, d, J = 7.4Hz), 7.61 (2H, d, J = 8.0Hz), 7.59-7.53 (1H, m), 7.51 ( 2H,d,J=3.2Hz),7.44(2H,t,J=8.0Hz),7.33(2H,t,J=7.1Hz),6.66-6.32(1H,m),5.45(1H,d,J=10.8Hz),5.2 9(1H,d,J=10.8Hz),5.12-4.88(1H,m),4.84(1H,d,J=6.8Hz),4.39-4.25(3H,m),3.46-3.35(1H,m),3.34-3 .22(1H,m),2.95-2.66(2H,m),2.37-2.26(1H,m),1.97-1.88(2H,m),1.56-1.44(11H,m),1.37-1.27(2H,m).

[0458] Intermediate A-3-4: 3-((2S,4S)-4-((7-bromo-8-hydroxyquinoxalin-2-yl)amino)piperidine-2-carboxamide)propyl benzoate

[0459] [Chemistry 49]

[0460]

[0461] Tert-butyl (2S,4S)-2-((3-(benzoyloxy)propyl)carbamoyl)-4-((8-(benzyloxy)-7-bromoquinoxalin-2-yl)amino)piperidine-1-carboxylate (Intermediate A-3-3; 108 mg, 0.12 mmol) was dissolved in dichloromethane (2.5 mL), and a 1M solution of boron tribromide in dichloromethane (0.742 mL, 0.74 mmol) was added under ice cooling, followed by stirring for 30 minutes. After the starting material disappeared, methanol (2.5 mL) was added dropwise at 0°C to stop the reaction. The resulting reaction mixture was directly purified by SCX to obtain 3-((2S,4S)-4-((7-bromo-8-hydroxyquinoxalin-2-yl)amino)piperidine-2-carboxamido)propyl benzoate (77 mg, yield 97%).

[0462] LCMS(LC-1);RT=1.52,m / z528[M+H] +

[0463] 1H-NMR(CDCl3): δ(ppm)8.87(1H,brs),8.18(1H,s),8.09-8.03(2H,m),7.66-7.59(1H,m),7.57-7.51(1H,m ),7.48-7.40(3H,m),7.29(1H,d,J=8.4Hz),4.91(1H,d,J=5.6Hz),5.81(2H,t,J=5.6Hz),5.06-4.95(1H,m), 3.69(1H,t,J=3.9Hz),3.62-3.51(2H,m),3.21(1H,d,J=12.8Hz),3.08(1H,dt,J=4.4,3.7Hz),2.92-2.80(1 H,m),2.06(2H,quint,J=6.5Hz),1.94-1.88(1H,m),1.54-1.45(2H,m),1.27(1H,ddd,J=12.6,10.0,4.7Hz).

[0464] Intermediate A-3-5: tert-butyl (2S, 4S)-2-((3-(benzoyloxy)propyl)carbamoyl)-4-((7-bromo-8-hydroxyquinoxalin-2-yl)amino)piperidine-1-carboxylate

[0465] [Chemistry 50]

[0466]

[0467] 3-((2S,4S)-4-((7-bromo-8-hydroxyquinoxalin-2-yl)amino)piperidine-2-carboxamido)propyl benzoate (Intermediate A-3-4; 77 mg, 0.146 mmol) was dissolved in dichloromethane (7.4 mL), triethylamine (0.204 mL, 1.46 mmol) and di-tert-butyl dicarbonate (240 mg, 1.10 mmol) were added, and stirred at room temperature for 1 hour. Thereafter, the reaction mixture was directly purified by autoclaved silica gel column chromatography (eluent; chloroform:methanol = 100:0 to 80:20) to obtain tert-butyl (2S,4S)-2-((3-(benzoyloxy)propyl)carbamoyl)-4-((7-bromo-8-hydroxyquinoxalin-2-yl)amino)piperidine-1-carboxylate (77 mg, yield 84%).

[0468] LCMS(LC-1);RT=1.98,m / z628[M+H] +

[0469] 1H-NMR(CDCl3): δ(ppm)9.28-8.76(1H,m),8.48-7.90(3H,m),7.78-7.16(4H,m),6.92-5.92(1H,m),4.96-4.85(1H,m), 4.49-4.01(4H,m),3.52-3.33(2H,m),2.98(1H,d,J=6.7Hz),2.10-1.88(2H,m),1.56-1.45(11H,m),1.37-1.18(4H,m).

[0470] Intermediate A-3-6: tert-butyl (2S, 4S)-4-((7-bromo-8-hydroxyquinoxalin-2-yl)amino)-2-((3-hydroxypropyl)carbamoyl)piperidine-1-carboxylate

[0471] [Chemistry 51]

[0472]

[0473] Tert-butyl (2S, 4S)-2-((3-(benzoyloxy)propyl)carbamoyl)-4-((7-bromo-8-hydroxyquinoxalin-2-yl)amino)piperidine-1-carboxylate (Intermediate A-3-5; 77 mg, 0.12 mmol) was dissolved in methanol (2.5 mL), potassium carbonate (170 mg, 1.23 mmol) was added, and stirred at room temperature for 15 minutes. Thereafter, the reaction mixture was directly purified by autoclaved silica gel column chromatography (eluent; chloroform:methanol = 100:0 to 60:40) to obtain tert-butyl (2S, 4S)-4-((7-bromo-8-hydroxyquinoxalin-2-yl)amino)-2-((3-hydroxypropyl)carbamoyl)piperidine-1-carboxylate (45 mg, yield 70%)

[0474] LCMS(LC-1);RT=1.47,m / z524[M+H] +

[0475] 1H-NMR(CDCl3): δ(ppm)8.88(1H,brs),8.26-8.17(1H,m),7.70-7.44(1H,m),7.33-7.28(1H,m),6.68(1H,brs),5.04-4.83(2H,m),4.4 5-4.00(2H,m),3.71-3.43(5H,m),3.40-2.86(2H,m),1.96(1H,d,J=12.0Hz),1.82-1.67(2H,m),1.66-1.45(9H,m),1.42-1.17(2H,m).

[0476] Intermediate A-3-7: tert-butyl (3 2 S,3 4 S)-1 7 -Bromo-4-oxo-9-oxa-2,5-diaza-1(2,8)-quinoxaline-3(4,2)-piperidin-3-cyclononazoline 1 -Formate

[0477] [Chemistry 52]

[0478]

[0479] Tert-butyl (2S, 4S)-4-((7-bromo-8-hydroxyquinoxaline-2-yl)amino)-2-((3-hydroxypropyl)carbamoyl)piperidine-1-carboxylate (Intermediate A-3-6; 45 mg, 0.086 mmol) was dissolved in tetrahydrofuran (17.2 mL), and triphenylphosphine (56 mg, 0.22 mmol) and di-tert-butyl azodicarboxylate 20% toluene solution (0.30 mL) were added, and stirred at room temperature for 12 hours. Thereafter, the reaction mixture was concentrated under reduced pressure. The obtained crude product was purified by autoclaved silica gel column chromatography (eluent; chloroform: methanol = 100:0 to 90:10), thereby obtaining tert-butyl (3 2 S,3 4 S)-1 7 -Bromo-4-oxo-9-oxa-2,5-diaza-1(2,8)-quinoxaline-3(4,2)-piperidin-3-cyclononazoline 1 -formate (26.3 mg, yield 61%).

[0480] LCMS(LC-1);RT=1.56,m / z506[M+H] +

[0481] 1H-NMR (CDCl3): δ (ppm) 8.22 (1H, d, J = 5.4Hz), 7.60-7.52 (2H, m), 5.16-5.04 (1.5H, m), 4.91-4 .85(0.5H,m),4.47-4.38(1H,m),4.35-4.26(1.5H,m),4.19-4.01(1.5H,m),3.86-3.71(1.5H, m),3.70-3.59(0.5H,m),3.13(0.5H,dt,J=16.0,4.0Hz),2.95(1.5H,dt,J=16.0,4.0Hz),2.24 -2.03(2H,m),1.99-1.86(1H,m),1.75-1.62(1H,m),1.53-1.45(9.5H,m),1.39-1.18(1.5H,m).

[0482] [Chemistry 53]

[0483] Method B-1

[0484]

[0485] Intermediate B-1-2: 1-(tert-butyl) 2-methyl (S)-4-oxopiperidine-1,2-dicarboxylate

[0486] [Chemistry 54]

[0487]

[0488] (S)-1-(tert-butoxycarbonyl)-4-oxopiperidine-2-carboxylic acid (intermediate B-1-1; 38.9 g, 160 mmol) was dissolved in a mixed solvent of toluene (800 mL) and methanol (266 mL), and trimethylsilyldiazomethane 2M-diethyl ether solution (100 mL, 200 mmol) was added dropwise under ice cooling, and stirred at room temperature for 3 hours. After the reaction was completed, acetic acid (100 mL) was added under ice cooling and concentrated under reduced pressure. Water (200 mL) was then added, and after extraction with ethyl acetate, the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product (41.1 g). It was used in the next step of the reaction without being refined.

[0489] LCMS(LC-1);RT=1.12,m / z258[M+H] +

[0490] 1H-NMR(CDCl3): δ(ppm)5.18-5.08(0.5H,m),4.91-4.82(0.5H,m),4.16-4.02(1H,m), 3.75(3H,s),3.72-3.56(1H,m),2.78(2H,d,J=6.2Hz),2.55-2.46(2H,m),1.48(9H,s).

[0491] Intermediate B-1-3: 1-(tert-butyl) 2-methyl (2S, 4R)-4-hydroxypiperidin-1,2-dicarboxylate

[0492] [Chemistry 55]

[0493]

[0494] 1-(tert-butyl) 2-methyl (S) -4-oxopiperidine-1,2-dicarboxylate (Intermediate B-1-2; 11.1 g, 43.1 mmol) was dissolved in tetrahydrofuran (86 mL), and L-Selectride (lithium tri-sec-butylborohydride) 1M-tetrahydrofuran solution (65 mL, 64.7 mmol) was added at -78°C and stirred for 2 hours. After the reaction was completed, saturated aqueous ammonium chloride solution (200 mL) was added, and after extraction with ethyl acetate, the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent; hexane: ethyl acetate = 100:0 to 0:100) to obtain 1-(tert-butyl) 2-methyl (2S, 4R) -4-hydroxypiperidine-1,2-dicarboxylate (8.69 g, yield 78%).

[0495] LCMS(LC-1);RT=0.77,m / z260[M+H] +

[0496] 1H-NMR(CDCl3): δ(ppm)5.07-4.57(1H,m),4.19-4.08(1H,m),3.96-3.60(4H,m),3.47-3.21(1H ,m),2.42(1H,d,J=14.2Hz),1.92(1H,ddd,J=14.2,6.8,2.4Hz),1.79-1.62(3H,m),1.47(9H,s).

[0497] Intermediate B-1-4: 1-(tert-butyl)2-methyl(2S,4R)-4-((methylsulfonyl)oxy)piperidine-1,2-dicarboxylate

[0498] [Chemistry 56]

[0499]

[0500] 1-(tert-butyl) 2-methyl (2S, 4R) -4-hydroxypiperidine-1,2-dicarboxylate (intermediate B-1-3; 16.5 g, 63.6 mmol) was dissolved in dichloromethane (127 mL), triethylamine (36 mL, 255 mmol) and methanesulfonyl chloride (9.85 mL, 127 mmol) were added under ice cooling, and stirred at room temperature for 1 hour. It was then extracted with ethyl acetate, and the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The crude product (21.5 g) was used for the next reaction without purification.

[0501] LCMS(LC-1);RT=1.32,m / z338[M+H] +

[0502] Intermediate B-1-5: 1-(tert-butyl) 2-methyl (2S, 4S)-4-azidopiperidine-1,2-dicarboxylate

[0503] [Chemistry 57]

[0504]

[0505] 1-(tert-butyl) 2-methyl (2S, 4R) -4- ((methylsulfonyl) oxy) piperidine-1,2-dicarboxylate (Intermediate B-1-4; 21.5 g, the above crude product) was dissolved in N, N-dimethylformamide (319 mL), sodium azide (8.29 g, 127 mmol) was added, and stirred at 80 ° C for 11 hours. After the reaction was completed, it was extracted with ethyl acetate, and then the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained crude product (18.1 g) was used for the next reaction without purification.

[0506] LCMS(LC-1);RT=1.53,m / z285[M+H] +

[0507] 1H-NMR(CDCl3): δ(ppm)5.12-4.60(1H,m),4.24-4.13(0.5H,m),4.10-4.02(0.5H,m),3.81-3.72(3H,m),3.43 -3.32(1H,m),3.11-2.89(1H,m),2.56-2.38(1H,m),2.04-1.85(1H,m),1.75-1.60(2H,m),1.52-1.39(9H,m).

[0508] Intermediate B-1-6: 1-(tert-butyl) 2-methyl (2S, 4S)-4-aminopiperidin-1,2-dicarboxylate

[0509] [Chemistry 58]

[0510]

[0511] 1-(tert-butyl) 2-methyl (2S, 4S) -4-azidopiperidine-1,2-dicarboxylate (Intermediate B-1-5; 18.1 g, 63.7 mmol) was dissolved in methanol (318 mL), palladium hydroxide (3.8 g, 20 wt%) was added, and stirred at room temperature for 21 hours under a hydrogen atmosphere. The reaction system was replaced under a nitrogen atmosphere, and then filtered with diatomaceous earth. The filtrate was concentrated under reduced pressure to obtain 1-(tert-butyl) 2-methyl (2S, 4S) -4-aminopiperidine-1,2-dicarboxylate (15.0 g, 3-step yield 91%).

[0512] LCMS(LC-1);RT=0.81,m / z259[M+H] +

[0513] 1H-NMR (CDCl3): δ (ppm) 4.99 (0.5H, d, J = 4.8Hz), 4.80 (0.5H, d, J = 4.8Hz), 4.18-4 .14(0.5H,m),4.12-3.94(1H,m),3.76-3.69(4H,m),3.37-3.30(0.5H,t,J=4.0Hz ),2.71(1H,t,J=11.3Hz),2.47-2.28(1H,m),2.26-2.14(0.5H,m),1.91(0.5H,dd d,J=14.4,6.8,2.6Hz),1.85-1.64(2H,m),1.56-1.40(9H,m),1.33-1.16(1H,m).

[0514] Intermediate B-1-7: 1-(tert-butyl)2-methyl(2S,4S)-4-((8-(benzyloxy)-7-bromoquinoxalin-2-yl)amino)piperidine-1,2-dicarboxylate

[0515] [Chemistry 59]

[0516]

[0517] 1-(tert-butyl) 2-methyl (2S, 4S) -4-aminopiperidine-1,2-dicarboxylate (Intermediate B-1-6; 11.2 g, 43.2 mmol) was dissolved in dimethyl sulfoxide (79 mL), 8-(benzyloxy)-7-bromo-2-chloroquinoxaline (Intermediate A-1-7; 13.7 g, 39.3 mmol) and N, N-diisopropylethylamine (27.4 mL, 157 mmol) were added, and stirred at 100 ° C for 18 hours. Thereafter, water (300 mL) was added to the reaction mixture, and after extraction with ethyl acetate, the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained crude product was purified by silica gel column chromatography (eluent; chloroform:methanol=100:0 to 90:10) to obtain 1-(tert-butyl)2-methyl(2S,4S)-4-((8-(benzyloxy)-7-bromoquinoxalin-2-yl)amino)piperidine-1,2-dicarboxylate (11.7 g, yield 39%).

[0518] LCMS(LC-1);RT=2.12,m / z571[M+H] +

[0519] 1H-NMR (CDCl3): δ (ppm) 8.19-8.13 (1H, m), 7.63-7.50 (4H, m), 7.44-7.28 (3H, m), 5.34 (2H, q, J = 10.6Hz), 5.16-4.87 (1H, m), 4.79 (1H, d, J = 7.2H z),4.23-4.12(2H,m),3.65(3H,s),3.09(1H,brs),2.64(1H,d,J=12.6H z),2.38-2.30(1H,m),1.72(1H,dt,J=12.6,6.2Hz),1.54-1.27(10H,m).

[0520] Intermediate B-1-8: (2S,4S)-4-((8-(benzyloxy)-7-bromoquinoxalin-2-yl)amino)-1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid

[0521] [Chemistry 60]

[0522]

[0523] 1-(tert-butyl) 2-methyl (2S, 4S) -4- ((8- (benzyloxy) -7-bromoquinoxalin-2-yl) amino) piperidine-1,2-dicarboxylate (Intermediate B-1-7; 11.7 g, 20.6 mmol) was dissolved in methanol (680 mL), 1M sodium hydroxide aqueous solution (206 mL) was added, and stirred at 40 ° C for 1 hour. After the reaction was completed, 2M hydrochloric acid aqueous solution (103 mL) was added, and after extraction with chloroform, the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained crude product was purified by silica gel column chromatography (eluent; chloroform:methanol=100:0 to 80:20) to obtain (2S,4S)-4-((8-(benzyloxy)-7-bromoquinoxalin-2-yl)amino)-1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid (8.97 g, yield 78%).

[0524] LCMS (LC-1); RT=1.41, m / z555[MH] +

[0525] 1H-NMR(CDCl3): δ(ppm)8.17(1H,brs),7.62-7.41(5H,m),7.40-7.27(4H,m),5.35-5.15(3H,m),5. 12-4.84(2H,m),4.12-4.00(1H,m),3.20-3.12(1H,m),2.69(2H,s),1.47(9H,s),1.02-0.95(1H,m).

[0526] Intermediate B-1-9: (2S,4S)-4-((7-bromo-8-hydroxyquinoxalin-2-yl)amino)piperidine-2-carboxylic acid

[0527] [Chemistry 61]

[0528]

[0529] (2S,4S)-4-((8-(Benzyloxy)-7-bromoquinoxalin-2-yl)amino)-1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid (Intermediate B-1-8; 8.97 g, 16.1 mmol) was dissolved in dichloromethane (161 mL), and a 1M dichloromethane solution of boron tribromide (96.7 mL, 96.7 mmol) was added under ice cooling at 0°C, followed by stirring for 2 hours. After the starting material disappeared, tert-butanol (160 mL) was added dropwise at 0°C to stop the reaction. The resulting reaction mixture was directly purified by SCX to obtain (2S,4S)-4-((7-bromo-8-hydroxyquinoxalin-2-yl)amino)piperidine-2-carboxylic acid (6.13 g, yield 100%).

[0530] LCMS(LC-1);RT=0.89,m / z367[M+H] +

[0531] 1H-NMR (CD3OD): δ (ppm) 8.00 (1H, d, J = 6.6Hz), 7.46-7.34 (2H, m), 7.26-7.09 (2H, m), 4.32-4.24 (1H, m), 3.65 -3.46(2H,m),3.24-3.07(2H,m),2.48-2.29(1H,m),2.15-1.94(2H,m),1.94-1.82(1H,m),1.81-1.68(1H,m).

[0532] Intermediate B-1-10: (2S,4S)-4-((7-bromo-8-hydroxyquinoxalin-2-yl)amino)-1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid

[0533] [Chemistry 62]

[0534]

[0535] (2S,4S)-4-((7-bromo-8-hydroxyquinoxaline-2-yl)amino)piperidine-2-carboxylic acid (intermediate B-1-9; 5.31 g, 14.5 mmol) was dissolved in N,N-dimethylformamide (725 mL), triethylamine (6.05 mL, 43.5 mmol) and di-tert-butyl dicarbonate (4.75 g, 21.8 mmol) were added, and stirred at room temperature for 1 hour. 1M-hydrochloric acid aqueous solution was then added, and after extraction with ethyl acetate, the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The crude product obtained was used for the next reaction without purification.

[0536] LCMS(LC-1);RT=1.08,m / z467[M+H] +

[0537] [Chemistry 63]

[0538] Method B-2

[0539]

[0540] Intermediate B-2-1: tert-butyl (2S, 4S)-4-((7-bromo-8-hydroxyquinoxalin-2-yl)amino)-2-((3-((tert-butyldiphenylsilyl)oxy)propyl)carbamoyl)piperidine-1-carboxylate

[0541] [Chemistry 64]

[0542]

[0543] (2S, 4S)-4-((7-bromo-8-hydroxyquinoxalin-2-yl)amino)-1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid (Intermediate B-1-10; 4.23 g, 9.07 mmol) and 3-((tert-butyldiphenylsilyl)oxy)propane-1-amine (4.26 g, 13.6 mmol) were dissolved in dichloromethane (45 mL), and N-methylmorpholine (2.49 mL, 22.7 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (5.64 g, 36.3 mmol) and 1-hydroxybenzotriazole (2.69 g, 19.9 mmol) were added, and stirred at room temperature for 2 hours. After the reaction was completed, the mixture was extracted with dichloromethane, and then the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained crude product was used in the next reaction without purification.

[0544] LCMS(LC-1);RT=2.56,m / z764[M+H] +

[0545] Intermediate A-3-6: tert-butyl (2S, 4S)-4-((7-bromo-8-hydroxyquinoxalin-2-yl)amino)-2-((3-hydroxypropyl)carbamoyl)piperidine-1-carboxylate

[0546] [Chemistry 65]

[0547]

[0548] Tert-butyl (2S, 4S)-4-((7-bromo-8-hydroxyquinoxalin-2-yl)amino)-2-((3-((tert-butyldiphenylsilyl)oxy)propyl)carbamoyl)piperidine-1-carboxylate (Intermediate B-2-1; 4.64 g, 6.10 mmol) was dissolved in tetrahydrofuran (30 mL), and tetrabutylammonium fluoride 1M-tetrahydrofuran solution (30 mL, 30 mmol) was added, and stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was directly purified by autoclaved silica gel column chromatography (eluent; chloroform:methanol = 100:0 to 60:40), thereby obtaining tert-butyl (2S, 4S)-4-((7-bromo-8-hydroxyquinoxalin-2-yl)amino)-2-((3-hydroxypropyl)carbamoyl)piperidine-1-carboxylate (2.90 g, yield 91%).

[0549] LCMS(LC-1);RT=1.47,m / z524[M+H] +

[0550] 1H-NMR(CDCl3): δ(ppm)8.88(1H,brs),8.26-8.17(1H,m),7.70-7.44(1H,m),7.33-7.28(1H,m),6.68(1H,brs),5.04-4.83(2H,m),4.45-4.00(2 H,m),3.71-3.43(5H,m),3.40-2.86(2H,m),1.96(1H,d,J=12.0Hz),1.8 2-1.67(2H,m),1.66-1.53(8H,m),1.50-1.45(1H,m),1.42-1.17(2H,m).

[0551] Intermediate A-3-7: tert-butyl (3 2 S,3 4 S)-1 7 -Bromo-4-oxo-9-oxa-2,5-diaza-1(2,8)-quinoxaline-3(4,2)-piperidin-3-cyclononaphenanthene 1 -Formate

[0552] [Chemistry 66]

[0553]

[0554] Tert-butyl (2S, 4S)-4-((7-bromo-8-hydroxyquinoxaline-2-yl)amino)-2-((3-hydroxypropyl)carbamoyl)piperidine-1-carboxylate (Intermediate B-3-6; 2.90 g, 5.55 mmol) was dissolved in THF (1109 mL), and triphenylphosphine (3.64 mg, 13.8 mmol) and di-tert-butyl azodicarboxylate 20% toluene solution (19.2 mL) were added, and stirred at room temperature for 2 hours. The reaction mixture was then concentrated under reduced pressure. The obtained crude product was purified by automatic silica gel column chromatography (eluent; chloroform: methanol = 100:0 to 90:10), thereby obtaining tert-butyl (3 2 S,3 4 S)-1 7 -Bromo-4-oxo-9-oxa-2,5-diaza-1(2,8)-quinoxaline-3(4,2)-piperidin-3-cyclononaphenanthene 1 -formate (1.96 g, yield 70%).

[0555] LCMS(LC-1);RT=1.56,m / z506[M+H] +

[0556] 1H-NMR (CDCl3): δ (ppm) 8.22 (1H, d, J = 5.4Hz), 7.60-7.52 (2H, m), 5.16-5.04 (1.5H, m), 4.91-4 .85(0.5H,m),4.47-4.38(1H,m),4.35-4.26(1.5H,m),4.19-4.01(1.5H,m),3.86-3.71(1.5H, m),3.70-3.59(0.5H,m),3.13(0.5H,dt,J=16.0,4.0Hz),2.95(1.5H,dt,J=16.0,4.0Hz),2.24 -2.03(2H,m),1.99-1.86(1H,m),1.75-1.62(1H,m),1.53-1.45(9.5H,m),1.39-1.18(1.5H,m).

[0557] [Chemistry 67]

[0558] Method C-1

[0559]

[0560] Intermediate C-1-1: tert-butyl (3 2 S,3 4 S)-4-oxo-17 -(2-(Propoxymethyl)pyrimidin-5-yl)-9-oxa-2,5-diaza-1(2,8)-quinoxaline-3(4,2)-piperidin-3-cyclononaphenanthene-3 1 -Formate

[0561] [Chemistry 68]

[0562]

[0563] The tert-butyl (3 2 S,3 4 S)-1 7 -Bromo-4-oxo-9-oxa-2,5-diaza-1(2,8)-quinoxaline-3(4,2)-piperidin-3-cyclononaphenanthene 1 -formate (intermediate A-3-7; 51 mg, 0.099 mmol), (2-(propyloxymethyl)pyrimidin-5-yl)boronic acid (165 mg, 45 wt%, 0.25 mmol) were dissolved in a mixed solvent of 1,4-dioxane (2.0 mL) and water (0.50 mL), potassium carbonate (40 mg, 0.30 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane adduct (20.2 mg, 0.020 mmol) were added, and stirred at 100 ° C for 4 hours under microwave irradiation. Thereafter, the reaction solution was filtered through celite, and the filtrate was concentrated under reduced pressure. The crude product was purified by automatic amine oxide silica gel column chromatography (eluent; chloroform: ethyl acetate = 50:50) to obtain a crude purified product (313 mg). It was used in the next step without further purification.

[0564] LCMS(LC-1);RT=1.44,m / z578[M+H] +

[0565] Intermediate C-1-2: (3 2 S,3 4 S)-1 7 -(2-(Propoxymethyl)pyrimidin-5-yl)-9-oxa-2,5-diaza-1(2,8)-quinoxaline-3(4,2)-piperidinocyclononaphenan-4-one

[0566] [Chemistry 69]

[0567]

[0568] The tert-butyl (3 2 S,3 4 S)-4-oxo-1 7-(2-(Propoxymethyl)pyrimidin-5-yl)-9-oxa-2,5-diaza-1(2,8)-quinoxaline-3(4,2)-piperidin-3-cyclononaphenanthene-3 1 -formate (intermediate C-1-1; 313 mg, 0.54 mmol, crude product) was dissolved in dichloromethane (1 mL), trifluoroacetic acid (0.25 mL) was added, and stirred at room temperature for 14 hours. The resulting reaction mixture was directly subjected to crude purification using SCX. It was then purified using automated amine oxide silica gel column chromatography (eluent; chloroform: methanol = 100:0 to 90:10) to obtain (3 2 S,3 4 S)-1 7 -(2-(Propoxymethyl)pyrimidin-5-yl)-9-oxa-2,5-diaza-1(2,8)-quinoxalino-3(4,2)-piperidinocyclononaquinone-4-one (29.9 mg, 63% yield over 2 steps).

[0569] LCMS(LC-1);RT=1.02,m / z478[M+H] +

[0570] Example a-01-07 (final body C-1-3): (3 2 S,3 4 S)-3 1 -methyl-1 7 -(2-(Propoxymethyl)pyrimidin-5-yl)-9-oxa-2,5-diaza-1(2,8)-quinoxaline-3(4,2)-piperidinocyclononaphenan-4-one

[0571] [Chemistry 70]

[0572]

[0573] (3 2 S,3 4 S)-1 7 -(2-(Propoxymethyl)pyrimidin-5-yl)-9-oxa-2,5-diaza-1(2,8)-quinoxaline-3(4,2)-piperidinocyclononaquinone-4-one (Intermediate C-1-2; 29.9 mg, 0.063 mmol) was dissolved in a mixed solvent of dichloromethane (0.32 mL) and methanol (0.32 mL), and 37% formaldehyde aqueous solution (0.014 mL, 0.19 mmol) and sodium triacetoxyborohydride (20 mg, 0.094 mmol) were added and stirred at room temperature for 1 hour. The obtained reaction mixture was directly purified by SCX and then purified by reverse phase liquid column chromatography to obtain (3 2 S,3 4 S)-3 1-methyl-1 7 -(2-(Propoxymethyl)pyrimidin-5-yl)-9-oxa-2,5-diaza-1(2,8)-quinoxalino-3(4,2)-piperidinocyclononaphenan-4-one (4.8 mg, yield 15%).

[0574] LCMS(LC-1);RT=1.07,m / z492[M+H] +

[0575] 1H-NMR (CD3OD): δ (ppm) 9.05 (2H, s), 8.20 (1H, s), 7.66 (1H, d, J = 8.4Hz), 7.41 (1H, d,J=8.4Hz),4.78-4.65(3H,m),4.20-4.10(1H,m),3.88-3.74(3H,m),3.62(2H,t, J=6.8Hz),3.57-3.48(1H,m),3.36-3.33(2H,m),2.93-2.73(2H,m),2.57(4H,s),2 .26(1H,d,J=7.8Hz),2.01-1.93(1H,m),1.90-1.61(5H,m),0.98(3H,t,J=7.8Hz).

[0576] The compounds in the following table were synthesized by the same method. In the following table, "Reference Methods" indicates that the examples of the production method should be referred to.

[0577] [Table 2-1]

[0578]

[0579] [Table 2-2]

[0580]

[0581] [Table 2-3]

[0582]

[0583] [Table 2-4]

[0584]

[0585] [Table 2-5]

[0586]

[0587] [Table 2-6]

[0588]

[0589] [Table 2-7]

[0590]

[0591] [Chemistry 71]

[0592] Method D-1

[0593]

[0594] Intermediate D-1-2: Quinolin-6-yl acetate

[0595] [Chemistry 72]

[0596]

[0597] Quinoline-6-ol (intermediate D-1-1; 20.0 g, 138 mmol) was dissolved in dichloromethane (222 mL), and pyridine (13.3 mL, 165 mmol) and acetyl chloride (11.7 mL, 164 mmol) were added under ice cooling, and stirred at room temperature for 1 hour. After the reaction was completed, saturated sodium bicarbonate aqueous solution (300 mL) was added and stirred at room temperature for 45 minutes until the foaming subsided. After extraction with chloroform, the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained crude product (26.1 g) was used for the next reaction without purification.

[0598] LCMS(LC-1);RT=1.05,m / z188[M+H] +

[0599] 1H-NMR (CDCl3): δ (ppm) 8.91 (1H, dd, J = 4.2, 1.7Hz), 8.13 (2H, d, J = 1.7Hz), 7.57 (1H ,d,J=2.6Hz),7.47(1H,dd,J=8.3,2.6Hz),7.42(1H,dd,J=8.3,4.2Hz),2.37(3H,s).

[0600] Intermediate D-1-3: 3-bromoquinolin-6-yl acetate

[0601] [Chemistry 73]

[0602]

[0603] Quinolin-6-yl acetate (intermediate D-1-2; 26.1 g, the above crude product) was dissolved in carbon tetrachloride (500 mL), and pyridine (28 mL, 343 mmol) and bromine (50 g, 313 mmol) were added using a dropping funnel under ice cooling. Thereafter, the mixture was stirred at 90°C for 3 hours. After the reaction was completed, dichloromethane (300 mL) and saturated sodium bicarbonate aqueous solution (250 mL) were added, and the mixture was stirred at room temperature for 15 minutes. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by automatic oxidation silica gel column chromatography (eluent; chloroform: methanol = 100:0 to 90:10) to obtain 3-bromoquinolin-6-yl acetate (25.9 g, yield 71%).

[0604] LCMS(LC-1);RT=1.46,m / z266[M+H] +

[0605] 1H-NMR (CDCl3): δ (ppm) 8.89 (1H, d, J = 2.1Hz), 8.28 (1H, d, J = 2.1Hz), 8.10 (1H, d, J = 8.9Hz), 7.52-7.45 (2H, m), 2.37 (3H, s).

[0606] Intermediate D-1-4: 3-bromoquinolin-6-ol

[0607] [Chemistry 74]

[0608]

[0609] 3-Bromoquinolin-6-yl acetate (intermediate D-1-3; 25.9 g, 97.6 mmol) was dissolved in methanol (130 mL), and water (78 mL) and potassium carbonate (27.0 g, 195 mmol) were added, and stirred at room temperature for 1.5 hours. After the reaction was completed, methanol was removed by distillation under reduced pressure. The crude product was washed with water (20 mL) three times and dried under reduced pressure at 40 ° C for 4 hours to obtain 3-bromoquinolin-6-ol (21.0 g, yield 96%).

[0610] LCMS(LC-1);RT=1.19,m / z224[M+H] +

[0611] 1H-NMR (CDCl3): δ (ppm) 8.75 (1H, d, J = 2.2Hz), 8.16 (1H, d, J = 2.2Hz), 7.99 (1H, d,J=9.3Hz),7.32(1H,dd,J=9.3,2.6Hz),7.03(1H,d,J=2.6Hz),5.24(1H,brs).

[0612] Intermediate D-1-5: 3-bromo-5-iodoquinolin-6-ol

[0613] [Chemistry 75]

[0614]

[0615] 3-Bromoquinolin-6-ol (intermediate D-1-4; 21.0 g, 93.8 mmol) was suspended in 2M sodium hydroxide aqueous solution (204 mL), and a solution obtained by dissolving iodine (28.6 g, 112 mmol) in 20% potassium iodide aqueous solution (potassium iodide 54 g / water 270 mL) was added dropwise over 45 minutes, and stirred at room temperature for 1 hour. After the reaction was completed, acetic acid (27 mL) was added, and the mixture was stirred at room temperature for 1 hour, and then filtered. The crude product was washed with water (100 mL) 3 times, and dried under reduced pressure at 40°C for 12 hours to obtain 3-bromo-5-iodoquinolin-6-ol (33.6 g).

[0616] LCMS(LC-1);RT=1.54,m / z349[M+H] +

[0617] 1H-NMR (CDCl3): δ (ppm) 8.73 (1H, d, J = 2.1Hz), 8.42 (1H, dd, J = 2.1, 0.6Hz), 7.98 (1H, d, J = 9.2Hz), 7.49 (1H, d, J = 9.2Hz), 5.98 (1H, brs).

[0618] Intermediate D-1-6: 6-(Benzyloxy)-3-bromo-5-iodoquinoline

[0619] [Chemistry 76]

[0620]

[0621] 3-Bromo-5-iodoquinolin-6-ol (intermediate D-1-5; 33.6 g, 93.8 mmol) was dissolved in N,N-dimethylformamide (313 mL), cesium carbonate (36.6 g, 112 mmol) and benzyl bromide (12.3 mL, 103 mmol) were added, and stirred at room temperature for 2 hours. After the reaction was completed, water (300 mL) was added, and the mixture was stirred at room temperature for 45 minutes, and then filtered. The crude product was dried under reduced pressure to obtain 6-(benzyloxy)-3-bromo-5-iodoquinoline (39.9 g, yield 96%).

[0622] LCMS(LC-1);RT=2.32,m / z440[M+H] +

[0623] 1H-NMR (CDCl3): δ (ppm) 8.73 (1H, d, J = 2.1Hz), 8.64 (1H, d, J = 2.1Hz), 8.02 (1H, d, J =9.2Hz),7.53(2H,d,J=7.6Hz),7.47-7.39(3H,m),7.38-7.31(1H,m),5.35(2H,s).

[0624] Intermediate D-1-7: (6-(Benzyloxy)-3-bromoquinolin-5-yl)boronic acid

[0625] [Chemistry 77]

[0626]

[0627] 6-(Benzyloxy)-3-bromo-5-iodoquinoline (intermediate D-1-6; 17.6 g, 40.0 mmol) was dissolved in tetrahydrofuran (400 mL), and trimethyl borate (9.8 mL, 87.9 mmol) was added at room temperature. The reaction solution was cooled to -78°C, and a 2M tetrahydrofuran solution of isopropylmagnesium chloride (50 mL, 100 mmol) was added dropwise over 15 minutes. Thereafter, the mixture was stirred for 2 hours while warming to room temperature. After the reaction was completed, acetic acid (200 mL) and water (200 mL) were added, and the mixture was stirred at room temperature for 30 minutes. Next, after extraction with ethyl acetate, the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained crude product (11.7 g) was used in the next reaction without purification.

[0628] LCMS(LC-1);RT=1.45,m / z358[M+H] +

[0629] Intermediate D-1-8: 6-(Benzyloxy)-3-bromoquinolin-5-ol

[0630] [Chemistry 78]

[0631]

[0632] (6-(Benzyloxy)-3-bromoquinolin-5-yl)boric acid (intermediate D-1-7; 11.5 g, the above crude product) was dissolved in acetone (400 mL), and water (200 mL) and potassium peroxymonosulfate (Oxone) (40.2 g, 65.6 mmol) were added, and stirred at room temperature for 1 hour. After the reaction was completed, a saturated sodium thiosulfate aqueous solution (200 mL) was added, and after extraction with chloroform, the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained crude product (10.6 g) was used for the next reaction without purification.

[0633] LCMS(LC-1);RT=1.69,m / z330[M+H] +

[0634] 1H-NMR (CDCl3): δ (ppm) 8.76 (1H, d, J = 2.2Hz), 8.65-8.60 (1H, m), 7.63 (1H, d, J=9.3Hz),7.50(1H,d,J=9.3Hz),7.48-7.35(5H,m),6.09(1H,s),5.25(2H,s).

[0635] [Chemistry 79]

[0636] Method D-2

[0637]

[0638] Intermediate D-2-2: 1-(tert-butyl)2-methyl(2S,4S)-4-((6-(benzyloxy)-5-((triisopropylsilyl)oxy)quinolin-3-yl)amino)piperidine-1,2-dicarboxylate

[0639] [Chemistry 80]

[0640]

[0641] 6-(Benzyloxy)-3-bromo-5-((triisopropylsilyl)oxy)quinoline (Intermediate D-2-1; 3.60 g, 7.41 mmol) and 1-(tert-butyl)2-methyl(2S,4S)-4-aminopiperidine-1,2-dicarboxylate (Intermediate B-1-6; 3.20 g, 12.4 mmol) were dissolved in toluene (22 mL), and [(2-di-tert-butylphosphino-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl)-2-(2'-amino-1,1'-biphenyl)]methanesulfonate palladium (II) (320 mg, 0.37 mmol) and phosphazene base P2-Et (5 mL, 15 mmol) were added, and stirred at room temperature for 30 minutes. After the reaction, the reaction mixture was directly purified by automatic silica gel column chromatography (eluent; chloroform: methanol = 100:0 to 80:20) to obtain 1-(tert-butyl) 2-methyl (2S, 4S)-4-((6-(benzyloxy)-5-((triisopropylsilyl)oxy)quinolin-3-yl)amino)piperidine-1,2-dicarboxylate (2.10 g, yield 43%).

[0642] LCMS(LC-6);RT=2.10,m / z664[M+H] +

[0643] 1H-NMR (CDCl3): δ (ppm) 8.24 (1H, d, J = 2.8Hz), 7.52-7.28 (9H, m), 7.15 (1H, d, J = 9.2Hz), 5.25 -5.08(0.5H,m),4.93(0.5H,brs),4.18(0.5H,d,J=14.2Hz),4.05(0.5H,d,J=14.2Hz),3.80- 3.71(3H,m),3.47-3.30(1H,m),3.22-2.95(1H,m),2.58(1H,brs),2.41-2.16(1H,m),2.15-1 .89(1H,m),1.80-1.61(1H,m),1.53-1.42(9H,m),1.36-1.17(4H,m),1.03(18H,d,J=7.3Hz).

[0644] Intermediate D-2-3: (2S,4S)-4-((6-(benzyloxy)-5-((triisopropylsilyl)oxy)quinolin-3-yl)amino)-1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid

[0645] [Chemistry 81]

[0646]

[0647] 1-(tert-butyl)2-methyl(2S,4S)-4-((6-(benzyloxy)-5-((triisopropylsilyl)oxy)quinolin-3-yl)amino)piperidine-1,2-dicarboxylate (Intermediate D-2-2; 2.10 g, 3.16 mmol) was dissolved in methanol (210 mL), 1M-sodium hydroxide aqueous solution (32 mL) was added, and the mixture was stirred at 40°C for 15 hours. After the reaction was completed, 1M-hydrochloric acid aqueous solution (33 mL) was added, and the organic layer was washed with water and saturated brine after extraction with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained crude product (2.15 g) was used in the next reaction without purification.

[0648] LCMS(LC-1);RT=1.95,m / z650[M+H] +

[0649] Intermediate D-2-4: tert-butyl (2S, 4S)-4-((6-(benzyloxy)-5-((triisopropylsilyl)oxy)quinolin-3-yl)amino)-2-((2-fluoro-3-hydroxypropyl)carbamoyl)piperidine-1-carboxylate

[0650] [Chemistry 82]

[0651]

[0652] (2S,4S)-4-((6-(benzyloxy)-5-((triisopropylsilyl)oxy)quinolin-3-yl)amino)-1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid (Intermediate D-2-3; 2.15 g, 3.16 mmol) and 3-amino-2-fluoropropane-1-ol (348 mg, 3.79 mmol) were dissolved in N,N-dimethylformamide (16 mL), and N-methylmorpholine (0.87 mL, 7.90 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (2.45 g, 12.6 mmol) and 1-hydroxybenzotriazole (1.01 g, 6.96 mmol) were added, and stirred at room temperature for 30 minutes. After the reaction was completed, the mixture was extracted with ethyl acetate, and the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by automated silica gel column chromatography (eluent; ethyl acetate:methanol = 100:0 to 98:2) to give tert-butyl (2S,4S)-4-((6-(benzyloxy)-5-((triisopropylsilyl)oxy)quinolin-3-yl)amino)-2-((2-fluoro-3-hydroxypropyl)carbamoyl)piperidine-1-carboxylate (886 mg, 39% yield).

[0653] LCMS(LC-1);RT=2.35,m / z725[M+H] +

[0654] 1H-NMR(CDCl3): δ(ppm)8.27-8.23(1H,m),7.54-7.46(1H,m),7.44-7.28(6H,m),7.14(1H ,d,J=9.2Hz),5.16(2H,s),4.98(1H,brs),4.77-4.44(1H,m),4.12(1H,qJ=7.2Hz),3.71( 5H,m),3.28-3.10(1H,m),2.96(1H,brs),2.75-2.49(1H,m),2.29(1H,d,J=10.8Hz),2.05 (1H,s),1.54-1.47(1H,m),1.35-1.17(9H,m),1.35-1.17(5H,m),1.03(18H,d,J=7.3Hz).

[0655] Intermediate D-2-5: tert-butyl (2S, 4S)-4-((6-(benzyloxy)-5-hydroxyquinolin-3-yl)amino)-2-((2-fluoro-3-hydroxypropyl)carbamoyl)piperidine-1-carboxylate

[0656] [Chemistry 83]

[0657]

[0658] Tert-butyl (2S, 4S)-4-((6-(benzyloxy)-5-((triisopropylsilyl)oxy)quinolin-3-yl)amino)-2-((2-fluoro-3-hydroxypropyl)carbamoyl)piperidine-1-carboxylate (Intermediate D-2-4; 886 mg, 1.22 mmol) was dissolved in tetrahydrofuran (6.1 mL), tetrabutylammonium fluoride 1M-tetrahydrofuran solution (2.44 mL, 2.44 mmol) was added, and the mixture was stirred at room temperature for 30 minutes. After the reaction, the reaction mixture was directly purified by automatic silica gel column chromatography (eluent; chloroform: methanol = 100:0 to 80:20) to obtain tert-butyl (2S, 4S)-4-((6-(benzyloxy)-5-hydroxyquinolin-3-yl)amino)-2-((2-fluoro-3-hydroxypropyl)carbamoyl)piperidine-1-carboxylate (660 mg, yield 95%).

[0659] LCMS(LC-1);RT=1.46,m / z569[M+H] +

[0660] 1H-NMR (CDCl3): δ (ppm) 8.29 (1H, d, J = 2.8Hz), 7.55-7.28 (6H, m), 7.22-7.12 (2H, m),6.92-6.37(1H,m),6.03(1H,brs),4.99(1H,brs),4.73(0.5H,brs),4.61(0.5 H,brs),4.46-4.06(2H,m),3.93-3.70(3H,m),3.66(2H,brs),3.10-2.95(2H,m), 2.93-2.57(2H,m),2.10(2H,d,J=11.8Hz),1.53-1.48(9H,m),1.47-1.22(2H,m).

[0661] Intermediate D-2-6: tert-butyl (3 2 S,3 4 S)-1 6 -(Benzyloxy)-7-fluoro-4-oxo-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenanthene-3 1 -Formate

[0662] [Chemistry 84]

[0663]

[0664] Tert-butyl (2S, 4S)-4-((6-(benzyloxy)-5-hydroxyquinolin-3-yl)amino)-2-((2-fluoro-3-hydroxypropyl)carbamoyl)piperidine-1-carboxylate (intermediate D-2-5; 660 mg, 1.161 mmol) was dissolved in toluene (240 mL), and triphenylphosphine (773 mg, 2.90 mmol) and di-tert-butyl azodicarboxylate 20% toluene solution (4.16 mL, 3.48 mmol) were added, and stirred at room temperature for 1 hour. The reaction mixture was then concentrated under reduced pressure. The crude product was purified by autoclaved silica gel column chromatography (eluent; chloroform:methanol = 100:0 to 90:10), thereby obtaining tert-butyl (3 2 S,3 4 S)-1 6 -(Benzyloxy)-7-fluoro-4-oxo-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenanthene-3 1 -formate (431 mg, yield 67%).

[0665] LCMS(LC-1);RT=1.62,m / z551[M+H] +

[0666] 1H-NMR (CDCl3): δ (ppm) 8.29 (1H, d, J = 2.8Hz), 7.72-7.62 (1H, m), 7.53-7.28 (5H, m), 7.21 (1H, d, J = 9.4Hz), 5.91 (1H ,d,J=7.2Hz),5.31(1H,d,J=12.0Hz),5.22(1H,d,J=12.0Hz),4.96(0.5H,brs),4.91(0.5H,brs),4.81(0.5H,brs),4 .61(1H,dd,J=8.9,3.5),4.48-4.32(1.5H,m),4.07-3.99(1H,m),3.78-3.71(2H,m),3.68-3.57(1H,m),3.56-3.37( 2H,m),2.72(1H,d,J=11.6Hz),1.99-1.92(1H,m),1.85(2H,td,J=6.8,3.2Hz),1.73-1.59(1H,m),1.53-1.39(9H,m).

[0667] [Chemistry 85]

[0668] Method D-3

[0669]

[0670] Intermediate D-3-1: tert-butyl (3 2 S,3 4 S)-7-Fluoro-1 6 -Hydroxy-4-oxo-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene 1 -Formate

[0671] [Chemistry 86]

[0672]

[0673] The tert-butyl (3 2 S,3 4 S)-1 6 -(Benzyloxy)-7-fluoro-4-oxo-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenanthene-3 1 -formate (intermediate D-2-6; 325 mg, 0.59 mmol) was dissolved in a mixed solvent of methanol (3 mL) and tetrahydrofuran (3 mL), and palladium hydroxide (65 mg, 20 wt%) was added, and stirred at room temperature for 18 hours under a hydrogen atmosphere. The reaction system was replaced under a nitrogen atmosphere, and then filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure to obtain tert-butyl (3 2 S,3 4 S)-7-Fluoro-1 6 -Hydroxy-4-oxo-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene 1 -formate (330 mg, yield 92%). The crude product was used in the next step without purification.

[0674] LCMS(LC-1);RT=1.13,m / z461[M+H] +

[0675] Intermediate D-3-2: tert-butyl (3 2 S,3 4 S)-7-fluoro-4-oxo-1 6 -(((trifluoromethyl)sulfonyl)oxy)-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-3-yl)- 1 -Formate

[0676] [Chemistry 87]

[0677]

[0678] The tert-butyl (3 2 S,3 4S)-7-Fluoro-1 6 -Hydroxy-4-oxo-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene 1 -formate (intermediate D-3-1; 330 mg, 0.72 mmol) was dissolved in 1,4-dioxane (7.2 mL), and N,N-dimethylformamide (6 drops), N,N-diisopropylethylamine (0.748 mL, 4.30 mmol), N-phenyl-bis(trifluoromethanesulfonimide) (824 mg, 2.30 mmol) were added, and stirred at room temperature for 7 hours. After the reaction was completed, the reaction mixture was directly purified by automatic silica gel column chromatography (eluent; chloroform: methanol = 100:0 to 90:10), thereby obtaining tert-butyl (3 2 S,3 4 S)-7-fluoro-4-oxo-1 6 -(((trifluoromethyl)sulfonyl)oxy)-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-3-yl)- 1 -formate (420 mg, 99%).

[0679] LCMS(LC-1);RT=1.65,m / z593[M+H] +

[0680] 1H-NMR (DMSO-d6): δ (ppm) 8.55 (1H, d, J = 2.6Hz), 8.18 (1H, d, J = 7.0Hz), 7.75 (1H, d, J = 9.2Hz), 7.2 3(1H,d,J=7.9Hz),7.05(1H,s),6.93-6.87(1H,m),5.14(0.5H,brs),5.08-4.93(0.5H,m),4.71(0 .5H,d,J=2.4Hz),4.65-4.52(0.5H,m),4.46-4.22(2H,m),4.11(1H,brs),3.98(1H,d,J=9.0Hz),3 .65-3.48(3H,m),3.29-3.11(2H,m),1.99-1.87(1H,m),1.59(1H,d,J=13.4Hz),1.42-1.23(9H,m).

[0681] Intermediate D-3-3: tert-butyl-(3 2 S,3 4 S)-7-fluoro-4-oxo-1 6 -(2-(Propyloxymethyl)pyrimidin-5-yl)-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-31 -Formate

[0682] [Chemistry 88]

[0683]

[0684] The tert-butyl (3 2 S,3 4 S)-7-fluoro-4-oxo-1 6 -(((trifluoromethyl)sulfonyl)oxy)-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-3-yl)- 1 -formate (intermediate D-3-2; 420 mg, 0.71 mmol), 2-(propyloxymethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (1.30 g, 31 wt%, 1.77 mmol) were dissolved in a mixed solvent of 1,4-dioxane (2.8 mL) and water (0.28 mL), and cesium carbonate (705 mg, 2.12 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane adduct (117 mg, 0.14 mmol) were added, and the mixture was stirred at 100 ° C for 2 hours under microwave irradiation. The reaction solution was filtered through celite, the filtrate was concentrated under reduced pressure, and the crude product was purified by automatic silica gel column chromatography (eluent; chloroform:methanol=100:0-90:10) to obtain tert-butyl-(3 2 S,3 4 S)-7-fluoro-4-oxo-1 6 -(2-(Propyloxymethyl)pyrimidin-5-yl)-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-3 1 -formate (180 mg, yield 43%). The crude product was used in the next reaction without further purification.

[0685] LCMS(LC-1);RT=1.44,m / z595[M+H] +

[0686] Intermediate D-3-4: (3 2 S,3 4 S)-7-Fluoro-1 6 -(2-(Propoxymethyl)pyrimidin-5-yl)-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenan-4-one

[0687] [Chemistry 89]

[0688]

[0689] The tert-butyl-(3 2 S,3 4 S)-7-fluoro-4-oxo-1 6 -(2-(Propyloxymethyl)pyrimidin-5-yl)-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-3 1 -formate (intermediate D-3-3; 180 mg, 0.30 mmol) was dissolved in dichloromethane (3.0 mL), trifluoroacetic acid (0.75 mL) was added, and stirred at room temperature for 30 minutes. The resulting reaction mixture was directly purified by SCX to obtain (3 2 S,3 4 S)-7-Fluoro-1 6 -(2-(Propoxymethyl)pyrimidin-5-yl)-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaquin-4-one (148 mg, yield 98%). The crude product was used in the next reaction without further purification.

[0690] LCMS(LC-1);RT=1.01,m / z495[M+H] +

[0691] Example a-02-02 (final body D-3-5): (3 2 S,3 4 S)-7-Fluoro-3 1 -methyl-1 6 -(2-(Propoxymethyl)pyrimidin-5-yl)-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenan-4-one

[0692] [Chemistry 90]

[0693]

[0694] (3 2 S,3 4 S)-7-Fluoro-1 6-(2-(Propoxymethyl)pyrimidin-5-yl)-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaquinone-4-one (Intermediate D-3-4; 148 mg, 0.30 mmol) was dissolved in a mixed solvent of dichloromethane (1.5 mL) and methanol (1.5 mL), and 37% formaldehyde aqueous solution (0.068 mL, 0.91 mmol) and sodium triacetoxyborohydride (96 mg, 0.45 mmol) were added and stirred at room temperature for 1 hour. The obtained reaction mixture was directly purified by SCX and then purified by reverse phase liquid column chromatography to obtain (3 2 S,3 4 S)-7-Fluoro-3 1 -methyl-1 6 -(2-(Propoxymethyl)pyrimidin-5-yl)-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaquin-4-one (106 mg, 69% yield over 2 steps).

[0695] LCMS(LC-1);RT=1.11,m / z509[M+H] +

[0696] 1H-NMR (CDCl3): δ (ppm) 9.07 (2H, s), 8.43 (1H, d, J = 2.7Hz), 7.87 (1H, d, J = 8.7Hz), 7.46-7 .39(2H,m),6.64(1H,brs),5.20-4.87(1H,m),4.83(2H,s),4.23-4.10(1H,m),3.97-3.78( 3H,m),3.74-3.62(3H,m),3.30-3.20(2H,m),2.84-2.76(1H,m),2.41(3H,s),2.34(1H,brs ), 2.21 (1H, d, J = 13.1Hz), 2.03 (1H, d, J = 9.2Hz), 1.80-1.63 (4H, m), 0.99 (3H, t, J = 7.4Hz).

[0697] [Chemistry 91]

[0698] Method E-1

[0699]

[0700] Intermediate E-1-1: 6-(Benzyloxy)-3-bromo-5-(3-((tert-butyldiphenylsilyl)oxy)propoxy)quinoline

[0701] [Chemistry 92]

[0702]

[0703] 6-(Benzyloxy)-3-bromoquinolin-5-ol (Intermediate D-1-8; 3.00 g, 9.1 mmol) was dissolved in toluene (91 mL), and 3-((tert-butyldiphenylsilyl)oxy)propane-1-ol (4.2 g, 18.2 mmol), triphenylphosphine (4.80 g, 18.2 mmol), and tert-butyl azodicarboxylate (18.2 mmol) were added, and stirred at room temperature for 1 hour. After the reaction was completed, the solvent was removed under reduced pressure, and the crude product was crudely purified by automatic silica gel column chromatography (eluent; hexane: ethyl acetate = 100:0 to 70:30) to obtain 6-(benzyloxy)-3-bromo-5-(3-((tert-butyldiphenylsilyl)oxy)propoxy)quinoline (6.49 g) as a crude product. The crude product was used in the next reaction without further purification.

[0704] LCMS(LC-6);RT=2.71,m / z626[M+H] +

[0705] Intermediate E-1-2: 3-((6-(Benzyloxy)-3-bromoquinolin-5-yl)oxy)propan-1-ol

[0706] [Chemistry 93]

[0707]

[0708] 6-(Benzyloxy)-3-bromo-5-(3-((tert-butyldiphenylsilyl)oxy)propoxy)quinoline (Intermediate E-1-1; 6.49 g, 10.36 mmol) was dissolved in tetrahydrofuran (80 mL), tetrabutylammonium fluoride (30 mL, 1M-THF solution) was added, and stirred at room temperature for 16 hours. After the reaction was completed, it was extracted with ethyl acetate, and the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by autoclaved silica gel column chromatography (eluent; chloroform: methanol = 100:0 to 50:50) to obtain 3-((6-(benzyloxy)-3-bromoquinolin-5-yl)oxy)propan-1-ol (4.72 g) as a crude purified product.

[0709] LCMS(LC-1);RT=1.66,m / z388[M+H] +

[0710] 1H-NMR (CDCl3): δ (ppm) 8.77 (1H, d, J = 2.2Hz), 8.58 (1H, dd, J = 2.2, 0.7Hz), 7.93-7.75 (1H, m), 7.55-7. 29(6H,m),5.27(2H,s),4.28(2H,t,J=5.8Hz),3.90(2H,q,J=5.8Hz),3.70(1H,brs),2.11-2.02(2H,m).

[0711] Intermediate E-1-3: 2-(3-((6-(benzyloxy)-3-bromoquinolin-5-yl)oxy)propyl)1-(tert-butyl)(2S,4S)-4-azidopiperidine-1,2-dicarboxylate

[0712] [Chemistry 94]

[0713]

[0714] 3-((6-(Benzyloxy)-3-bromoquinolin-5-yl)oxy)propane-1-ol (Intermediate E-1-2; 4.02 g, 10.3 mmol) and (2S, 4S)-4-azido-1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid (4.81 g, 17.8 mmol) were dissolved in dichloromethane (100 mL), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (4.06 g, 21.1 mmol) and N,N-dimethylaminopyridine (2.70 g, 22.1 mmol) were added, and stirred at room temperature for 3 hours. After the reaction was completed, the mixture was extracted with dichloromethane, and the organic layer was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by autoclave silica gel column chromatography (eluent; hexane:ethyl acetate = 90:10-0:100) to obtain 2-(3-((6-(benzyloxy)-3-bromoquinolin-5-yl)oxy)propyl)1-(tert-butyl)(2S,4S)-4-azidopiperidine-1,2-dicarboxylate (5.69 g) as a crude product. The crude product was used in the next reaction without further purification.

[0715] LCMS(LC-1);RT=2.36,m / z640[M+H] +

[0716] Intermediate E-1-4: 2-(3-((6-(benzyloxy)-3-bromoquinolin-5-yl)oxy)propyl)1-(tert-butyl)(2S,4S)-4-aminopiperidine-1,2-dicarboxylate

[0717] [Chemistry 95]

[0718]

[0719] 2-(3-((6-(benzyloxy)-3-bromoquinolin-5-yl)oxy)propyl)1-(tert-butyl)(2S,4S)-4-azidopiperidine-1,2-dicarboxylate (Intermediate E-1-3; 5.69 g, 8.88 mmol) was dissolved in tetrahydrofuran (100 mL), and triphenylphosphine (5.0 g, 19.0 mmol) and water (5.0 mL) were added, followed by stirring at 70° C. for 15 hours. After completion of the reaction, the solvent was removed under reduced pressure, and the crude product was purified by autoclaved silica gel column chromatography (eluent; hexane:ethyl acetate=90:10-0:100) to obtain 2-(3-((6-(benzyloxy)-3-bromoquinolin-5-yl)oxy)propyl)1-(tert-butyl)(2S,4S)-4-aminopiperidine-1,2-dicarboxylate (5.78 g) as a crude product. The crude product was used in the next reaction without further purification.

[0720] LCMS(LC-1);RT=1.70,m / z614[M+H] +

[0721] Intermediate E-1-5: tert-butyl (3 2 S,3 4 S)-1 6 -(Benzyloxy)-4-oxo-5,9-dioxa-2-aza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenanthene-3 1 -Formate

[0722] [Chemistry 96]

[0723]

[0724] 2-(3-((6-(benzyloxy)-3-bromoquinolin-5-yl)oxy)propyl)1-(tert-butyl)(2S,4S)-4-aminopiperidine-1,2-dicarboxylate (Intermediate E-1-4; 5.46 g, 8.89 mmol) was dissolved in 1,4-dioxane (90 mL), cesium carbonate (9.00 g, 27.6 mmol), [(2-di-tert-butylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)-2-(2'-amino-1,1'-biphenyl)]methanesulfonate palladium (II) (1.10 g, 1.38 mmol) were added, and stirred at 120° C. for 3 days. After the reaction, the reaction mixture was filtered through celite, and the filtrate was concentrated under reduced pressure. The obtained crude product was purified by automated silica gel column chromatography (eluent; hexane:ethyl acetate=90:10-0:100) to obtain tert-butyl (3 2 S,3 4 S)-1 6-(Benzyloxy)-4-oxo-5,9-dioxa-2-aza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenanthene-3 1 -formate (360 mg, yield 7%).

[0725] LCMS(LC-1);RT=1.98,m / z534[M+H] +

[0726] 1H-NMR (CDCl3): δ (ppm) 8.76 (1H, d, J = 2.3Hz), 8.58-8.53 (1H, m), 7.79 (1H, d, J = 9.3Hz), 7.53-7.3 0(6H,m),5.28-5.21(0.5H,m),4.97(0.5H,d,J=5.3Hz),4.46-4.34(2H,m),4.25(2H,t,J=6.2Hz),4 .15-4.01(0.5H,m),3.95(0.5H,d,J=12.5Hz),3.06-2.84(1H,m),2.66(1H,dt,J=11.4,3.7Hz),2. 31(1H,t,J=10.0Hz),2.23-2.12(2H,m),1.80-1.63(1H,m),1.50-1.37(13H,m),1.33-1.15(1H,m).

[0727] [Chemistry 97]

[0728] Method F-1

[0729]

[0730] Intermediate F-1-1: tert-butyl (3-((6-(benzyloxy)-3-bromoquinolin-5-yl)oxy)propyl)carbamate

[0731] [Chemistry 98]

[0732]

[0733] 6-(Benzyloxy)-3-bromoquinolin-5-ol (intermediate D-1-8; 1.0 g, 3.03 mmol) was dissolved in toluene (15 mL), tert-butyl (3-hydroxypropyl) carbamate (1.59 g, 9.09 mmol) and triphenylphosphine (1.99 g, 7.57 mmol) were added, and finally a 20% toluene solution of di-tert-butyl azodicarboxylate (10 mL, 9.09 mmol) was added, and stirred at room temperature for 1 hour. The solvent of the reaction solution was distilled off, and the reaction solution was purified by autoclaved silica gel column chromatography (eluent; hexane: ethyl acetate = 1:1), thereby obtaining tert-butyl (3-((6-(benzyloxy)-3-bromoquinolin-5-yl)oxy)propyl) carbamate (3.11 g, yield 99%).

[0734] LCMS(LC-1);RT=2.11,m / z487[M+H] +

[0735] 1H-NMR (CDCl3): δ (ppm) 8.76 (1H, d, J = 2.0Hz), 8.56 (1H, d, J = 2.0Hz), 7.80 (1H, d, J = 9.0Hz), 7.53 (1H, s), 7.40 (5H,s),5.29(2H,s),5.11-4.84(2H,m),4.26-4.17(2H,m),3.44-3.32(2H,m),2.04-1.97(2H,m),1.44(9H,s).

[0736] Intermediate F-1-2: tert-butyl (3-((6-(benzyloxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-5-yl)oxy)propyl)carbamate

[0737] [Chemistry 99]

[0738]

[0739] Tert-butyl (3-((6-(benzyloxy)-3-bromoquinolin-5-yl)oxy)propyl)carbamate (intermediate F-1-1; 1.0 g, 3.03 mmol) was dissolved in 1,4-dioxane (15 mL), and bis(pinacol)diboron (451 mg, 1.79 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium (II) (175 mg, 0.24 mmol), and potassium acetate (237 mg, 2.38 mmol) were added, and stirred at 100° C. for 14 hours. The reaction solution was cooled to room temperature, and the precipitated solid was removed by filtration, and the solvent was distilled off to obtain tert-butyl (3-((6-(benzyloxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-5-yl)oxy)propyl)carbamate as a crude product.

[0740] LCMS(LC-1);RT=2.14,m / z534[M+H] +

[0741] Intermediate F-1-3: tert-butyl (3-((6-(benzyloxy)-3-hydroxyquinolin-5-yl)oxy)propyl)carbamate

[0742] [Chemical 100]

[0743]

[0744] Tert-butyl (3-((6-(benzyloxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-5-yl)oxy)propyl)carbamate (Intermediate F-1-2; 636 mg, 1.19 mmol) was dissolved in tetrahydrofuran (13 mL), and 1M sodium hydroxide aqueous solution (520 μL) and 20% hydrogen peroxide (520 μL) were added under ice cooling, and stirred at the same temperature for 2 hours. Saturated sodium thiosulfate aqueous solution and 1M hydrochloric acid were added to the reaction mixture, and the mixture was extracted with chloroform and dried over magnesium sulfate. The solvent was distilled off and purified by autoclaved silica gel column chromatography (eluent; hexane:ethyl acetate = 50:50) to obtain tert-butyl (3-((6-(benzyloxy)-3-hydroxyquinolin-5-yl)oxy)propyl)carbamate (678 mg, yield 99%).

[0745] LCMS(LC-1);RT=1.68,m / z425[M+H] +

[0746] 1H-NMR(CDCl3): δ(ppm)8.65-8.48(1H,m),8.37-8.10(1H,m),8.04-7.86(1H,m),7.85-7.69(1H,m),7.52-7.43(2H,m ),7.43-7.27(4H,m),5.25(2H,s),4.18-4.13(2H,m),3.61-3.50(2H,m),1.96-1.86(2H,m),1.26(2H,s),1.24(9H,s).

[0747] Intermediate F-1-4: 5-(3-aminopropoxy)-6-(benzyloxy)quinolin-3-ol

[0748] [Chemistry 101]

[0749]

[0750] Tert-butyl (3-((6-(benzyloxy)-3-hydroxyquinolin-5-yl)oxy)propyl)carbamate (Intermediate F-1-3; 678 mg, 1.60 mmol) was dissolved in dichloromethane (17 mL), trifluoroacetic acid (4.0 mL) was added at room temperature, and stirred for 20 minutes. The reaction mixture was concentrated and treated with an SCX column to obtain 5-(3-aminopropoxy)-6-(benzyloxy)quinolin-3-ol (312 mg, yield 60%).

[0751] LCMS(LC-1);RT=0.96,m / z325[M+H] +

[0752] 1H-NMR (CDCl3): δ (ppm) 8.64 (1H, d, J = 2.5Hz), 7.83-7.76 (1H, m), 7.76-7.72 (1H, m), 7.49-7.44 (2H ,m),7.43-7.28(4H,m),5.25-5.20(2H,m),4.25-4.17(2H,m),3.09-2.99(2H,m),2.03-1.90(2H,m).

[0753] Intermediate F-1-5: tert-Butyl (2S, 4R)-2-((3-((6-(benzyloxy)-3-hydroxyquinolin-5-yl)oxy)propyl)carbamoyl)-4-hydroxypiperidine-1-carboxylate

[0754] [Chemistry 102]

[0755]

[0756] 5-(3-Aminopropoxy)-6-(benzyloxy)quinolin-3-ol (intermediate F-1-4; 312 mg, 0.81 mmol) was dissolved in dichloromethane (4.0 mL), and N-methylmorpholine (222 μL, 2.01 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (627 mg, 3.22 mmol), 1-hydroxybenzotriazole (239 mg, 1.77 mmol), (2S, 4R)-1-(tert-butoxycarbonyl)-4-hydroxypiperidine-2-carboxylic acid (376 mg, 1.45 mmol) were added, and the mixture was stirred at room temperature for 3 hours. Water was added to the reaction mixture, extracted with chloroform, the solvent was distilled off, and the product was purified by automatic oxidation silica gel column chromatography (eluent; chloroform:methanol = 9:1) to obtain tert-butyl (2S,4R)-2-((3-((6-(benzyloxy)-3-hydroxyquinolin-5-yl)oxy)propyl)carbamoyl)-4-hydroxypiperidine-1-carboxylate (122 mg, yield 27%).

[0757] LCMS(LC-1);RT=1.43,m / z552[M+H] +

[0758] Intermediate F-1-6: tert-butyl (3 2 S,3 4 S)-1 6 -(Benzyloxy)-4-oxo-2,9-dioxa-5-aza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenanthene-3 1 -Formate

[0759] [Chemistry 103]

[0760]

[0761] Tert-butyl (2S, 4R)-2-((3-((6-(benzyloxy)-3-hydroxyquinolin-5-yl)oxy)propyl)carbamoyl)-4-hydroxypiperidine-1-carboxylate (Intermediate F-1-5; 122 mg, 0.22 mmol) was dissolved in toluene (20 mL), and triphenylphosphine (149 mg, 0.54 mmol) and 20% di-tert-butyl azodicarboxylate toluene solution (780 μL, 0.65 mmol) were added, and stirred for 1 hour and 30 minutes. The reaction mixture was concentrated and purified by automatic silica gel column chromatography (eluent; chloroform:methanol=90:10), thereby obtaining tert-butyl (3 2 S,3 4 S)-1 6 -(Benzyloxy)-4-oxo-2,9-dioxa-5-aza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenanthene-3 1-formate (84 mg, 72%).

[0762] LCMS(LC-1);RT=1.60,m / z534[M+H] +

[0763] [Chemistry 104]

[0764] Method F-2

[0765]

[0766] Intermediate F-2-1: tert-butyl (3 2 S,3 4 S)-1 6 -Hydroxy-4-oxo-2,9-dioxa-5-aza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-3 1 -Formate

[0767] [Chemistry 105]

[0768]

[0769] The tert-butyl (3 2 S,3 4 S)-1 6 -(Benzyloxy)-4-oxo-2,9-dioxa-5-aza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenanthene-3 1 -formate (intermediate F-1-6; 84 mg, 0.15 mmol) was dissolved in methanol (0.8 mL) and tetrahydrofuran (0.8 mL), and nitrogen atmosphere was added. Palladium hydroxide (16.6 mg) was added, and the mixture was replaced with hydrogen. The mixture was stirred vigorously at room temperature for 14 hours. After removing the insoluble matter from the reaction mixture by filtration, the solvent was distilled off, and the mixture was purified by autoclave silica gel column chromatography (eluent; chloroform: methanol = 90:10), thereby obtaining tert-butyl (3 2 S,3 4 S)-1 6 -Hydroxy-4-oxo-2,9-dioxa-5-aza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-3 1 -formate (31.2 mg, yield 46%).

[0770] LCMS(LC-1);RT=1.12,m / z444[M+H] +

[0771] Intermediate F-2-2: tert-butyl (3 2 S,3 4 S)-1 6-(((trifluoromethyl)sulfonyl)oxy)-4-oxo-2,9-dioxa-5-aza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-3 1 -Formate

[0772] [Chemistry 106]

[0773]

[0774] The tert-butyl (3 2 S,3 4 S)-1 6 -Hydroxy-4-oxo-2,9-dioxa-5-aza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-3 1 -formate (intermediate F-2-1; 31.2 mg, 70 μmol) was dissolved in 1,4-dioxane (700 μL), and N,N-bis(trifluoromethylsulfonyl)aniline (85 mg, 0.22 mmol), diisopropylethylamine (73 μL, 0.42 mmol), and dimethylformamide (2 drops) were added, and stirred at room temperature for 3 hours. The reaction mixture was concentrated and purified by autoclaved silica gel column chromatography (eluent; chloroform:methanol = 90:10), thereby obtaining tert-butyl (3 2 S,3 4 S)-1 6 -(((trifluoromethyl)sulfonyl)oxy)-4-oxo-2,9-dioxa-5-aza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-3 1 -formate (44.3 mg, yield 99%).

[0775] LCMS(LC-1);RT=1.68,m / z576[M+H] +

[0776] 1H-NMR (CDCl3): δ (ppm) 8.80 (1H, d, J = 2.5Hz), 8.01 (1H, s), 7.93 (1H, d, J = 9.5Hz), 7 .84-7.79(1H,m),7.53-7.47(1H,m),7.43-7.34(2H,m),7.30(3H,s),5.76-5.59(1H, m),4.74-4.64(1H,m),4.42-4.22(3H,m),4.16-3.86(4H,m),3.43-3.26(1H,m),2.50 -2.40(1H,m),2.34-2.27(1H,m),2.21-2.13(1H,m),1.90-1.75(4H,m),1.46(9H,s).

[0777] Intermediate F-2-3: tert-butyl (3 2 S,3 4 S)-1 6 -(2-(Propyloxymethyl)pyrimidin-5-yl)-4-oxo-2,9-dioxa-5-aza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-3 1 -Formate

[0778] [Chemistry 107]

[0779]

[0780] The tert-butyl (3 2 S,3 4 S)-1 6 -(((trifluoromethyl)sulfonyl)oxy)-4-oxo-2,9-dioxa-5-aza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-3 1 -formate (intermediate F-2-2; 44 mg, 76 μmol) was dissolved in 1,4-dioxane (600 μL) and water (60 μL), and (2-(propyloxymethyl)pyrimidin-5-yl)boric acid (175 mg, 0.19 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) (13 mg, 15 μmol), and cesium carbonate (78 mg, 0.23 mmol) were added, and microwave irradiation was performed at 100°C for 3 hours. After removing the insoluble matter from the reaction mixture by diatomaceous earth filtration, the solvent was distilled off, and the mixture was purified by autoclaved silica gel column chromatography (eluent; chloroform:methanol=90:10), thereby obtaining tert-butyl (3 2 S,3 4 S)-1 6 -(2-(Propyloxymethyl)pyrimidin-5-yl)-4-oxo-2,9-dioxa-5-aza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-3 1 -formate (22.8 mg, yield 52%).

[0781] LCMS(LC-1);RT=1.42,m / z578[M+H] +

[0782] Intermediate F-2-4: (3 2 S,3 4 S)-1 6 -(2-(Propoxymethyl)pyrimidin-5-yl)-2,9-dioxa-5-aza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenan-4-one

[0783] [Chemistry 108]

[0784]

[0785] The tert-butyl (3 2 S,3 4 S)-1 6 -(2-(Propyloxymethyl)pyrimidin-5-yl)-4-oxo-2,9-dioxa-5-aza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-3 1 -formate (intermediate F-2-3; 22.8 mg, 39 μmol) was dissolved in dichloromethane (400 μL), trifluoroacetic acid (100 μL) was added, and stirred at room temperature for 20 minutes. The reaction mixture was treated with SCX to obtain (3 2 S,3 4 S)-1 6 -(2-(Propoxymethyl)pyrimidin-5-yl)-2,9-dioxa-5-aza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenan-4-one (13.4 mg, yield 99%).

[0786] LCMS(LC-1);RT=0.98,m / z478[M+H] +

[0787] Example a-02-25 (final body F-2-5): (3 2 S,3 4 S)-3 1 -methyl-1 6 -(2-(Propoxymethyl)pyrimidin-5-yl)-2,9-dioxa-5-aza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenan-4-one

[0788] [Chemistry 109]

[0789]

[0790] (3 2 S,3 4 S)-1 6-(2-(Propoxymethyl)pyrimidin-5-yl)-2,9-dioxa-5-aza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaquinone-4-one (Intermediate F-2-4; 13.4 mg, 39 μmol) was dissolved in dichloromethane (200 μL) and methanol (200 μL), and 37% formaldehyde aqueous solution (8.7 μL, 0.12 mmol) and triacetoxyborohydride (12.5 mg, 59 μmol) were added, and stirred at room temperature for 10 minutes. The reaction mixture was treated with SCX and purified by preparative thin layer chromatography (eluent; chloroform: 2M-ammonia methanol solution = 97:3), thereby obtaining (3 2 S,3 4 S)-3 1 -methyl-1 6 -(2-(Propoxymethyl)pyrimidin-5-yl)-2,9-dioxa-5-aza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenan-4-one (6.2 mg, yield 32%).

[0791] LCMS(LC-1);RT=1.00,m / z492[M+H] +

[0792] 1H-NMR (CD3OD): δ (ppm) 9.19 (2H, s), 8.82 (1H, d, J = 2.5Hz), 7.97 (1H, d, J = 9.0Hz), 7.90-7.84 (2H, m), 4 .78(2H,s),4.41(1H,dd,J=2.5,2.5Hz),4.30-4.22(1H,m),4.17-4.04(1H,m),3.86-3.69(1H,m),3.69- 3.55(4H,m),3.40(1H,d,J=6.8Hz),3.29-3.11(1H,m),2.59(3H,s),2.35-2.25(1H,m),2.19-2.04(3H,m ),1.98-1.84(1H,m),1.81-1.75(1H,m),1.75-1.67(2H,m),1.17(1H,t,J=7.5Hz),0.98(3H,t,J=7.5Hz.

[0793] [Chemistry 110]

[0794] Method G-1

[0795]

[0796] Intermediate G-1-3': (2S,4S)-4-azido-1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid

[0797] [Chemistry 111]

[0798]

[0799] 1-(tert-butyl) 2-methyl (2S, 4S)-4-azidopiperidine-1,2-dicarboxylate (5.3 g, 19 mmol) prepared according to the literature (Eur. J. Org. Chem., 2004, 2928-2935) was dissolved in methanol (220 mL), 1M sodium hydroxide aqueous solution (190 mL) was added, and the mixture was stirred at 40 degrees for 1 hour. 1M hydrochloric acid was added to the reaction mixture for neutralization, extracted with ethyl acetate, washed with saturated brine, dried with sodium sulfate, and the solvent was distilled off to obtain a crude reaction mixture containing (2S, 4S)-4-azido-1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid.

[0800] LCMS (LC-1); RT=0.89, m / z269[MH] +

[0801] 1H-NMR(CDCl3): δ(ppm)5.07(1H,brs),4.92(1H,brs),4.24-3.97(1H,m),3.49-3.36 (1H,m),3.18-2.92(1H,m),2.58-2.41(1H,m),2.01-1.88(1H,m),1.54-1.41(9H,s).

[0802] Intermediate G-1-1: 2-(4-((1s,5s)-9-borabicyclo[3.3.1]nonan-9-yl)butyl)isoindoline-1,3-dione

[0803] [Chemistry 112]

[0804]

[0805] 2-(But-3-en-1-yl)isoindoline-1,3-dione (2 g, 10 mmol) was dissolved in 0.5 M 9-borabicyclo[3.3.1]nonane tetrahydrofuran solution (20 mL) under ice cooling, and stirred at the same temperature for 1.5 hours. The solvent of the reaction mixture was distilled off to obtain a crude reaction mixture containing 2-(4-((1s,5s)-9-borabicyclo[3.3.1]nonane-9-yl)butyl)isoindoline-1,3-dione.

[0806] Intermediate G-1-2: 2-(4-(6-(Benzyloxy)-3-bromoquinolin-5-yl)butyl)isoindoline-1,3-dione

[0807] [Chemistry 113]

[0808]

[0809] 6-(Benzyloxy)-3-bromo-5-iodoquinoline (Intermediate D-1-8; 1.8 g, 4.1 mmol) was dissolved in 1,4-dioxane (8.2 mL) and water (820 μL), and 2-(4-((1s,5s)-9-borabicyclo[3.3.1]nonane-9-yl)butyl)isoindoline-1,3-dione (Intermediate G-1-1; 1.3 g, 4.1 mmol), 1,1'-bis(diphenylphosphino)ferrocene]palladium(II) (600 mg, 820 μmol), and potassium carbonate (1.7 g, 12 mmol) were added, and the mixture was heated and stirred at 100°C for 14 hours. After removing the insoluble matter from the reaction mixture solution by diatomaceous earth filtration, the solvent was distilled off and the product was purified by automated silica gel column chromatography (eluent; hexane:ethyl acetate = 50:50) to obtain 2-(4-(6-(benzyloxy)-3-bromoquinolin-5-yl)butyl)isoindoline-1,3-dione (340 mg, yield 16%).

[0810] LCMS(LC-1);RT=2.29,m / z440[M+H] +

[0811] Intermediate G-1-3: 4-(6-(Benzyloxy)-3-bromoquinolin-5-yl)butane-1-amine

[0812] [Chemistry 114]

[0813]

[0814] 2-(4-(6-(benzyloxy)-3-bromoquinolin-5-yl)butyl)isoindoline-1,3-dione (intermediate G-1-2; 553 mg, 1.07 mmol) was dissolved in ethanol (11 mL), hydrazine hydrate (105 μL, 2.15 mmol) was added, and the mixture was heated and stirred at 85 degrees for 9 hours. The obtained crude reaction mixture was concentrated, the insoluble matter was removed by filtration, and the solvent was further distilled off, and the mixture was purified by autoclaved silica gel column chromatography (eluent; hexane: ethyl acetate = 50:50 → chloroform: methanol 90:10) to obtain 4-(6-(benzyloxy)-3-bromoquinolin-5-yl)butane-1-amine (264 mg, yield 64%).

[0815] LCMS(LC-1);RT=1.30,m / z385[M+H] +

[0816] Intermediate G-1-4: tert-butyl (2S, 4S)-4-azido-2-((4-(6-(benzyloxy)-3-bromoquinolin-5-yl)butyl)carbamoyl)piperidine-1-carboxylate

[0817] [Chemistry 115]

[0818]

[0819] 4-(6-(Benzyloxy)-3-bromoquinolin-5-yl)butane-1-amine (Intermediate G-1-3; 214 mg, 0.55 mmol) was dissolved in dimethylformamide (2.8 mL), and N-methylmorpholine (150 μL, 1.39 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (638 mg, 3.33 mmol), 1-hydroxybenzotriazole (223 mg, 1.66 mmol), (2S, 4S)-4-azido-1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid (Intermediate G-1-3'; 150 mg, 0.55 mmol) were added, and stirred at room temperature for 14 hours. Water was added to the reaction mixture, extracted with chloroform, the solvent was distilled off, and the product was purified by automatic oxidation silica gel column chromatography (eluent; chloroform:methanol = 90:10) to obtain tert-butyl (2S,4R)-2-((3-((6-(benzyloxy)-3-hydroxyquinolin-5-yl)oxy)propyl)carbamoyl)-4-hydroxypiperidine-1-carboxylate (220 mg, yield 62%).

[0820] LCMS(LC-1);RT=2.23,m / z637[M+H] +

[0821] 1H-NMR(CDCl3): δ(ppm)8.85-8.72(1H,m),8.48-8.36(1H,m),7.98-7.89(1H,m),7.60-7.30(6H,m),6.37-6.11(1H,m),5.34-5.20(2H,m),4.8 8-4.72(1H,m),4.05-3.90(1H,m),3.90-3.70(1H,m),3.38-3.00(3H,m) ,2.87-2.39(3H,m),1.91-1.76(1H,m),1.60(1H,m),1.51-1.40(9H,m).

[0822] Intermediate G-1-5: tert-Butyl (2S, 4S)-4-amino-2-((4-(6-(benzyloxy)-3-bromoquinolin-5-yl)butyl)carbamoyl)piperidine-1-carboxylate

[0823] [Chemistry 116]

[0824]

[0825] Tert-butyl (2S, 4R)-2-((3-((6-(benzyloxy)-3-hydroxyquinolin-5-yl)oxy)propyl)carbamoyl)-4-hydroxypiperidine-1-carboxylate (Intermediate G-1-4; 190 mg, 298 μmol) was dissolved in tetrahydrofuran (1.2 mL), triphenylphosphine (86 mg, 0.33 mmol) was added, and the mixture was stirred at 50° C. for 5.5 hours under heating. Water was added to the obtained crude reaction mixture, extracted with ethyl acetate, washed with saturated brine, dried over sodium sulfate, and the solvent was distilled off. The mixture was purified by autoclaved silica gel column chromatography (eluent; chloroform:methanol=95:5) to obtain tert-butyl (2S, 4S)-4-amino-2-((4-(6-(benzyloxy)-3-bromoquinolin-5-yl)butyl)carbamoyl)piperidine-1-carboxylate (134 mg, yield 74%).

[0826] LCMS(LC-1);RT=1.62,m / z611[M+H] +

[0827] Intermediate G-1-6: tert-butyl (3 2 S,3 4 S)-1 6 -(Benzyloxy)-4-oxo-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenanthene-3 1 -Formate

[0828] [Chemistry 117]

[0829]

[0830] Tert-butyl (2S, 4S)-4-amino-2-((4-(6-(benzyloxy)-3-bromoquinolin-5-yl)butyl)carbamoyl)piperidine-1-carboxylate (Intermediate G-1-5; 27 mg, 44 μmol) was dissolved in toluene (1.5 mL), and [(2-di-tert-butylphosphino-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl)-2-(2'-amino-1,1'-biphenyl)]methanesulfonate palladium (II) (1.9 mg, 2.2 μmol) and phosphazene base P2-Et (29 μL, 88 μmol) were added, and stirred at room temperature. The reaction mixture was purified by autoclaved silica gel column chromatography (eluent; chloroform:methanol = 90:10), thereby obtaining tert-butyl (3 2 S,3 4 S)-1 6-(Benzyloxy)-4-oxo-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenanthene-3 1 -formate (9 mg, yield 39%).

[0831] LCMS(LC-1);RT=1.72,m / z531[M+H] +

[0832] [Chemistry 118]

[0833] Method G-2

[0834]

[0835] Intermediate G-2-1: tert-butyl (3 2 S,3 4 S)-1 6 -Hydroxy-4-oxo-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-3 1 -Formate

[0836] [Chemistry 119]

[0837]

[0838] The tert-butyl (3 2 S,3 4 S)-1 6 -(Benzyloxy)-4-oxo-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenanthene-3 1 -formate (intermediate G-1-6; 100 mg, 0.19 mmol) was dissolved in methanol (2.7 mL), ethyl acetate (4 mL), and toluene (2.6 mL), and nitrogen atmosphere was added. Palladium hydroxide (25 mg) was added, and the mixture was replaced with hydrogen. The mixture was stirred vigorously at room temperature for 14 hours. After filtering the insoluble matter from the reaction mixture, the solvent was distilled off to obtain tert-butyl (3 2 S,3 4 S)-1 6 -Hydroxy-4-oxo-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene 1 -formate (70 mg, yield 84%).

[0839] LCMS(LC-1);RT=1.21,m / z441[M+H] +

[0840] Intermediate G-2-2: tert-butyl (3 2 S,3 4 S)-16 -(((trifluoromethyl)sulfonyl)oxy)-4-oxo-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-3-yl)- 1 -Formate

[0841] [Chemistry 120]

[0842]

[0843] The tert-butyl (3 2 S,3 4 S)-1 6 -Hydroxy-4-oxo-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene 1 -formate (intermediate G-2-1; 70 mg, 159 μmol) was dissolved in 1,4-dioxane (1.6 mL), and N,N-bis(trifluoromethylsulfonyl)aniline) (181 mg, 0.51 mmol), diisopropylethylamine (170 μL, 0.95 mmol), and dimethylformamide (6 drops) were added, and stirred at room temperature for 3 hours. The reaction mixture was concentrated and purified by autoclaved silica gel column chromatography (eluent; chloroform:methanol = 90:10), thereby obtaining tert-butyl (3 2 S,3 4 S)-1 6 -(((trifluoromethyl)sulfonyl)oxy)-4-oxo-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-3-yl)- 1 -formate (88 mg, yield 97%).

[0844] LCMS(LC-1);RT=1.76,m / z573[M+H] +

[0845] Intermediate G-2-3: tert-butyl (3 2 S,3 4 S)-1 6 -(2-(Propyloxymethyl)pyrimidin-5-yl)-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-3 1 -Formate

[0846] [Chemistry 121]

[0847]

[0848] The tert-butyl (3 2 S,3 4 S)-1 6-(((trifluoromethyl)sulfonyl)oxy)-4-oxo-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-3-yl)- 1 -formate (intermediate G-2-2; 44 mg, 76 μmol) was dissolved in 1,4-dioxane (300 μL) and water (30 μL), and (2-(propyloxymethyl)pyrimidin-5-yl)boric acid (175 mg, 0.19 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) (32 mg, 38 μmol), and cesium carbonate (150 mg, 0.46 mmol) were added, and microwave irradiation was performed at 100°C for 3 hours. After removing the insoluble matter from the reaction mixture by diatomaceous earth filtration, the solvent was distilled off, and the mixture was purified by autoclaved silica gel column chromatography (eluent; chloroform:methanol=90:10), thereby obtaining tert-butyl (3 2 S,3 4 S)-1 6 -(2-(Propyloxymethyl)pyrimidin-5-yl)-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-3 1 -formate (44 mg, yield 99%).

[0849] LCMS(LC-1);RT=1.46,m / z575[M+H] +

[0850] Intermediate G-2-4: (3 2 S,3 4 S)-1 6 -(2-(Propoxymethyl)pyrimidin-5-yl)-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenan-4-one

[0851] [Chemistry 122]

[0852]

[0853] The tert-butyl (3 2 S,3 4 S)-1 6 -(2-(Propyloxymethyl)pyrimidin-5-yl)-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-3-cyclononaphenanthene-3 1 -formate (intermediate G-2-3; 22.8 mg, 39 μmol) was dissolved in dichloromethane (400 μL), trifluoroacetic acid (100 μL) was added, and stirred at room temperature for 20 minutes. The reaction mixture was treated with SCX to obtain (3 2 S,3 4 S)-1 6-(2-(Propoxymethyl)pyrimidin-5-yl)-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenan-4-one (19 mg, yield 46%).

[0854] LCMS(LC-1);RT=1.01,m / z475[M+H] +

[0855] Example a-02-24 (final body G-2-5): (3 2 S,3 4 S)-3 1 -methyl-1 6 -(2-(Propoxymethyl)pyrimidin-5-yl)-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenan-4-one

[0856] [Chemistry 123]

[0857]

[0858] (3 2 S,3 4 S)-1 6 -(2-(Propoxymethyl)pyrimidin-5-yl)-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononabiquinone-4-one (Intermediate G-2-4; 19 mg, 39 μmol) was dissolved in dichloromethane (290 μL) and methanol (290 μL), and 37% formaldehyde aqueous solution (10 μL, 0.26 mmol) and triacetoxyborohydride (27.7 mg, 130 μmol) were added and stirred at room temperature for 35 minutes. The reaction mixture was treated with SCX and purified by HPLC to obtain (3 2 S,3 4 S)-3 1 -methyl-1 6 -(2-(Propoxymethyl)pyrimidin-5-yl)-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenan-4-one (17.2 mg, yield 90%).

[0859] LCMS(LC-1);RT=1.09,m / z489[M+H] +

[0860] 1H-NMR (CD3OD): δ (ppm) 8.82 (2H, s), 8.43 (1H, d, J = 2.5Hz), 7.82-7.74 (1H, m, J = 8.5Hz) ,7.28-7.24(1H,m),7.05(1H,d,J=2.5Hz),4.79(2H,s),3.88-3.77(2H,m),3.68-3.55(4 H,m),3.12-3.02(1H,m),2.93-2.79(2H,m),2.57(3H,s),2.53-2.43(1H,m),2.07-2.01 (2H,m),1.91-1.81(1H,m),1.78-1.66(4H,m),1.63-1.42(2H,m),0.99(3H,t,J=7.5Hz).

[0861] [Chemistry 124]

[0862] Method H-1

[0863]

[0864] Intermediate H-1-2: Methyl (S,E)-4-oxo-2-(tritylamino)hept-5-enoic acid

[0865] [Chemistry 125]

[0866]

[0867] Methyl (S)-5-(dimethoxyphosphoryl)-4-oxo-2-(tritylamino)pentanoate (17 g, 35.3 mmol) prepared according to the literature (J. Org. Chem., 2012, 77, 10001-10009) was dissolved in acetonitrile (200 mL), potassium carbonate (5.1 g, 37 mmol) and acetaldehyde (5.92 mL, 106 mmol) were added, and stirred at 40°C for 48 hours. The reaction mixture was cooled to room temperature, the solvent was distilled off, and ethyl acetate was added. The organic layer was washed with water and saturated brine, dried over magnesium sulfate, and the solvent was distilled off. The product was purified by autoclaved silica gel column chromatography (eluent; hexane: ethyl acetate = 75:25) to obtain methyl (S, E)-4-oxo-2-(tritylamino) hept-5-enoic acid (11.5 g, yield 48%).

[0868] 1H-NMR(CDCl3): δ(ppm)7.55-7.41(6H,m),7.30-7.15(9H,m),6.80-6.72(1H,m),6.11-6.03(1H,m) ,3.79-3.63(1H,m),3.27(3H,s),2.90-2.72(2H,m),2.72-2.59(1H,m),1.89(3H,dd,J=7.0,2.0Hz).

[0869] Intermediate H-1-3: Methyl (S,E)-2-amino-4-oxohept-5-enoic acid trifluoroacetate

[0870] [Chemistry 126]

[0871]

[0872] Methyl (S, E)-4-oxohept-5-enoic acid (intermediate H-1-2; 11.5 g, 27.8 mmol) was dissolved in dichloromethane (92 mL), trifluoroacetic acid (92 mL) was added, and stirred at room temperature for 1 hour. The reaction mixture was concentrated, dissolved in water, washed with diethyl ether, and the solvent was distilled off to obtain methyl (S, E)-2-amino-4-oxohept-5-enoic acid trifluoroacetate (8.49 g, yield 99%).

[0873] 1H-NMR (DMSOd6): δ (ppm) 8.34 (3H, brs), 6.96 (1H, q, J = 7.0Hz), 7.00 (1H, q, J = 7.0 Hz),6.19(1H,m),4.37(2H,m),3.71(3H,s),3.31-3.17(2H,m),1.95-1.87(3H,m).

[0874] Intermediate H-1-4: Methyl (2S)-1-benzyl-6-methyl-4-oxopiperidin-2-carboxylate

[0875] [Chemistry 127]

[0876]

[0877] Methyl (S,E)-2-amino-4-oxohept-5-enoic acid trifluoroacetate (intermediate H-1-3; 7.92 g, 27.8 mmol) was dissolved in tetrahydrofuran (100 mL), molecular sieves 4A (8 g), triethylamine (3.87 mL, 27.8 mmol), and benzaldehyde (2.83 mL, 27.8 mmol) were added, and stirred at room temperature for 30 minutes. After removing the insoluble matter in the reaction mixture by filtration, the solvent was distilled off, and then dissolved in methanol (100 mL), sodium cyanoborohydride (27.8 mL, 27.8 mmol) was added, and stirred at room temperature for 14 hours. Saturated aqueous sodium bicarbonate solution was added to the reaction mixture, extracted with dichloromethane, washed with saturated aqueous sodium bicarbonate solution and saturated brine, and then dried over magnesium sulfate. The solvent was distilled off and purified by automatic silica gel column chromatography (eluent; hexane:ethyl acetate=75:15) to obtain methyl (2S)-1-benzyl-6-methyl-4-oxopiperidine-2-carboxylate (2.28 g, yield 31%).

[0878] LCMS(LC-1);RT=1.54,m / z262[M+H] +

[0879] Intermediate H-1-5: Methyl (2S)-6-methyl-4-oxopiperidin-2-carboxylate

[0880] [Chemistry 128]

[0881]

[0882] Methyl (2S)-1-benzyl-6-methyl-4-oxopiperidine-2-carboxylate (intermediate H-1-4; 100 mg, 0.38 mmol) was dissolved in methanol (2.5 mL), nitrogen atmosphere was applied, palladium hydroxide (18 mg) was added, replaced with hydrogen, and stirred vigorously at room temperature for 14 hours. After filtering the insoluble matter in the reaction mixture, the solvent was distilled off to obtain a crude product containing methyl (2S)-6-methyl-4-oxopiperidine-2-carboxylate (64 mg, yield 97%).

[0883] 1H-NMR(DMSOd6): δ(ppm)4.07-4.04(1H,m),3.78(1.5H,s),3.74(1.5H,s),3.27-3.23(1H,m),3.03-2.97(1H, m),2.73-2.59(3H,m),2.44-2.37(3H,m),2.17-2.07(3H,m),1.27(1.5H,d,J=6.0Hz),1.18(1.5H,d,J=6.0Hz).

[0884] Intermediate H-1-6: Methyl (2S)-1,6-methyl-4-oxopiperidin-2-carboxylate

[0885] [Chemistry 129]

[0886]

[0887] Methyl (2S)-6-methyl-4-oxopiperidine-2-carboxylate (Intermediate H-1-5; 1.54 g, 9.0 mol) was dissolved in dichloromethane (70 mL), and 37% aqueous formaldehyde solution (7 mL, 86 mmol) and triacetoxyborohydride (2.28 g, 10.8 mmol) were added, and stirred at room temperature for 1 hour. The reaction mixture was treated with SCX to obtain a crude product containing methyl (2S)-1,6-methyl-4-oxopiperidine-2-carboxylate (1.48 g, yield 89%).

[0888] LCMS(LC-1);RT=0.72,m / z186[M+H] +

[0889] Intermediate H-1-7: Methyl (2S)-4-(benzylamino)-1,6-dimethylpiperidine-2-carboxylate

[0890] [Chemistry 130]

[0891]

[0892] (2S)-1,6-methyl-4-oxopiperidin-2-carboxylate (intermediate H-1-6; 1.48 g, 7.99 mol) was dissolved in methanol (19 mL), and benzylamine (4.4 mL, 40 mmol) and tetraisopropoxytitanium (9.5 mL, 40 mmol) were added, and stirred at room temperature for 14 hours. Sodium borohydride (1.04 g, 27.6 mmol) was added to the reaction mixture under ice cooling, and stirred at the same temperature for 1.5 hours. 25% ammonia water was added to the reaction mixture, and after stirring for 14 hours, the insoluble matter was removed by diatomaceous earth filtration. After the solvent of the obtained organic layer was distilled off, it was diluted with saturated brine, extracted with chloroform-methanol (90:10), and dried with magnesium sulfate to dry the solvent to obtain a crude product containing methyl (2S)-4-(benzylamino)-1,6-dimethylpiperidine-2-carboxylate (9.91 g, yield 99%).

[0893] Intermediate H-1-8: Methyl (2S)-4-amino-1,6-dimethylpiperidine-2-carboxylate

[0894] [Chemistry 131]

[0895]

[0896] Methyl (2S)-4-(benzylamino)-1,6-dimethylpiperidine-2-carboxylate (intermediate H-1-7; 2.21 g, 8.0 mmol) was dissolved in methanol (50 mL), nitrogen atmosphere was applied, palladium hydroxide (2.21 g, 15.7 mmol) was added, replaced with hydrogen, and stirred vigorously at room temperature for 14 hours. After filtering out the insoluble matter in the reaction mixture, the solvent was distilled off to obtain a crude product containing methyl (2S)-4-amino-1,6-dimethylpiperidine-2-carboxylate (2.52 g, yield 99%).

[0897] LCMS(LC-1);RT=0.76,m / z186[M+H] +

[0898] Intermediate H-1-9: Methyl (2S)-4-((tert-butoxycarbonyl)amino)-1,6-dimethylpiperidine-2-carboxylate

[0899] [Chemistry 132]

[0900]

[0901] Methyl (2S)-4-amino-1,6-dimethylpiperidine-2-carboxylate (intermediate H-1-8; 1.4 g, 7.52 mmol) was dissolved in dichloromethane (38 mL), and di-tert-butyl dicarbonate (2.59 mL, 11.3 mmol) and triethylamine (2.1 mL, 15 mmol) were added, and stirred at room temperature for 3 hours. The reaction mixture was concentrated and purified by autoclaved silica gel column chromatography (eluent; chloroform: methanol: 25% ammonia water = 200:9:1) to obtain methyl (2S)-4-((tert-butoxycarbonyl)amino)-1,6-dimethylpiperidine-2-carboxylate (1.61 g, yield 75%).

[0902] LCMS(LC-1);RT=1.23,m / z287[M+H] +

[0903] Intermediate H-1-10: (2S)-4-((tert-butoxycarbonyl)amino)-1,6-dimethylpiperidine-2-carboxylic acid sodium salt

[0904] [Chemistry 133]

[0905]

[0906] Methyl (2S)-4-((tert-butoxycarbonyl)amino)-1,6-dimethylpiperidine-2-carboxylate (Intermediate H-1-9; 1.61 g, 11.2 mmol) was dissolved in methanol (28 mL), 2M-sodium hydroxide aqueous solution (5.6 mL, 11.3 mmol) was added, and stirred at room temperature for 2 hours. The reaction mixture was concentrated to obtain (2S)-4-((tert-butoxycarbonyl)amino)-1,6-dimethylpiperidine-2-carboxylic acid sodium salt (1.51 g, yield 99%).

[0907] LCMS(LC-1);RT=0.70,m / z273[M+H] +

[0908] [Chemistry 134]

[0909] Method H-2

[0910]

[0911] Intermediate H-2-2: (E)-2-(4-(6-(benzyloxy)-3-bromoquinolin-5-yl)but-3-en-1-yl)isoindoline-1,3-dione

[0912] [Chemistry 135]

[0913]

[0914] 6-(Benzyloxy)-3-bromo-5-iodoquinoline (intermediate D-1-6; 2.0 g, 4.5 mmol) was dissolved in toluene (50 mL), and 10% tri-tert-butylphosphine pentane solution (910 μL, 0.45 mmol), dicyclohexylmethylamine (2.6 g, 13.5 mmol), 2-(but-3-ene-1-yl)isoindoline-1,3-dione (1.1 g, 5.5 mmol) prepared according to the literature (J. Org. Chem., 1974, 39, 1979-1980), tris(dibenzylideneacetone)dipalladium(0) (206 mg, 0.23 mmol) were added, and heated and stirred at 120°C for 20 hours. After the reaction solution returned to room temperature, the solvent was concentrated and purified by silica gel column chromatography (eluent; hexane:ethyl acetate = 86:14) to obtain (E)-2-(4-(6-(benzyloxy)-3-bromoquinolin-5-yl)but-3-en-1-yl)isoindoline-1,3-dione (1.4 g, yield 61%).

[0915] Intermediate H-2-3: (E)-4-(6-(Benzyloxy)-3-bromoquinolin-5-yl)but-3-en-1-amine

[0916] [Chemistry 136]

[0917]

[0918] (E)-2-(4-(6-(benzyloxy)-3-bromoquinolin-5-yl)but-3-en-1-yl)isoindoline-1,3-dione (intermediate H-2-2; 1.29 g, 2.51 mmol) was dissolved in ethanol (25 mL), hydrazine hydrate (1.82 mL, 5.02 mmol) was added, and the mixture was heated under reflux for 4 hours. The reaction solution was cooled to room temperature, the solvent was distilled off, the residue was dissolved in water (25 mL), extracted with ethyl acetate, the organic layer was concentrated, and purified by silica gel column chromatography (eluent; hexane:ethyl acetate = 86:14) to obtain (E)-4-(6-(benzyloxy)-3-bromoquinolin-5-yl)but-3-en-1-amine (680 mg, 39%).

[0919] Intermediate H-2-4: tert-butyl ((2S)-2-(((E)-4-(6-(benzyloxy)-3-bromoquinolin-5-yl)but-3-en-1-yl)carbamoyl)-1,6-dimethylpiperidin-4-yl)carbamate

[0920] [Chemistry 137]

[0921]

[0922] (E)-4-(6-(Benzyloxy)-3-bromoquinolin-5-yl)but-3-en-1-amine (intermediate H-2-3; 193 mg, 0.50 mmol) was dissolved in dimethylformamide (5 mL), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (193 mg, 1.01 mmol), 1-hydroxybenzotriazole (154 mg, 1.01 mmol), (2S)-4-((tert-butoxycarbonyl)amino)-1,6-dimethylpiperidine-2-carboxylic acid sodium salt (intermediate H-1-10; 274 mg, 1.01 mmol) were added, and heated with stirring at 50°C for 14 hours. The reaction mixture was concentrated and purified by automated silica gel column chromatography (eluent; hexane:ethyl acetate = 50:50) to obtain tert-butyl ((2S)-2-(((E)-4-(6-(benzyloxy)-3-bromoquinolin-5-yl)but-3-en-1-yl)carbamoyl)-1,6-dimethylpiperidin-4-yl)carbamate (353 mg, yield 99%).

[0923] LCMS(LC-1);RT=1.95,m / z638[M+H] +

[0924] Intermediate H-2-5: (2S)-4-amino-N-((E)-4-(6-(benzyloxy)-3-bromoquinolin-5-yl)but-3-en-1-yl)-1,6-dimethylpiperidine-2-carboxamide

[0925] [Chemistry 138]

[0926]

[0927] Tert-butyl ((2S)-2-(((E)-4-(6-(benzyloxy)-3-bromoquinolin-5-yl)but-3-en-1-yl)carbamoyl)-1,6-dimethylpiperidin-4-yl)carbamate (Intermediate H-2-4; 242 mg, 0.38 mmol) was dissolved in dichloromethane (3.8 mL), trifluoroacetic acid (290 μL, 3.8 mmol) was added, and stirred at room temperature for 2 hours. The reaction solution was concentrated, neutralized with 25% ammonia water, extracted with chloroform, dried with magnesium sulfate, and the solvent was distilled off to obtain (2S)-4-amino-N-((E)-4-(6-(benzyloxy)-3-bromoquinolin-5-yl)but-3-en-1-yl)-1,6-dimethylpiperidine-2-carboxamide (203 mg, yield 99%).

[0928] LCMS(LC-1);RT=1.42,m / z538[M+H] +

[0929] Intermediate H-2-6: (3 2 S,E)-1 6 -(Benzyloxy)-3 1 ,3 6 -Dimethyl-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphyl-8-en-4-one

[0930] [Chemistry 139]

[0931]

[0932] (2S)-4-amino-N-((E)-4-(6-(benzyloxy)-3-bromoquinolin-5-yl)but-3-en-1-yl)-1,6-dimethylpiperidine-2-carboxamide (Intermediate H-2-5; 210 mg, 0.38 mmol) was dissolved in 1,4-dioxane (3.9 mL), tris(dibenzylideneacetone)dipalladium(0) (36 mg, 40 μmol), 2-dicyclohexylphosphine-2',4',6'-triisopropyl-1,1'-biphenyl (36 mg, 80 μmol), and sodium benzoate (90 mg, 0.78 mmol) were added, and heated under reflux for 14 hours. After the reaction mixture was cooled to room temperature, the solvent was distilled off, and the mixture was purified by autoclaved silica gel column chromatography (eluent; chloroform:methanol=9:1), thereby obtaining (3 2 S,E)-16-(Benzyloxy)-3 1 ,3 6 -Dimethyl-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-cyclononaquin-8-en-4-one (133 mg, yield 75%).

[0933] LCMS(LC-1);RT=1.49,m / z457[M+H] +

[0934] [Chemistry 140]

[0935] Method H-3

[0936]

[0937] Intermediate H-3-1: (3 2 S,E)-1 6 -Hydroxy-3 1 ,3 6 -Dimethyl-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphyl-8-en-4-one

[0938] [Chemistry 141]

[0939]

[0940] (3 2 S,E)-1 6 -(Benzyloxy)-3 1 ,3 6-Dimethyl-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-cyclonona-8-ene-4-one (intermediate H-2-6; 131 mg, 0.29 mmol) was dissolved in methanol (2.8 mL), nitrogen atmosphere was applied, palladium carbon (24 mg) was added, hydrogen was replaced, and the mixture was vigorously stirred at room temperature for 14 hours. After filtering the insoluble matter from the reaction mixture, the solvent was distilled off to obtain (3 2 S,E)-1 6 -Hydroxy-3 1 ,3 6 The crude product of -dimethyl-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-cyclononaquin-8-en-4-one (105 mg, yield 99%).

[0941] LCMS(LC-1);RT=0.86,m / z367[M+H] +

[0942] Intermediate H-3-2: (3 2 S,E)-3 1 ,3 6 -Dimethyl-4-oxo-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphyl-8-ene-1 6 -Trifluoromethanesulfonate

[0943] [Chemistry 142]

[0944]

[0945] (3 2 S,E)-1 6 -Hydroxy-3 1 ,3 6 -Dimethyl-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-cyclonona-8-ene-4-one (Intermediate H-3-1; 105 mg, 0.29 mmol) was dissolved in 1,4-dioxane (2.9 mL), and N,N-bis(trifluoromethylsulfonyl)aniline) (136 mg, 0.57 mmol) and diisopropylethylamine (80 μL, 0.57 mmol) were added and stirred at 70°C for 14 hours. The reaction mixture was concentrated to obtain a mixture containing (3 2 S,E)-3 1 ,3 6 -Dimethyl-4-oxo-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphyl-8-ene-1 6 -yl trifluoromethanesulfonate crude product (143 mg, yield 99%).

[0946] LCMS(LC-1);RT=1.61,m / z499[M+H] +

[0947] Example a-02-17 (final body H-3-3): (3 2 S,E)-3 1 ,3 6 -Dimethyl-1 6 -(2-methylpyrimidin-5-yl)-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphyl-8-en-4-one

[0948] [Chemistry 143]

[0949]

[0950] (3 2 S,E)-3 1 ,3 6 -Dimethyl-4-oxo-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphyl-8-ene-1 6 -yl trifluoromethanesulfonate (intermediate H-3-2; 120 mg, 0.24 mmol) was dissolved in 1,4-dioxane (2.4 mL) and water (240 μL), 2-methylpyrimidine-5-boronic acid pinacol ester (105 mg, 0.48 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium (II) (17 mg, 20 μmol), cesium carbonate (156 mg, 0.48 mmol) were added, and microwave irradiation was performed at 100°C for 3 hours. After removing the insoluble matter from the reaction mixture by diatomaceous earth filtration, the solvent was distilled off, and purified by HPLC to obtain (3 2 S,E)-3 1 ,3 6 -Dimethyl-1 6 -(2-methylpyrimidin-5-yl)-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphyl-8-en-4-one (1.1 mg, yield 1%).

[0951] LCMS(LC-1);RT=0.99,m / z443[M+H] +

[0952] 1H-NMR(CD3OD): δ(ppm)8.78-8.72(2H,m),8.57-8.54(1H,m),8.44-8.39(1H,m),7.88-7.83(1H,m) ,7.51-7.47(1H,m),7.38-7.33(1H,m),6.45-6.41(1H,m),6.40-6.36(1H,m),6.20-6.10(2H,m),3. 93-3.85(2H,m),3.68-3.62(2H,m),3.52-3.44(2H,m),3.19-3.09(2H,m),2.76(3H,s),2.72-2.63( 2H,m),2.54(3H,s),2.05-1.95(2H,m),1.62-1.41(4H,m),1.33-1.27(2H,m),1.17(3H,d,J=6.5Hz).

[0953] [Chemistry 144]

[0954] Method I-1

[0955]

[0956] Intermediate I-1-2: Methyl 1,2-dimethyl-4-oxopiperidin-2-carboxylate

[0957] [Chemistry 145]

[0958]

[0959] Methyl 1,2-dimethyl-4-oxo-1,2,3,4-tetrahydropyridine-2-carboxylate (1.3 g, 7.3 mmol) prepared according to the literature (Org. Lett., 2005, 435-437) was dissolved in tetrahydrofuran (8 mL), and L-Selectride was added at -78°C under nitrogen atmosphere. (R) (190 mL), stirred at this temperature for 2 hours. Methanol was added to the reaction mixture to quench the reaction, and then heated to room temperature. The reaction mixture was then concentrated and treated with an SCX column to obtain a crude reaction mixture of methyl 1,2-dimethyl-4-oxopiperidine-2-carboxylate.

[0960] LCMS(LC-1);RT=0.94,m / z186[M+H] + .

[0961] Intermediate I-1-3: Methyl 4-(benzylamino)-1,2-dimethylpiperidine-2-carboxylate

[0962] [Chemistry 146]

[0963]

[0964] Methyl 1,2-dimethyl-4-oxopiperidin-2-carboxylate (intermediate I-1-2; 1.0 g, 5.47 mol) was dissolved in methanol (13 mL), and benzylamine (3.0 mL, 27.4 mmol) and tetraisopropoxytitanium (6.5 mL, 21.9 mmol) were added, and stirred at room temperature for 14 hours. Sodium borohydride (715 mg, 18.9 mmol) was added to the reaction mixture under ice cooling, and stirred at the same temperature for 2 hours. 25% ammonia water was added to the reaction mixture, and after stirring for 14 hours, the insoluble matter was removed by diatomaceous earth filtration. After the solvent of the obtained organic layer was distilled off, it was diluted with saturated brine, extracted with chloroform-methanol (90:10), dried with magnesium sulfate, and the solvent was dried to obtain a crude product containing methyl 4-(benzylamino)-1,2-dimethylpiperidine-2-carboxylate (1.51 g, yield 99%).

[0965] Intermediate I-1-4: Methyl 4-amino-1,2-dimethylpiperidine-2-carboxylate

[0966] [Chemistry 147]

[0967]

[0968] Methyl 4-(benzylamino)-1,2-dimethylpiperidine-2-carboxylate (intermediate I-1-5; 1.51 g, 5.47 mmol) was dissolved in methanol (35 mL), nitrogen atmosphere was applied, palladium hydroxide (800 mg, 5.70 mmol) was added, replaced with hydrogen, and stirred vigorously at room temperature for 14 hours. After filtering to remove the insoluble matter in the reaction mixture, the solvent was distilled off to obtain a crude product containing methyl 4-amino-1,2-dimethylpiperidine-2-carboxylate (1.02 g, yield 99%).

[0969] Intermediate I-1-5: Methyl 4-((tert-butoxycarbonyl)amino)-1,2-dimethylpiperidine-2-carboxylate

[0970] [Chemistry 148]

[0971]

[0972] Methyl 4-amino-1,2-dimethylpiperidine-2-carboxylate (intermediate I-1-4; 1.02 g, 5.47 mmol) was dissolved in dichloromethane (38 mL), di-tert-butyl dicarbonate (3.58 mL, 16.4 mmol) and triethylamine (7.63 mL, 54.7 mmol) were added, and stirred at room temperature for 3 hours. The reaction mixture was concentrated and purified by automatic oxidation silica gel column chromatography (eluent; hexane: ethyl acetate = 20:80) to obtain methyl 4-((tert-butoxycarbonyl)amino)-1,2-dimethylpiperidine-2-carboxylate (205 mg, yield 13%).

[0973] LCMS(LC-1);RT=1.26,m / z287[M+H] +

[0974] 1H-NMR(CDCl3): δ(ppm)4.53-4.32(1H,m),3.78-3.68(3H,m),2.90-2.76(1H,m),2.64-2.45 (1H,m),2.25-2.15(2H,m),1.98-1.84(2H,m),1.80-1.68(1H,m),1.43(7H,s),1.29(2H,s).

[0975] Intermediate I-1-6: 4-((tert-butoxycarbonyl)amino)-1,2-dimethylpiperidine-2-carboxylic acid sodium salt

[0976] [Chemistry 149]

[0977]

[0978] Methyl 4-((tert-butoxycarbonyl)amino)-1,2-dimethylpiperidine-2-carboxylate (Intermediate I-1-5; 687 mg, 2.40 mmol) was dissolved in 1M sodium hydroxide aqueous solution (10 mL, 10 mmol) and stirred at room temperature for 2 hours. The reaction mixture was concentrated to obtain 4-((tert-butoxycarbonyl)amino)-1,2-dimethylpiperidine-2-carboxylic acid sodium salt (853 mg, yield 99%).

[0979] [Chemistry 150]

[0980] Method 1-2

[0981]

[0982] Intermediate I-2-2: 3-((6-(Benzyloxy)-3-bromoquinolin-5-yl)oxy)-2-fluoropropane-1-amine

[0983] [Chemistry 151]

[0984]

[0985] Tert-butyl (S)-(3-((6-(benzyloxy)-3-bromoquinolin-5-yl)oxy)-2-fluoropropyl)carbamate (Intermediate I-2-1; 6.59 g, 13.0 mmol) was dissolved in dichloromethane (40 mL), trifluoroacetic acid (10 mL) was added, and stirred at room temperature for 3 hours. The reaction mixture was treated with SCX to give (S)-3-((6-(benzyloxy)-3-bromoquinolin-5-yl)oxy)-2-fluoropropane-1-amine (2.78 g, 53% yield).

[0986] LCMS(LC-1);RT=1.38,m / z405[M+H] +

[0987] 1H-NMR (CDCl3): δ (ppm) 8.84-8.76 (1H, m), 8.69-8.63 (1H, m), 7.83 (1H, d, J = 9.3Hz), 7.53 (1H, d, J = 9. 3Hz),7.49-7.32(5H,m),5.32-5.18(2H,m),4.90-4.68(1H,m),4.40-4.29(2H,m),3.08-2.97(2H,m).

[0988] Intermediate I-2-3: tert-butyl (2-((3-((6-(benzyloxy)-3-bromoquinolin-5-yl)oxy-2-fluoropropyl)carbamoyl)-1,2-dimethylpiperidin-4-yl)carbamate

[0989] [Chemistry 152]

[0990]

[0991] 3-((6-(Benzyloxy)-3-bromoquinolin-5-yl)oxy)-2-fluoropropane-1-amine (Intermediate I-2-2; 1.02 g, 2.52 mmol) was dissolved in dichloromethane (20 mL), and N-methylmorpholine (695 μL, 2.52 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.93 g, 10.1 mmol), 1-hydroxybenzotriazole (750 mg, 5.55 mmol), 4-((tert-butoxycarbonyl)amino)-1,2-dimethylpiperidine-2-carboxylic acid sodium salt (Intermediate I-1-6; 687 mg, 2.52 mmol) were added, and stirred at room temperature for 14 hours. Water was added to the reaction mixture, extracted with chloroform, the solvent was distilled off, and the product was purified by automatic oxidation silica gel column chromatography (eluent; hexane:ethyl acetate = 30:70) to obtain tert-butyl (2-((3-((6-(benzyloxy)-3-bromoquinolin-5-yl)oxy-2-fluoropropyl)carbamoyl)-1,2-dimethylpiperidin-4-yl)carbamate (765 mg, yield 42%).

[0992] LCMS(LC-1);RT=2.05,m / z659[M+H] +

[0993] 1H-NMR (CDCl3): δ (ppm) 8.77 (1H, d, J = 2.0Hz), 8.67-8.63 (1H, m), 7.81 (1H, d, J = 9.0Hz), 7. 55-7.49(1H,m),7.49-7.35(5H,m),5.27(2H,s),4.98(1H,dd,J=10.0,7.0Hz),4.92-4.64( 1H,m),4.44-4.25(3H,m),4.12(1H,dd,J=7.0,7.0Hz),3.83-3.67(1H,m),3.63-3.41(2H,m ),2.89-2.63(2H,m),2.36(3H,s),2.34-2.22(1H,m),1.45-1.39(9H,m),1.29-1.24(2H,m).

[0994] Intermediate I-2-4: 4-amino-N-(3-((6-(benzyloxy)-3-bromoquinolin-5-yl)oxy)-2-fluoropropyl)-1,2-dimethylpiperidine-2-carboxamide

[0995] [Chemistry 153]

[0996]

[0997] Tert-butyl (2-((3-((6-(benzyloxy)-3-bromoquinolin-5-yl)oxy-2-fluoropropyl)carbamoyl)-1,2-dimethylpiperidin-4-yl)carbamate (Intermediate I-2-3; 765 mg, 1.16 mmol) was dissolved in dichloromethane (8 mL), trifluoroacetic acid (2 mL) was added and stirred at room temperature for 20 minutes. The reaction mixture was treated with SCX to give 4-amino-N-(3-((6-(benzyloxy)-3-bromoquinolin-5-yl)oxy)-2-fluoropropyl)-1,2-dimethylpiperidine-2-carboxamide (645 mg, 100% yield).

[0998] LCMS(LC-1);RT=1.43,m / z559[M+H] +

[0999] Intermediate I-2-5:1 6 -(Benzyloxy)-7-fluoro-3- 1 ,3 2 -Dimethyl-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenan-4-one

[1000] [Chemistry 154]

[1001]

[1002] 4-amino-N-(3-((6-(benzyloxy)-3-bromoquinolin-5-yl)oxy)-2-fluoropropyl)-1,2-dimethylpiperidine-2-carboxamide (intermediate I-2-4; 598 mg, 1.07 mmol) was dissolved in 1,4-dioxane (10 mL), tris(dibenzylideneacetone)dipalladium(0) (98 mg, 107 μmol), dicyclohexylphosphine-2',4',6'-triisopropyl-1,1'-biphenyl (102 mg, 214 μmol), sodium benzoate (248 mg, 2.14 mmol) were added, and heated under reflux for 14 hours. After the reaction mixture was cooled to room temperature, the solvent was distilled off, and the mixture was purified by autoclaved silica gel column chromatography (eluent; ethyl acetate:methanol = 90:10), thereby obtaining 1 6 -(Benzyloxy)-7-fluoro-3- 1 ,3 2 -Dimethyl-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-cyclononaquinone-4-one (179 mg, yield 32%).

[1003] LCMS(LC-1);RT=1.39,m / z479[M+H] +

[1004] 1H-NMR (CDCl3): δ (ppm) 8.32 (1H, d, J = 2.5Hz), 8.00 (1H, d, J = 2.5Hz), 7.67 (1H, d, J = 9.0Hz), 7.52-7 .29(5H,m),7.17(1H,d,J=9.0Hz),5.13-4.89(1H,m),4.27(1H,dd,J=11.5,9.0Hz),4.17-4.04(2H,m ),3.97(1H,d,J=4.4Hz),3.80-3.67(1H,m),3.54-3.26(1H,m),3.18(1H,d,J=6.0Hz),2.92(1H,td, J=12.0,4.0Hz),2.88-2.79(1H,m),2.69(2H,s),1.96-1.83(2H,m),1.50(3H,s),1.47-1.37(1H,m).

[1005] [Chemistry 155]

[1006] Method 1-3

[1007]

[1008] Intermediate I-3-1: 7-Fluoro-1 6 -Hydroxy-3 1 ,3 2 -Dimethyl-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenan-4-one

[1009] [Chemistry 156]

[1010]

[1011] 1 6 -(Benzyloxy)-7-fluoro-3- 1 ,3 2 7-Dimethyl-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-cyclonona-4-one (intermediate I-2-5; 180 mg, 0.38 mmol) was dissolved in methanol (8 mL), and nitrogen atmosphere was placed. 10% palladium carbon (90 mg) was added, and the mixture was replaced with hydrogen. The mixture was stirred vigorously at room temperature for 14 hours. After filtering the insoluble matter from the reaction mixture, the solvent was distilled off to obtain 7-fluoro-1 6 -Hydroxy-3 1 ,3 2 -Dimethyl-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-cyclononaquinone-4-one (138 mg, yield 95%).

[1012] LCMS(LC-1);RT=0.83,m / z389[M+H] +

[1013] 1H-NMR (CD3OD): δ (ppm) (1H, d, J = 3.0Hz), 7.53-7.43 (1H, m), 7.33-7.20 (1H, m), 7.18-7.07 (1H, m), 7.01 (1H, d, J = 9.0Hz), 6.89 -6.85(1H,m),5.29(1H,tdd,J=9.0,6.5,3.0Hz),5.23-5.14(1H,m),5.12-4.94(1H,m,),4.28(1H,ddd,J=17.5,11.0,7.5Hz),4 .17-3.86(3H,m),3.78-3.65(1H,m),3.51-3.39(1H,m),3.35(3H,s),3.13-3.01(1H,m),2.86(1H,ddd,J=11.0,5.0,2.0Hz),2. 62-2.56(3H,m),2.36-2.28(1H,m),1.99(1H,d,J=12.0Hz),1.75(1H,dq,J=12.0,5.0Hz),1.46-1.41(3H,m),1.28-1.16(2H,m).

[1014] Intermediate I-3-2: 7-Fluoro-3 1 ,3 2 -Dimethyl-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-1-cyclononaphenanthene 6 -Trifluoromethanesulfonate

[1015] [Chemistry 157]

[1016]

[1017] 7-Fluoro-1 6 -Hydroxy-3 1 ,3 2 -Dimethyl-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-cyclonona-4-one (Intermediate I-3-1; 138 mg, 0.36 mmol) was dissolved in dichloromethane (4 mL), trifluoromethanesulfonic anhydride (72 μL, 0.43 mmol) and pyridine (43 μL, 0.53 mmol) were added, and stirred at room temperature for 1 hour. The reaction mixture was concentrated to obtain (7-fluoro-3 1 ,3 2-Dimethyl-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-1-cyclononaphenanthene 6 -yl trifluoromethanesulfonate crude product (185 mg, yield 99%).

[1018] Example a-02-23 (final form I-3-3): 7-fluoro-3 1 ,3 2 -Dimethyl-1 6 -(2-methylpyrimidin-5-yl)-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidinocyclononaphenan-4-one

[1019] [Chemistry 158]

[1020]

[1021] 7-Fluoro-3 1 ,3 2 -Dimethyl-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-1-cyclononaphenanthene 6 -yl trifluoromethanesulfonate (intermediate I-3-2; 185 mg, 0.36 mmol) was dissolved in 1,4-dioxane (4 mL) and water (800 μL), 2-methylpyrimidine-5-boronic acid pinacol ester (147 mg, 1.07 mmol), [1,1'-bis(diphenylphosphino)ferrocene] palladium (II) (116 mg, 142 μmol), cesium carbonate (696 mg, 2.14 mmol) were added, and heated and stirred at 80°C for 2 hours. After removing the insoluble matter from the reaction mixture by diatomaceous earth filtration, the solvent was distilled off, and the product was purified by HPLC to obtain 7-fluoro-3- 1 ,3 2 -Dimethyl-1 6 -(2-methylpyrimidin-5-yl)-9-oxa-2,5-diaza-1(3,5)-quinolin-3(4,2)-piperidin-cyclononaquin-4-one (43.7 mg, yield 26%).

[1022] LCMS(LC-1);RT=1.03,m / z465[M+H] +

[1023] 1H-NMR (CD3OD): δ (ppm) 9.05 (2H, s), 8.42 (1H, d, J = 2.5Hz), 7.77 (1H, d, J = 8.5Hz), 7.50 (1H, d, J = 8.5Hz), 7.03 (1H,d,J=2.5Hz),5.25(1H,d,J=6.5Hz),5.14(1H,brs),4.26-4.12(1H,m),4.08(1H,dd,J=12.0,2.0Hz),3.93- 3.77(2H,m),3.69(1H,dt,J=12.0,3.5Hz),3.67-3.42(1H,m),2.96-2.81(2H,m),2.77(3H,s),2.57(3H,s),2. 25(1H,d,J=13.2Hz),2.02(1H,d,J=12.0Hz,1H),1.77(1H,dq,J=12.0,5.0Hz),1.40(3H,s),1.34-1.20(m,1H).

[1024] [Table 3-1]

[1025]

[1026] [Table 3-2]

[1027]

[1028] [Table 3-3]

[1029]

[1030] [Table 3-4]

[1031]

[1032] <Test Example 1: Determination of human IRAK-4 inhibitory activity>

[1033] (1) Measurement method

[1034] The activity of human IRAK-4 (Invitrogen, Cat. PV3362) was determined by the TR-FRET method for phosphorylation of an IRAK-4 peptide substrate (biotin-KKKKRFSFKKSFKC) in the presence of 10 μM ATP (Sigma Aldrich, Cat. A7699). The enzyme reaction was carried out in a reaction buffer consisting of 50 mM HEPES (pH 7.2), 1 mM DTT, 0.1 mM Na3VO4, 5 mM MgCl2, 1 mM MnCl2, and 0.1% bovine serum albumin. In order to determine the IRAK-4 inhibitory activity, the compound to be tested was added to a reaction buffer containing 1 nM IRAK-4, 0.5 μM peptide substrate, and 10 μM ATP, and incubated at 23°C for 30 minutes. Then, a detection solution consisting of europium cryptate-labeled antibody (0.3 μg / mL, the antibody was prepared using IRAK-4 peptide substrate as antigen), streptavidin-XL665 (2 μg / mL, CisBio, Cat. 610SAXLB), 50 mM HEPES (pH 7.2), 0.1% BSA, 120 mM KF, and 66.7 mM EDTA was added (each reagent is at the final concentration), and after the reaction was stopped, it was further incubated at 23°C for 60 minutes. The fluorescence intensity at wavelengths of 665 nm and 620 nm was measured using an ELISA reader, and the enzyme activity was calculated as the ratio of the fluorescence intensity at 665 nm / 620 nm. The IRAK-4 inhibition rate when 12.5 μM staurosporine (LC Laboratories, Cat. S-9300) was added was set as 100%, and the IRAK-4 inhibition rate when no test compound was added was set as 0%. The IC of the test compound was calculated using the 4-parameter logistic model of the data analysis software XLfit (ID Business Solutions Ltd.). 50 .

[1035] It should be noted that each operation and condition in the measurement can be appropriately changed within the range that can be understood by those skilled in the art and does not significantly affect the measurement.

[1036] (2) Measurement results

[1037] As shown below, one embodiment of the compound of the present invention exhibits excellent IRAK-4 inhibitory activity.

[1038] In addition, when multiple measurements are made, the average value is shown.

[1039] [Table 4]

[1040] Example <![CDATA[IC 50 (nM)]]> Example <![CDATA[IC 50 (nM) <!-- 96 -->]]> a-01-01 1.63 a-01-21 2.29 a-01-02 0.89 a-01-22 0.89 a-01-03 2.11 a-01-23 1.21 a-01-04 4.24 a-01-24 2.48 a-01-05 1.37 a-01-25 4.43 a-01-06 2.53 a-01-26 1.41 a-01-07 1.49 a-01-27 4.25 a-01-08 1.47 a-01-28 4.04 a-01-09 1.28 a-01-29 4.14 a-01-10 43.44 a-01-30 2.8 a-01-11 0.79 a-01-31 3.42 a-01-12 1.75 a-01-32 1.59 a-01-13 2.95 a-01-33 4.79 a-01-14 1.73 a-01-34 4.19 a-01-15 2.77 a-01-35 2.84 a-01-16 1.25 a-01-36 8.86 a-01-17 3.04 a-01-37 4.52 a-01-18 1.84 a-01-38 6.73 a-01-19 1.6 a-01-39 5.12 a-01-20 1.15 a-01-40 14.78

[1041] [Table 5]

[1042] Example <![CDATA[IC 60 (nM)]]> Example <![CDATA[IC 50 (nM)]]> a-01-41 10.04 a-02-11 1.02 a-01-42 6.61 a-02-12 0.93 a-01-44 2.36 a-02-13 1.12 a-01-45 3.28 a-02-14 6.46 a-02-01 2.33 a-02-15 2.23 a-02-02 1.09 a-02-16 0.81 a-02-03 2.51 a-02-17 1.76 a-02-04 5.63 a-02-18 1.66 a-02-05 2.47 a-02-19 3.9 a-02-06 2 a-02-20 3.21 a-02-07 2.04 a-02-21 2.2 a-02-08 5.73 a-02-23 9.7 a-02-09 0.86 a-02-24 13.18 a-02-10 2.96

[1043] <Test Example 2: LPS-stimulated TNFα production inhibition test using THP-1 cell line derived from human acute monocytic leukemia>

[1044] (1) Measurement method

[1045] The THP-1 assay can be used to evaluate the effect of the test compound on TNFα production induced by LPS stimulation. THP-1 cells (ATCC, Cat. TIB-202) were cultured at 1×10 5 cells / 160μL / well were inoculated in a 96-well plate, 20μL of the compound to be tested was added, and cultured at 37°C in a 5% CO2 incubator for 1 hour. Then 20μL of LPS (final concentration 2.5ng / mL, Sigma, Cat.L2630) was added and cultured for a further 4 hours. After culture, the plate was centrifuged and 100μL of supernatant was collected from each well for evaluation of TNFα based on HTRF (Cisbio, Cat.62TNFPEB). In the determination of TNFa amount, the supernatant was diluted 2 times with culture medium, 10μL was added to a 384-well plate, and then anti-TNFa-cryptate (5μL) and anti-TNFα-XL665 (5μL) were added and left to stand overnight. The fluorescence intensity ratio at a wavelength of 620 / 665nm was measured using an ELISA reader, and the amount of TNFα in the supernatant was calculated using a calibration curve. The inhibition rate of TNFα production when LPS was not added was set as 100%, and the inhibition rate of TNFα production when the test compound was not added was set as 0%. The IC value of the test compound was calculated using the 4-parameter logistic model of the data analysis software XLfit (ID Business Solutions Ltd.). 50 .

[1046] After removing 100 μL of supernatant, the cell viability was measured in a 96-well plate to evaluate the effect of the test compound on off-target effects. 5 μL of CCK-8 (Dojindo, Cat. CK04-10) was added and cultured at 37°C for 1 hour. The absorbance at 450 nm was measured using an ELISA reader. The cell viability without LPS was taken as 100%, and the IC of the test compound was calculated using XLfit. 50 .

[1047] It should be noted that each operation and condition in the measurement can be appropriately changed within the range that can be understood by those skilled in the art and does not significantly affect the measurement.

[1048] (2) Measurement results

[1049] As shown below, one embodiment of the compound of the present invention exhibits excellent TNFα production inhibitory activity.

[1050] In addition, when multiple measurements are made, the average value is displayed, and the fourth decimal place is rounded off.

[1051] [Table 6]

[1052] Example <![CDATA[IC 50 (μM)]]> Example <![CDATA[IC 50 (μM)]]> a-01-01 0.028 a-01-21 0.117 a-01-02 0.044 a-01-22 0.118 a-01-03 0.045 a-01-23 0.124 a-01-04 0.048 a-01-24 0.140 a-01-05 0.048 a-01-25 0.141 a-01-06 0.050 a-01-26 0.142 a-01-07 0.057 a-01-27 0.145 a-01-08 0.063 a-01-28 0.149 a-01-09 0.064 a-01-29 0.150 a-01-10 0.068 a-01-30 0.162 a-01-11 0.073 a-01-31 0.163 a-01-12 0.075 a-01-32 0.165 a-01-13 0.076 a-01-33 0.170 a-01-14 0.080 a-01-34 0.177 a-01-15 0.081 a-01-35 0.178 a-01-16 0.092 a-01-36 0.182 a-01-17 0.099 a-01-37 0.189 a-01-18 0.104 a-01-38 0.199 a-01-19 0.113 a-01-39 0.204 a-01-20 0.113 a-01-40 0.253

[1053] [Table 7]

[1054] Example <![CDATA[IC 50 (μM)]]> Example <![CDATA[IC 50 (μM)]]> a-01-41 0.293 a-02-11 0.045 a-01-42 0.246 a-02-12 0.047 a-01-43 0.237 a-02-13 0.048 a-01-44 0.210 a-02-14 0.058 a-01-45 0.227 a-02-15 0.064 a-02-01 0.012 a-02-16 0.065 a-02-02 0.013 a-02-17 0.066 a-02-03 0.013 a-02-18 0.081 a-02-04 0.023 a-02-19 0.102 a-02-05 0.023 a-02-20 0.117 a-02-06 0.024 a-02-21 0.135 a-02-07 0.033 a-02-22 0.324 a-02-08 0.036 a-02-23 0.716 a-02-09 0.036 a-02-24 0.378 a-02-10 0.043 a-02-25 0.500

[1055] Industrial Applicability

[1056] The compound of the general formula (1) or a salt thereof has excellent IRAK-4 inhibitory activity and is useful as an active ingredient of a drug for preventing and / or treating a disease associated with IRAK-4 inhibition.

Claims

1. A compound represented by the following general formula (1) or a salt thereof: [Chemistry 1] In the general formula (1), R 1 -H, C 1-6 alkyl; R 2 -H, C 1-3 alkyl; R 3 -H, C 1-3 alkyl; Ar is a 5- to 6-membered heteroaryl group, wherein Ar may be substituted with a group selected from G 2 1 to 3 identical or different substituents in the group; The G 2 Group C 1-6 Alkyl, hydroxyl C 1-6 Alkyl and R Ar1 -OC 1-3 A group consisting of alkyl groups; R Ar1 C 1-6 Alkyl or 3-7 membered saturated ring group, said R Ar1 It can be substituted with 1 to 3 hydroxyl groups; X 1 N or CH; X 2 NH or O; X 3 It is the following general formula (1-1), the following general formula (1-2) or the following general formula (1-3): [Chemistry 2] [Chemistry 3] [Chemistry 4] In general formula (1-1), general formula (1-2) and general formula (1-3), a and b represent bonding directions; R 21 and R 22 Each independently is -H, C 1-3 alkyl; X 4 The following general formula (2-1): [Chemistry 5] In the general formula (2-1), b and c represent the bonding directions; In the general formula (2-1), n is an integer from 1 to 3; Y is NR 51 or O; R 31 and R 32 Each independently is -H, C 1-3 alkyl; R 41 and R 42 are independently -H, -F, C 1-3 alkyl; or R 41 With R 42 They can form a 3- to 6-membered saturated ring together; R 51 -H, C 1-3 alkyl.

2. The compound or salt thereof according to claim 1, in, X 2 For NH.

3. The compound or salt thereof according to claim 1 or 2, in, X 3 The following general formula (1-1): R 21 and R 22 Same meaning as above.

4. The compound or salt thereof according to claim 1 or 2, in, X 3 The following general formula (1-1-1):

5. The compound or salt thereof according to claim 1 or 2, in, X 4 In the general formula (2-1), n ​​is 1.

6. The compound or salt thereof according to claim 1 or 2, in, Ar is the following general formula (3-1): [Chemistry 8] In the general formula (3-1), R Ar2 -H, C 1-6 Alkyl, hydroxyl C 1-6 Alkyl or R Ar1 -OC 1-3 Alkyl, R Ar1 Same meaning as above.

7. The compound or salt thereof according to claim 1 or 2, in, Ar is the general formula (3-1): [Chemistry 8] In the general formula (3-1), R Ar2 -H, methyl, hydroxymethyl, -CH 2 -OR Ar1 , R Ar1 Same meaning as above.

8. The compound or salt thereof according to claim 1 or 2, in, R 3 is -H.

9. The compound or salt thereof according to claim 1 or 2, in, R 2 It is -H or methyl.

10. The compound or salt thereof according to claim 1 or 2, in, R 1 -H or C 1-3 alkyl.

11. A compound represented by the following formula or a salt thereof: [Chemistry 9] 12. A compound represented by the following formula or a salt thereof: [Chemistry 10] 13. A compound represented by the following formula or a salt thereof: [Chemistry 11] 14. A compound represented by the following formula or a salt thereof: [Chemistry 12] 15. A compound represented by the following formula or a salt thereof: [Chemistry 13] 16. A compound represented by the following formula or a salt thereof: [Chemistry 14] 17. A compound represented by the following formula or a salt thereof: [Chemistry 15]

Citation Information

Patent Citations

  • Heterocycle amines and uses thereof

    WO2012068546A1

  • Bicyclic heterocycles as IRAK4 inhibitors

    WO2013042137A1

  • IRAK inhibitors and uses thereof

    WO2015048281A1

  • Bicyclic-fused heteroaryl or ARYL compounds and their use as IRAK4 inhibitors

    WO2015150995A1

  • Inhibitors of IRAK4 activity

    WO2016053771A1